<!DOCTYPE html PUBLIC "-//w3c//dtd html 4.0 transitional//en">
 <html>
  <head>
   <meta content="text/html; charset=utf-8" http-equiv="Content-Type"/>
   <meta content="Mozilla/4.73 (Macintosh; I; PPC) [Netscape]" name="GENERATOR"/>
   <title>
    http://www.Lymenet.de
   </title>
   <basefont size="2">
   </basefont>
  </head>
  <body bgcolor="#0FFFF0">
   <table bgcolor="#000080" border="0" cellpadding="0" cellspacing="0" cols="1" width="100%">
    <tr>
     <td align="CENTER" valign="CENTER">
      <center>
       <b>
        <font face="Comic Sans MS,Arial,Helvetica">
         <font color="#FFFFFF">
          <font size="+3">
           Lyme-Borreliose-Informationen
          </font>
         </font>
        </font>
       </b>
      </center>
      <p>
      </p>
     </td>
    </tr>
   </table>
   <table bgcolor="#BAA6F8" border="0" cols="1" width="100%">
    <tr>
     <td>
      <center>
       <font face="Verdana">
        <font size="-2">
         Wir,
         <a href="about.htm">
          die Initiatoren dieser Website
         </a>
         , haben es uns zur Aufgabe gemacht, Ihnen soviel verläßliche Information bereitzustellen, wie uns möglich ist. Wir möchten Ihnen helfen, in einen autonomen Dialog mit dem Arzt einzutreten, und deshalb haben wir uns um richtige, nachvollziehbare, d.h. mit den medizinischen Quellen belegte, und präzise Darstellungen bemüht.
        </font>
       </font>
       <p>
        <font face="Verdana">
         <font size="-2">
          Vielleicht haben wir Material einseitig ausgewählt, obwohl uns Ausgewogenheit unerläßlich erschien.
         </font>
        </font>
       </p>
       <p>
        <font face="Verdana">
         <font size="-2">
          Sie müssen sich bei allem darüber im Klaren sein, daß wir keine Mediziner sind und damit keine Verantwortung für fehlerhafte Informationen oder die Folgen deren Gebrauchs übernehmen können (beachten Sie auch unsere
          <a href="indexordner/ilinks.htm#HINWEIS">
           Distanzierung
          </a>
          von angegebenen Links).
         </font>
        </font>
       </p>
       <p>
        <b>
         <font face="Verdana">
          <font size="-2">
           Um medizinische Hilfe zu erhalten, müssen Sie sich an einen Arzt wenden.
          </font>
         </font>
        </b>
        <br/>
        <b>
         <font face="Verdana">
          <font size="-2">
           Wir können Ihnen keine Arztempfehlungen in Deutschland geben. Wenn Sie einen Arzt suchen, schauen Sie vielleicht auch ins
           <a href="http://www.borreliose.de/forum">
            deutsche Borreliose-Forum
           </a>
           .
          </font>
         </font>
        </b>
       </p>
       <p>
        <b>
         <font face="Verdana">
          <font size="-2">
           <a href="about.htm">
            ÜBER
 LYMENET.DE
           </a>
          </font>
         </font>
        </b>
       </p>
      </center>
     </td>
    </tr>
   </table>
   <br/>
   <table border="0" cellpadding="5" cellspacing="0" cols="2" width="100%">
    <tr>
     <td align="LEFT" valign="TOP" width="30%">
      <!--Google Search-->
      <form action="http://www.google.de/search" method="GET">
       <!--<INPUT type=text name=q size=31 maxlength=256 value="SearchTerm site:www.lymenet.de"> 
 <INPUT TYPE=hidden name=hl value=de>-->
       <input maxlength="256" name="q" size="31" type="text" value=""/>
       <input name="q" type="hidden" value="site:www.lymenet.de"/>
       <input name="safe" type="hidden" value="off"/>
       <input name="btnG" type="submit" value="Google-Suche auf Lymenet.de"/>
       <br/>
      </form>
      <!--End Google Search-->
     </td>
     <td>
      <!--Google Scholar-->
      <div align="right">
       <form action="http://scholar.google.com/scholar" name="f">
        <span id="hf">
        </span>
        <table cellpadding="0" cellspacing="0">
         <tr valign="top">
          <td width="150">
          </td>
          <td align="center">
           <input maxlength="256" name="q" size="40" value=""/>
           <input name="ie" type="hidden" value="UTF-8"/>
           <input name="oe" type="hidden" value="UTF-8"/>
           <input name="hl" type="hidden" value="en"/>
           <br/>
           <input name="btnG" type="submit" value="Google Advanced Scholar Web Search"/>
          </td>
          <td>
          </td>
          <td nowrap="" valign="top">
           <font size="-2">
            <a href="http://scholar.google.com/advanced_scholar_search">
             Google Advanced Scholar Search
            </a>
            <br/>
            <a href="http://scholar.google.com/scholar/about.html">
             Scholar Help
            </a>
           </font>
          </td>
         </tr>
        </table>
       </form>
      </div>
      <!--END GOOGLE SCHOLAR-->
     </td>
    </tr>
    <tr>
     <td align="LEFT" valign="TOP" width="30%">
      <font face="Verdana">
       <font size="-2">
        Hier haben wir
        <b>
         alle
        </b>
        Informationen zusammengetragen, die wir für unsere Arbeit an Fragen zur Lyme-Borreliose gebraucht haben.
       </font>
      </font>
      <p>
       <font face="Verdana">
        <font size="-2">
         Einige wesentliche Aufsätze haben wir ins Deutsche übersetzt, ebenso einen großen Teil der Hilfen zur Bewertung der diagnostischen Methoden.
        </font>
       </font>
      </p>
      <p>
       <font face="Verdana">
        <font size="-2">
         Lose Einzelheiten haben wir im
         <a href="terms.htm">
          Lexikon
         </a>
         gesammelt.
        </font>
       </font>
       <br/>
      </p>
      <table border="0" cellpadding="5" cellspacing="0" cols="1" width="100%">
       <tr>
        <td bgcolor="#339900">
         <font face="Verdana">
          <font size="-2">
           Über das hier angebotene Material hinaus können wir zur Zeit Ihre persönlichen Fragen nur noch gegen Beteiligung an den
           <u>
            <a href="about.htm#kosten">
             laufenden Kosten
            </a>
           </u>
           dieser Website beantworten.
          </font>
         </font>
        </td>
       </tr>
       <tr>
        <td>
         <p>
         </p>
        </td>
       </tr>
       <tr>
        <td bgcolor="#BAA6F8">
         <font face="verdana">
          <font size="-2">
           <br/>
           <a name="rueckfallfrei">
           </a>
           <h4>
            Rückfallfreie Zeit nach einer als MS fehldiagnostizierten Neuroborreliose
           </h4>
           <h6>
            <a href="indexordner/ims.htm#lyme_oder_ms">
             Warum zuerst experimentell gegen Neuroborreliose behandelt wurde
            </a>
            - und
            <a href="symptoms/cycles/statistics.htm">
             wie
            </a>
            .
           </h6>
           <li>
            Opticus Neuritis, Fazialisparese: Aug., Sept. 1997
           </li>
           <li>
            Magnetresonanztomogramme (
            <a href="labtests/mamri.htm">
             1997/8
            </a>
            ),
            <blockquote>
             Interpretation in:
             <li>
              Deutschland:
              <a href="labtests/mamri.htm#ms">
               Verdacht
              </a>
              auf MS,
             </li>
             <li>
              USA.: MS
              <a href="labtests/mamri.htm#not_ruled_out">
               nicht ausgeschlossen
              </a>
             </li>
            </blockquote>
           </li>
           <li>
            Gesundheitsreport (
            <a href="symptoms/cycles/report.htm">
             1997/8
            </a>
            ),
            <br/>
           </li>
           <li>
            <a href="symptoms/cycles/statistics.htm#sympl">
             Symptome und Labortests
            </a>
            <br/>
           </li>
           <li>
            <a href="symptoms/cycles/statistics.htm#medication">
             Therapie
            </a>
            ,
            <a href="symptoms/cycles/tentative.htm">
             zu Grunde liegende Annahmen
            </a>
            <p>
             Rückfallfreie Zeit (Stand 26. Juni 2018):
            </p>
            <ul>
             <li>
              18 Jahre + 5 Monate seit Therapieende (24.1.2000)
             </li>
             <li>
              20 Jahre  + 6 Monate seit Therapiebeginn (5.12.1997)
             </li>
            </ul>
            <br/>
            <p>
            </p>
           </li>
          </font>
         </font>
        </td>
       </tr>
      </table>
      <br/>
      <font face="Verdana">
       <font size="-2">
       </font>
      </font>
      <table bgcolor="#106DA2" border="0" cellpadding="5" cellspacing="0" cols="1" width="100%">
       <tr>
        <td>
         <b>
          <font face="verdana">
           <font size="-1">
            <a href="http://www.lymenet.de">
             <font color="#FFFFFF">
              Lymenet.de
 - Home
             </font>
            </a>
           </font>
          </font>
         </b>
         <br/>
         <hr/>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="neuordner/index.htm">
              <font color="#FFFFFF">
               Neues
 auf Lymenet.de
              </font>
             </a>
            </font>
           </font>
          </b>
          <br/>
          <b>
           <font face="verdana">
            <font size="-1">
             <font color="#FFFFFF">
              Ergänzungen
 und Veränderungen
             </font>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/iueber.htm">
              <font color="#FFFFFF">
               Über
 Lyme-Borreliose
              </font>
             </a>
            </font>
           </font>
          </b>
          <br/>
          <a name="klinische Info">
          </a>
          <br/>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/iklinikinfo.htm">
              <font color="#FFFFFF">
               Klinische
 Informationen
              </font>
             </a>
            </font>
           </font>
          </b>
          <br/>
          <b>
           <font face="verdana">
            <font size="-1">
             <font color="#FFFFFF">
              Symptome, Diagnose, Behandlung
             </font>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/ihintergrund.htm">
              <font color="#FFFFFF">
               Hintergrund und medizinische Fachliteratur
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <ul>
          <li style="font: 10.0px verdana">
           <a href="literatur/lyme_issues&amp;hypotheses.html">
            <font color="#FFFFFF">
             Lyme Disease: Issues and Hypotheses
            </font>
           </a>
           <font color="#FFFFFF">
            (J. Gruber, ed.)
           </font>
          </li>
          <li style="font: 10.0px verdana">
           <a href="symptoms/cycles/index.htm">
            <font color="#FFFFFF">
             Immunantwort
            </font>
           </a>
           <font color="#FFFFFF">
            bei Neuroborreliose (Diskussionspapiere, J. Gruber)
           </font>
          </li>
          <li style="font: 10.0px verdana">
           <a href="literatur/kuby/index.htm">
            <font color="#FFFFFF">
             Immunology Primer
            </font>
           </a>
          </li>
         </ul>
         <a name="lymems">
         </a>
         <b>
          <font face="verdana">
           <font size="-1">
            <a href="indexordner/ims.htm">
             <font color="#FFFFFF">
              Lyme
 und Multiple Sklerose
             </font>
            </a>
           </font>
          </font>
         </b>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/ials.htm">
              <font color="#FFFFFF">
               Lyme
 und ALS
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/itagungen.htm">
              <font color="#FFFFFF">
               Berichte
 über Tagungen und Info-Veranstaltungen
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/ikrankenvers.htm">
              <font color="#FFFFFF">
               Krankenversicherungen
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/iethik.htm">
              <font color="#FFFFFF">
               Lyme-Aktivismus, Ethik, Menschenrechte
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/iselbsthg.htm">
              <font color="#FFFFFF">
               Beiträge
 von Selbsthilfegruppen
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/imedien.htm">
              <font color="#FFFFFF">
               Beiträge
 in Zeitschriften, Radio und TV
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="terms.htm">
              <font color="#FFFFFF">
               Lexikon
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/ikontakte.htm">
              <font color="#FFFFFF">
               Kontakte
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/ilinks.htm">
              <font color="#FFFFFF">
               Links
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="indexordner/isuchen.htm">
              <font color="#FFFFFF">
               Suchen
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="faq.htm">
              <font color="#FFFFFF">
               FAQs: Häufig gestellte Fragen
               <br/>
              </font>
             </a>
            </font>
           </font>
          </b>
         </p>
         <p>
          <b>
           <font face="verdana">
            <font size="-1">
             <font color="#FFFFFF">
              Hinweise
 zum
              <a href="struktur.htm#relativelinks">
               <font color="#FFFFFF">
                Offline-Lesen
               </font>
              </a>
             </font>
            </font>
           </font>
          </b>
          <br/>
          <b>
           <font face="verdana">
            <font size="-1">
             <a href="struktur.htm">
              <font color="#FFFFFF">
               Dateistruktur
              </font>
             </a>
            </font>
            <font color="#FFFFFF">
             von Lymenet.de
            </font>
           </font>
          </b>
         </p>
        </td>
       </tr>
      </table>
      <table>
       <tr>
        <td>
         <hr/>
         <font face="verdana" size="-2">
          Version:
          <!--14. Dezember 2017, 4. M&auml;rz 2018, 9. April 2018-->
          1. Juli 2018
          <br/>
          <a href="http://www.lymenet.de/index.htm">
           Adresse dieser Seite
          </a>
          <br/>
          <a href="http://www.acamedia.info/sciences/J_G/index.htm">
           Joachim Gruber
          </a>
          <hr/>
         </font>
        </td>
       </tr>
      </table>
      <font face="Verdana">
       <font size="-1">
       </font>
      </font>
     </td>
     <td align="LEFT" bgcolor="#FFFFFF" valign="CENTER">
      <br/>
      <a name="neuigkeiten">
      </a>
      <center>
       <font face="Verdana">
        <h5>
         Neuigkeiten - Bekanntmachungen
        </h5>
       </font>
      </center>
      <p>
       <font face="verdana">
        <font size="-2">
         <hr/>
         <b>
          (Datum: 1. Juli 2018)
         </b>
         <br/>
         Connie Strasheim,
         <b>
          <a href="http://lymebook.com/new-paradigms-connie-strasheim-book/">
           New Paradigms in Lyme Disease Treatment: 10 Top Doctors Reveal Healing Strategies That Work
          </a>
         </b>
         , 2016
         <br/>
         <p>
          Link: The Microbiology Information Portal,
          <a href="https://microbes.info/search/node/lyme">
           <b>
            Lyme disease
           </b>
          </a>
         </p>
         <p>
         </p>
         <hr/>
         <font face="verdana">
          <font size="-2">
           <b>
            (Datum: 9. April 2018)
           </b>
           <br/>
           W. Berghoff,
           <a href="http://www.praxis-berghoff.de/dokumente/KlinischeGrundlagenBorreliose-07.07.pdf">
            Klinische Grundlagen der antibiotischen Behandlung bei Borreliose
           </a>
           , 2007 (im
           <a href="literatur/Berghoff-KlinischeGrundlagenBorreliose-07.07.pdf">
            Cache
           </a>
           )
           <blockquote>
            <font size="-2">
             ... Das Erythema migrans tritt möglicherweise erst Wochen oder Monate nach Zeckenstich auf. In solchen Situationen ist es fraglich, ob das Erythema migrans hilft, den Zeitpunkt der Dissemination zu bestimmen. Zudem sei bereits an dieser Stelle erwähnt, dass auch nach "adäquat behandeltem Erythema migrans" eine Spätborreliose auftreten kann. Dies impliziert selbstverständlich, dass durch eine solche adäquate Behandlung des Erythema migrans die Dissemination nicht verhindert wurde oder zum Zeitpunkt der vermeintlich adäquaten antibiotischen Behandlung nicht mehr ein lokalisiertes, sondern bereits ein disseminiertes Frühstadium vorlag.
             <p>
              In der Spätphase ist es nicht möglich, zwischen Krankheitsmanifestationen des Spätstadiums oder einer chronischen Borreliose zu unterscheiden. Dies ist auch aufgrund pathophysiologischer Überlegungen nicht zu erwarten, da es sich in beiden Fällen um eine persistierende generalisierte Infektion mit Borrelien handelt.
             </p>
             <p>
              ... Da das Erythema migrans als pathognomonisches und krankheitsbeweisendes Phänomen, also in etwa 30-50 % der Fälle nicht auftritt oder nicht festgestellt wird, muss sich die Diagnose auf die übrigen Symptome der Borreliose stützen. Bezüglich der vielfältigen Symptomatik der Borreliose sei wiederum auf Tabelle 7 (nach Sigal (4)) und Tabelle 9 (nach ILADS (3)) verwiesen.
             </p>
             <p>
              Die Deutsche Borreliose-Gesellschaft hat eine Übersicht über die Symptomatik der Borreliose zusammengestellt und die vielfältigen Krankheitsmanifestationen nach Organsystemen geordnet. Diese Übersicht enthält die Tabelle 9a, Seite 18). Die Übersicht stützt sich auf Angaben von Ärzten der Deutschen Borreliose-Gesellschaft unter Einbeziehung verschiedener Literaturquellen. ...
             </p>
             <p>
             </p>
            </font>
           </blockquote>
           <hr/>
           <b>
            (Datum: 4. März 2018)
           </b>
           <br/>
           Alan B. MacDonald,
           <b>
            <a href="https://f1000research.com/posters/5-79">
             Nematode filarial Worms in Cerebrospinal Fluid of a Multiple Sclerosis Patient at Autopsy
            </a>
           </b>
           , 2016
           <!--(Alan MacDonald, M.D. 8427 Benelli Court, Naples, Florida, 34114-2754 inmacdonald@yahoo.com)-->
           (im
           <a href="literatur/macdonald-nematode_filarial_worms_in_csf_of_an_MS_patient.pdf">
            Cache
           </a>
           )
           <blockquote>
            <font size="-2">
             Abstract: 
 Multiple Sclerosis is classified according to current nosology as a human neurodegenerative [demyelinating] disorder, which is favored to be an autoimmune process. The actual causation of Multiple Sclerosis has not been agreed upon. Loss of myelin in the brain and spinal cord tissues is accompanied by diverse additional microscopic abnormalities in the plaques of MS. Subsequent investigation raised the possibility of chronic deep brain and spinal cord spirochetal infections {Steiner, Ichelson, Marshall and others} as the de facto cause of mylein loss in Multiple Sclerosis.
            </font>
           </blockquote>
          </font>
         </font>
        </font>
       </font>
      </p>
      <p>
       Herein is described image based evidence for the detection of cerebrospinal fluid infection/infestation with worms, probably vectored by ixodid ticks (Ref. 3), to produce nematode filarial CSF infection which is followed by worm [nematode filarial] invasion of the brain solid tissue to produce areas of myelin destruction, which typify the clinical and pathological signatures of Multiple Sclerosis in the human host. It is herein proposed, that the worms enter the deep brain white matter regions via direct extension from CSF worm infestations, and that worms slough their outer sheath tissues as detritus. A cascade of host responses which terminates in the destruction of axonal myelin, and entire brain neural and glial elements produces Multiple Sclerosis. Further host insult by the invading worms in deep brain white matter ensues from the comet like trail of nematode filarial eggs and zygotes in brain tissue. Collectively, the worm foreign material terminates in a host response which destroys the native architecture of the white matter. The inciting worm in brain tissue may not be evident at autopsy, because the worms may either have died or moved to a new topographical site remote from the plaques.
      </p>
      <p>
       <font face="verdana">
        <font size="-2">
         <b>
          <a href="https://www.webwire.com/ViewPressRel.asp?aId=203268">
           Lyme Bacteria Hides Inside Parasitic Worms, Causing Chronic Brain Diseases
          </a>
         </b>
         , WEBWIRE, Washington, DC, May 19, 2016 (im
         <a href="literatur/macdonald-Lyme_Bacteria_Hides_Inside_Parasitic_Worms-WebWire.pdf">
          Cache
         </a>
         )
        </font>
       </font>
      </p>
      <blockquote>
       The examination of autopsied brain tissues from patients who died of serious neurological conditions has revealed that many tick-borne infections, such as Lyme disease, go undiagnosed and untreated. Board-certified pathologist, Alan B. MacDonald, MD, says his research shows "tick infections are not easily detected with routine tests, nor are they easily cured with short courses of antibiotics". ... MacDonald found two Borrelia pathogens, including B. burgdorferi the causative agent of Lyme disease, thriving inside parasitic nematode worms, worm eggs or larvae in the brain tissue of nineteen deceased patients. These microscopic worms are endosymbionts, meaning the Borrelia bacteria dwell inside the worms. A tick bite delivers the nematode into the human body.
       <p>
        ... The Rocky Mountain Multiple Sclerosis Center Tissue Bank provided MacDonald with ten specimens from deceased MS patients; all ten specimens showed evidence of Borrelia infected nematodes. Infected worms were also found in five tissue specimens from patients who succumbed to the highly malignant brain tumor Glioblastoma multiforme, the same cancer which took the life of Senator Edward Kennedy (D-MA). Ironically, in 1993, Senator Kennedy chaired a hearing of the Labor and Human Resources committee titled:
        <a href="http://archive.org/stream/lymediseasediagn00unit/lymediseasediagn00unit_djvu.txt">
         Lyme disease: A Diagnostic and Treatment Dilemma
        </a>
        . Finally, four specimens from patients who died from Lewy Body dementia, the same illness which afflicted comedian
        <a href="http://www.realclearscience.com/2015/11/05/robin_williams_had_lewy_body_dementia_267494.html">
         Robin Williams
        </a>
        , also showed the presence of infected nematodes.
       </p>
      </blockquote>
      <p>
       <font face="verdana">
        <font size="-2">
         Alan B. MacDonald,
         <b>
          <a href="https://vimeo.com/166688480">
           Borrelia Burgdorferi Group Spirochetes Detected in Blood and CSF in (ELISA &amp; Western Blot) Seronegative Patients
          </a>
         </b>
         ,  London (England) Lecture, May 15, 2016, Lyme Disease Science and Policy Challenges Forum, Washington, DC,  May 19, 2016 (hosted by the Lyme Action Network)
        </font>
       </font>
      </p>
      <blockquote>
       <font face="verdana">
        <font size="-2">
         Spirochetes reside inside of the nematodes (endosymbiont borrelia). Endosymbiont released after the death of the nematode. Migrating worm destroys myelin in the brain. Hundreds of brain specimen slides studied to find one worm. It is much easier to find worms in csf.
 Additional spinal fluids from the Multiple Sclerosis Brain Bank requested: 9 more CSFs examined, all of the 9 are positive for nematode parasites.
        </font>
       </font>
      </blockquote>
      <p>
       <font face="verdana">
        <font size="-2">
         <hr/>
         <b>
          (Datum: 14. Dezember 2017)
         </b>
         <br/>
         Alison W. Rebman
         <sup>
          1
         </sup>
         , Kathleen T. Bechtold
         <sup>
          2
         </sup>
         , Ting Yang
         <sup>
          1
         </sup>
         , Erica A. Mihm
         <sup>
          1
         </sup>
         , Mark J. Soloski
         <sup>
          1
         </sup>
         , Cheryl B. Novak
         <sup>
          1
         </sup>
         and John N. Aucott
         <sup>
          1*
         </sup>
         (1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2 Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, United States),
         <b>
          <a href="https://www.frontiersin.org/articles/10.3389/fmed.2017.00224/full">
           The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome
          </a>
         </b>
         , Front. Med., 14 December 2017
         <br/>
         <blockquote>
          <font size="-2">
           Conclusion: Although physical exam and clinical laboratory tests showed few objective abnormalities, standardized symptom questionnaires revealed that patients with PTLDS are highly and clinically significantly symptomatic, with poor health-related quality of life. PTLDS patients exhibited levels of fatigue, musculoskeletal pain, sleep disturbance, and depression which were both clinically relevant and statistically significantly higher than controls. Our study shows that PTLDS can be successfully identified using a systematic approach to diagnosis and symptom measurement. As the prevalence of PTLDS continues to rise, there will be an increased need for physician education to more effectively identify and manage PTLDS as part of integrated patient care.
          </font>
         </blockquote>
         <p>
          Monica E. Embers, Nicole R. Hasenkampf, Mary B. Jacobs, Amanda C. Tardo, Lara A. Doyle-Meyers, Mario T. Philipp, Emir Hodzic,
          <b>
           <a href="">
            Variable manifestations, diverse seroreactivity and post-treatment persistence in non-human primates exposed to Borrelia burgdorferi by tick feeding
           </a>
          </b>
          ,  PLoS ONE 12(12): e0189071, Dec. 13, 2017.
         </p>
         <p>
          Nicholas A. Crossland, Xavier Alvarez, Monica E. Embers,
          <b>
           <a href="http://ajp.amjpathol.org/article/S0002-9440(17)30894-5/fulltext">
            Late Disseminated Lyme Disease: Associated Pathology and Spirochete Persistence Post-Treatment in Rhesus Macaques
           </a>
          </b>
          , The American Journal of Pathology 2791, 16 Nov. 2017
         </p>
         <p>
          <font face="verdana">
           <font size="-2">
            <hr/>
            <b>
             (Datum: 25. November 2017)
            </b>
            <br/>
            <b>
             <a href="shgs/corryw/index.htm">
              Corry Welker
             </a>
             , Rundmail
             <a href="shgs/corryw/Rundmails/Rund_64/Rundm_64.pdf">
              64
             </a>
            </b>
            (13. November 2017) mit
            <a href="shgs/corryw/Rundmails/index.html#rundmail_64">
             Anhängen
            </a>
            <p>
             Filmtipp:
             <a href="http://www.ardmediathek.de/tv/FilmMittwoch-im-Ersten/Götter-in-Wei§/Das-Erste/Video?bcastId=10318946&amp;documentId=47603622">
              Götter in Weiß
             </a>
             , 15.11.2017 | 88 Min. | UT | Verfügbar bis 15.12.2017 in ard-Mediathek (Wertung in Ärztezeitung:
             <a href="https://www.aerztezeitung.de/panorama/article/947250/fernsehtipp-klinikaerzte-konflikt.html">
              Klinikärzte im Konflikt
             </a>
             )
            </p>
            <p>
             <font face="verdana">
              <font size="-2">
               <hr/>
               <b>
                (Datum: 20. April 2017)
               </b>
               <br/>
               Nachricht von Günther Schust, 20. April 2017
               <ul class="ul1">
                <li style="font:10.0 px verdana">
                 <a href="http://www.borreliose-gesellschaft.de/Texte/Leitlinien.pdf">
                  <span class="s1">
                   Hier finden sich die aktuellen
                   <b>
                    Behandlungsleitlinien
                   </b>
                   sowohl für die Lyme-Borreliose, Hautformen und die Neuroborreliose.
                  </span>
                 </a>
                 <span class="s2">
                  (Anmerkung: Leitlinien der Deutschen Borreliose-Gesellschaft!)
                 </span>
                </li>
                <li style="font:10.0 px verdana">
                 <a href="http://www.borreliose-nachrichten.de/borreliose-selbsthilfe-gruppen/">
                  <span class="s1">
                   Übersicht über
                   <b>
                    Selbsthilfegruppen
                   </b>
                   nach Postleitzahl geordnet
                  </span>
                 </a>
                </li>
                <li style="font:10.0 px verdana">
                 <a href="http://www.rki.de/DE/Home/homepage_node.html">
                  <span class="s1">
                   Internetseite des
                   <b>
                    Robert-Koch-Institutes
                   </b>
                   . Unter den Suchbegriffen Borreliose und FSME können Sie die Risikogebiete für Deutschland und neue Forschungsergebnisse rund um Zecken finden.
                  </span>
                 </a>
                </li>
                <li style="font:10.0 px verdana">
                 <a href="https://www.zecken.de/">
                  <span class="s1">
                   Weitgehend werbefreie
                   <b>
                    Internetseite
                   </b>
                   , die vieles rund um das Thema Zecken und vor allem FSME bietet.
                  </span>
                 </a>
                </li>
               </ul>
               <p>
               </p>
               <hr/>
               <b>
                (Datum: 5. März 2017)
               </b>
               <br/>
               <a href="http://www.google.de/search?client=safari&amp;rls=en&amp;q=sue+ferrara+phd&amp;ie=UTF-8&amp;oe=UTF-8&amp;gfe_rd=cr&amp;ei=PRS8WOy7AqHi8Af046XACA">
                Sue Ferrara
               </a>
               ,
               <a href="https://www.facebook.com/denise.longman/posts/10153694576616325">
                <b>
                 Lyme Bacteria Hides Inside Parasitic Worms, Causing Chronic Brain Diseases
                </b>
               </a>
               , May 19, 2016 (im
               <a href="literatur/macdonald_nematodes_2016.html">
                Cache
               </a>
               ).
               <br/>
               Recent discovery confirmed by state-of-the-art Molecular Beacon DNA probes
               <p>
                (Washington, DC) The examination of autopsied brain tissues from patients who died of serious neurological conditions has revealed that many tick-borne infections, such as Lyme disease, go undiagnosed and untreated. Board-certified pathologist, Alan B. MacDonald, MD, says his research shows "tick infections are not easily detected with routine tests, nor are they easily cured with short courses of antibiotics.Ó
               </p>
               <p>
                MacDonald will present his findings Thursday on Capitol Hill, in the Rayburn House Office Building, at a forum to explore the scientific, economic, and policy challenges posed by the epidemic of Lyme disease and associated tick-borne illnesses.
               </p>
               <p>
                MacDonald found three Borrelia pathogens, including B. burgdorferi the causative agent of Lyme disease, thriving inside parasitic nematode worms, worm eggs or larvae in the brain tissue of nineteen deceased patients. These microscopic worms are endosymbionts, meaning the Borrelia bacteria dwell inside the worms. A tick bite delivers the nematode into the human body.
               </p>
               <p>
               </p>
               <table>
                <tr>
                 <td valign="top">
                  <a href="literatur/macdonald_us2durayleafletmay16.png">
                   <img height="200" src="literatur/macdonald_us2durayleafletmay16.png" width="300"/>
                  </a>
                  <br/>
                  <font size="-2">
                   An Alzheimer plaque stains equally for beta-amyloid and Borrelia DNA. Many researchers now believe that the amyloid is not a cause of dementia, but an anti-microbial peptide defending the body by coating the infecting organisms.
                   <br/>
                   Quelle:
                   <a href="https://durayresearch.wordpress.com/borrelia-dwells-in-parasitic-nematodes-in-neurodegenerative-disease/">
                    Dr. Paul Duray Research Fellowship Endowment Inc.
                   </a>
                  </font>
                 </td>
                 <td valign="top">
                  <font size="-2">
                   Alan MacDonald,
                   <a href="https://durayresearch.wordpress.com/borrelia-dwells-in-parasitic-nematodes-in-neurodegenerative-disease/">
                    <b>
                     Borrelia Dwells in Parasitic Nematodes in Glioma &amp; Neurodegenerative Disease
                    </b>
                   </a>
                   (im
                   <a href="literatur/macdonald_us2durayleafletmay16.pdf">
                    Cache
                   </a>
                   )
                   <br/>
                   For decades our public health agencies have insisted that current antibody testing and short courses of antibiotics for Lyme disease are adequate.
 This view now needs to be discarded.
                   <p>
                    At the Dr. Paul Duray Research Fellowship Endowment Inc., pathologist Alan MacDonald MD, FCAP, FASCP, has been using highly specific Molecular Beacon DNA probes to in-vestigate the role of Borrelia in neurological diseases. The results have been no less than astonishing.
 Using the technique of Fluorescent in situ hybridization (FISH), Borrelia biofilms (both Borrelia burgorferi and relapsing-fever typeÑmiyamotoi) have been repeatedly detected in antibody-negative patients, as well as in patients treated with antibiotics.
                   </p>
                   <p>
                    In May 2016, the Duray foundation discovered that Borrelia endosymbionts dwell inside parasitic nematode worms which invade brain tissue, trampling neurons, and leaving a trail of destruction in their wake. Endosymbionts live in harmony with their nematode host, but cause devastation once released into the brain.
                   </p>
                  </font>
                 </td>
                </tr>
               </table>
               <p>
               </p>
               <hr/>
               <b>
                (Datum: 11. Februar 2017)
               </b>
               <br/>
               Emily R. Adrion, John Aucott , Klaus W. Lemke, Jonathan P. Weiner,
               <b>
                <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767">
                 Health Care Costs, Utilization and Patterns of Care following Lyme Disease
                </a>
               </b>
               , Public Library of Science PLoS ONE 10(2): e0116767, February 4, 2015.
               <a href="http://dx.doi.org/10.1371/journal.pone.0116767">
                http://dx.doi.org/10.1371/journal.pone.0116767
               </a>
               <br/>
               deutsche Zusammenfassung:
               <a href="http://www.borreliose-nachrichten.de/analyse-der-weltweit-groessten-borreliose-studie/">
                Analyse der Johns-Hopkins-Studie zum Thema Behandlungskosten von Borreliose-Patienten nach initialer Antibiotikatherapie
               </a>
               , Borreliose-Nachrichten, 18. März 2016.
               <p>
               </p>
               <blockquote>
                Approximately 10 - 20% of patients treated for Lyme disease with a
                <i>
                 recommended 2 - 4 week course of antibiotics
                </i>
                will have patient-reported symptoms that may last for weeks, months or years. [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref007">
                 7
                </a>
                ] [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref008">
                 8
                </a>
                ] Post-treatment Lyme disease symptoms have been described by numerous investigators and include fatigue, musculoskeletal pain, and neurocognitive complaints such as poor memory and concentration and extremity dysthesias. In some cases, symptoms may be severe, chronic and adversely affect health-related function. [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref008">
                 8
                </a>
                ] [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref009">
                 9
                </a>
                ] [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref010">
                 10
                </a>
                ] [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref011">
                 11
                </a>
                ] When post-treatment Lyme disease symptoms (PTLDS) persist for six months or longer and are associated with functional limitations in the patient, the illness has been termed "Post-treatment Lyme Disease Syndrome" by the Centers for Disease Control. [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref007">
                 7
                </a>
                ] Because no sensitive biomarker for remotely treated Lyme disease exists, the true number of individuals at risk for the syndrome is unknown. [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref012">
                 12
                </a>
                ] [
                <a class="ref-tip" href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref013">
                 13
                </a>
                ]
                <p>
                 Costs for the Lyme disease group might be expected to be higher, particularly if expensive long term intravenous antibiotics were used, a practice that has been reported in the treatment of the more heterogeneous and complex group of patients with long term chronic symptoms where Lyme disease may not be the sole cause of illness. [
                 <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.ref026">
                  26
                 </a>
                 ] However, we did not find increased costs associated with IV antibiotics in our study population [
                 <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.s004">
                  S3
                 </a>
                 and
                 <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116767#pone.0116767.s005">
                  S4
                 </a>
                 Tables].
                </p>
                <p>
                 <b>
                  Welche finanziellen Auswirkungen hat die Lyme-Borreliose auf das amerikanische Gesundheitswesen?
                 </b>
                </p>
                <ul>
                 <li>
                  $ 2.968  höhere Gesamt-Behandlungskosten im Durchschnitt pro Person in der Lyme-Borreliose-Gruppe im Vergleich zur Kontrollgruppe
                 </li>
                 <li>
                  87% mehr ambulante Kontakte in einem Zeitraum von 12 Monaten und dadurch $ 2.125  höhere Kosten für ambulante Behandlungen im Durchschnitt pro Person in der Lyme-Borreliose-Gruppe im Vergleich zur Kontrollgruppe
                 </li>
                 <li>
                  71% mehr Krankenhausaufenthalte der Borreliose-Patienten in einem Zeitraum von 12 Monaten und dadurch $ 230 höhere Kosten im Durchschnitt pro Patient aus der Borreliose-Gruppe im Vergleich mit der Kontrollgruppe
                 </li>
                </ul>
                <b>
                 Welcher Zusammenhang besteht zwischen der Lyme-Borreliose und dem Post-Treatment Lyme Disease Syndrome (PTLDS), und mit welcher Wahrscheinlichkeit kommt es zur Entwicklung von PTLDS?
                </b>
                <ul>
                 <li>
                  63,1% der Borreliose-Patienten zeigten klinische Symptome, die unter der Vokabel PTLDS zusammengeführt werden, in der Kontrollgruppe zeigten jedoch nur 27,6% der Probanden eine ähnliche Symptomatik. Das Risiko für die Entstehung von Symptomen, die vereinbar mit PTLDS sind, ist bei einem Borreliose-Erkrankten - nach antibiotischer Therapie - 4,77 Mal größer als in der Kontrollgruppe.
                 </li>
                 <li>
                  32,7% der Borreliose-Patienten litten nach antibiotischer Therapie unter unverhältnismäßig großer Abgeschlagenheit und Erschöpfung. Diese Symptomatik zeigte sich nur bei 8,4% der Kontrollgruppe.
                 </li>
                 <li>
                  Das Risiko für diese klinische Symptomatik ist bei Borreliose-Erkrankten 5,47 Mal höher als in der Vergleichsgruppe.
                 </li>
                 <li>
                  Bei 45,2% der Borreliose-Patienten zeigten sich Myopathien, in der Kontrollgruppe wurde dieses Symptom nur bei 18,9% diagnostiziert. Das Risiko für die Entstehung von Myopathien ist bei Borreliose-Erkrankten 3,62 Mal höher als in der Kontrollgruppe.
                 </li>
                 <li>
                  Bei 7,7% der Lyme-Borreliose-Patienten wurde nach antibiotischer Behandlung Arthrose diagnostiziert, bei der Kontrollgruppe zeigten nur 1,8% Symptome einer Arthrose. Das Risiko für die Entwicklung einer Arthrose liegt bei den Borreliose-Patienten 4,51 Mal höher als bei der Kontrollgruppe.
                 </li>
                </ul>
                <b>
                 Welche finanziellen Belastungen entstehen im amerikanischen Gesundheitswesen durch das Post-Lyme-Syndrom?
                </b>
                <ul>
                 <li>
                  Die durchschnittlichen Behandlungskosten liegen pro Borreliose-Patient mit PTLDS mit $ 3.798  über den Behandlungskosten der Borreliose-Patienten ohne PTLDS.
                 </li>
                 <li>
                  66% mehr ambulante Kontakte der Patienten mit PTLDS im Vergleich zu den Patienten ohne PTLDS (12 Monate). Es sind also $ 2.786  höhere Kosten pro Patient in der PTLDS-Gruppe durch ambulante Behandlungen entstanden.
                 </li>
                 <li>
                  Zusätzlich gab es 89% mehr Notfallkontakte in der PTLDS-Gruppe.
                 </li>
                </ul>
               </blockquote>
               <hr/>
               <b>
                (Datum: 11. August 2016)
               </b>
               <br/>
               <b>
                <a href="shgs/corryw/index.htm">
                 Corry Welker
                </a>
                , Rundmail
                <a href="shgs/corryw/Rundmails/Rund_62/Rundm_62,2-16.pdf">
                 62
                </a>
               </b>
               (35 Seiten, 7. Februar 2016)
               <br/>
               darin unter anderem:
               <br/>
               <ul>
                <li>
                 J. Feng, P.G. Auwaerter, Y. Zhang, "
                 <b>
                  <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0117207">
                   Drug Combinations against Borrelia burgdorferi Persisters In Vitro: Eradication Achieved by Using Daptomycin, Cefoperazone and Doxycycline
                  </a>
                 </b>
                 ", PLoS ONE 10(3): e0117207, March 25, 2015.
                </li>
                <p>
                </p>
                <li>
                 Gary P. Wormser, Erica Weitzner, Donna McKenna, Robert B. Nadelman, Carol Scavarda, Irida Molla, Rhea Dornbush, Paul Visintainer, and John Nowakowski, "
                 <b>
                  <a href="http://cid.oxfordjournals.org/content/61/2/244.long">
                   Long-term Assessment of Health-Related Quality of Life in Patients With Culture-Confirmed Early Lyme Disease
                  </a>
                 </b>
                 ", Clin Infect Dis. (2015) 61 (2): 244-247.
 doi: 10.1093/cid/civ277, April 17, 2015.
                 <br/>
                 <blockquote>
                  <font size="-2">
                   <i>
                    Another limitation of our study is that it was not directed at patients with extracutaneous manifestations of Lyme disease. Data from certain European studies have suggested that impairment in health-related quality of life may occur as a consequence of neurologic Lyme disease specifically [
                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/21303350?dopt=Abstract">
                     9
                    </a>
                    ,
                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/22876748?dopt=Abstract">
                     11
                    </a>
                    ].
                   </i>
                  </font>
                 </blockquote>
                </li>
                <li>
                 R.C. Bransfield, "
                 <b>
                  <a href="https://aima.net.au/media/files/page/87757d46/Australia_1_Inflammation_Bransfield_6-29-15.pdf">
                   Inflammation in Chronic Brain Diseases
                  </a>
                 </b>
                 , 21. Annual International Integrative Medicine Conference, Melbourne, Australia, July 18, 2015 (im
                 <a href="literatur/bransfield/australia_2015/Australia_1_Inflammation_Bransfield_6-29-15.pdf">
                  Cache
                 </a>
                 ).
                 <p>
                 </p>
                 <table>
                  <tr>
                   <td valign="top">
                    <a href="literatur/bransfield/australia_2015/47.png">
                     <img height="160" src="literatur/bransfield/australia_2015/47.png" width="240"/>
                    </a>
                    <p>
                    </p>
                   </td>
                   <td href="literatur/bransfield/australia_2015/48.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/48.png" width="240"/>
                    <p>
                    </p>
                   </td>
                   <td href="literatur/bransfield/australia_2015/49.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/49.png" width="240"/>
                    <p>
                    </p>
                   </td>
                  </tr>
                  <tr>
                   <td href="literatur/bransfield/australia_2015/50.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/50.png" width="240"/>
                    <p>
                    </p>
                   </td>
                   <td href="literatur/bransfield/australia_2015/51.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/51.png" width="240"/>
                    <br/>
                    <center>
                     <font face="verdana">
                      <font size="-2">
                       MDD = Major Depressive Disorder
                      </font>
                     </font>
                    </center>
                   </td>
                   <td href="literatur/bransfield/australia_2015/52.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/52.png" width="240"/>
                    <p>
                    </p>
                   </td>
                  </tr>
                  <tr>
                   <td href="literatur/bransfield/australia_2015/55.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/55.png" width="240"/>
                    <p>
                    </p>
                   </td>
                   <td href="literatur/bransfield/australia_2015/82.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/82.png" width="240"/>
                    <p>
                    </p>
                   </td>
                   <td href="literatur/bransfield/australia_2015/86.png" valign="top">
                    <img height="160" src="literatur/bransfield/australia_2015/86.png" width="240"/>
                    <p>
                    </p>
                   </td>
                  </tr>
                 </table>
                </li>
               </ul>
               <hr/>
               <b>
                (Datum: 21. Dezember 2015)
               </b>
               <br/>
               Alexandra Vogl,
               <b>
                <a href="http://www.jameda.de/gesundheit/infektionen-viren/borreliose-warum-anzeichen-meist-schwer-zu-erkennen-sind/">
                 Borreliose - Warum Anzeichen meist schwer zu erkennen sind
                </a>
               </b>
               <p>
               </p>
               <hr/>
               <b>
                (Datum: 4. Dezember 2015)
               </b>
               <br/>
               Elsner RA, Hastey CJ and Baumgarth N,
               <b>
                <a href="http://iai.asm.org/content/83/1/48.long">
                 CD4+ T Cells Promote Antibody Production but Not Sustained Affinity Maturation during Borrelia burgdorferi Infection
                </a>
               </b>
               , 
 Infect Immun. 2015 Jan;83(1):48-56. doi: 10.1128/IAI.02471-14. Epub 2014 Oct 13
               <blockquote>
                CD4 T cells are crucial for enhancing B cell-mediated immunity, supporting the induction of high-affinity, class-switched antibody responses, long-lived plasma cells, and memory B cells [
                <a href="https://en.wikipedia.org/wiki/T_helper_cell#Th1.2FTh2_Model_for_helper_T_cells">
                 humoral response
                </a>
                ]. Previous studies showed that the immune response to Borrelia burgdorferi appears to lack robust T-dependent B cell responses, as neither long-lived plasma cells nor memory B cells form for months after infection, and nonswitched IgM antibodies are produced continuously during this chronic disease. ...
                <p>
                 Our
                 <a href="http://www.jimmunol.org/content/188/11/5612.full.pdf">
                  recent studies
                 </a>
                 suggested that germinal center responses were nonfunctional after primary B. burgdorferi infection, as long-lived antibody-secreting plasma cells and memory B cells were not induced for months after infection.
                </p>
                <p>
                 ...  while
                 <a href="https://en.wikipedia.org/wiki/Affinity_maturation">
                  affinity maturation
                 </a>
                 of antibodies against a prototypic T-dependent B. burgdorferi protein, Arthritis-related protein (Arp), were initiated, these increases were reversed later, coinciding with the previously observed involution of
                 <a href="https://en.wikipedia.org/wiki/Germinal_center">
                  germinal centers
                 </a>
                 . The cessation of affinity maturation was not due to the appearance of inhibitory or exhausted CD4 T cells or a strong induction of regulatory T cells. In vitro T-B cocultures demonstrated that T cells from B. burgdorferi-infected ... mice supported the rapid differentiation of B cells into antibody-secreting plasma cells rather than continued proliferation, mirroring the induction of rapid short-lived instead of long-lived T-dependent antibody responses in vivo. The data further suggest that B. burgdorferi infection drives the
                 <a href="https://en.wikipedia.org/wiki/T_helper_cell#/media/File:Lymphocyte_activation.png">
                  humoral response
                 </a>
                 away from protective, high-affinity, and long-lived antibody responses and toward the rapid induction of strongly induced, short-lived antibodies of limited efficacy.
                </p>
               </blockquote>
               For immune systems basics see
               <ul>
                <li>
                 Wikipedia:
                 <a href="https://en.wikipedia.org/wiki/T_helper_cell">
                  T helper cell
                 </a>
                 ,
                </li>
                <li>
                 Wikipedia: T
                 <sub>
                  h
                 </sub>
                 1/T
                 <sub>
                  h
                 </sub>
                 2
                 <a href="literatur/kuby/index.htm#T_helper_cell-Wikipedia">
                  Model
                 </a>
                 ,
                </li>
                <li>
                 Janis Kuby:
                 <a href="literatur/kuby/lymphocyteactivation.htm">
                  lymphoscyte activation
                 </a>
                 .
                </li>
                <li>
                 Wikipedia:
                 <a href="https://en.wikipedia.org/wiki/Germinal_center">
                  Germinal centers
                 </a>
                 are an important part of the B cell
                 <a href="https://en.wikipedia.org/wiki/T_helper_cell#Th1.2FTh2_Model_for_helper_T_cells">
                  humoral immune response
                 </a>
                 , acting as central factories for the generation of affinity matured B cells specialized in producing improved antibodies that effectively recognize infectious agents, and for the production of durable memory B cells. Histologically, the GCs describe microscopically distinguishable parts in lymphoid tissues.
                </li>
               </ul>
               Hastey CJ, Elsner RA, Barthold SW, Baumgarth N,
               <a href="http://www.jimmunol.org/content/188/11/5612.full.pdf">
                <b>
                 Delays and Diversions Mark the Development of B Cell Responses to Borrelia burgdorferi Infection
                </b>
               </a>
               , J Immunol. 2012 Jun 1;188(11):5612-22. doi: 10.4049/jimmunol.1103735. Epub 2012 Apr 30.
               <blockquote>
                B cell responses modulate disease during infection with Borrelia burgdorferi, the causative agent of Lyme disease, but
                <b>
                 are unable to clear the infection
                </b>
                .
                <p>
                 Previous studies have demonstrated that B. burgdorferi infection induces predominantly T-independent B cell responses, potentially explaining some of these findings. However, others have shown effects of T cells on the isotype profile and the magnitude of the B. burgdorferi-specific Abs.
                </p>
                <p>
                 This study aimed to further investigate the humoral response to B. burgdorferi and its degree of T cell dependence, with the ultimate goal of elucidating the mechanisms underlying the failure of effective immunity to this emerging infectious disease agent. Our study identifies distinct stages in the B cell response using a mouse model, all marked by the generation of unusually strong and persistent
                 <a href="https://en.wikipedia.org/wiki/B_cell#T_cell-dependent_activation">
                  T-dependent
                 </a>
                 and
                 <a href="https://en.wikipedia.org/wiki/B_cell#T_cell-independent_activation">
                  T-independent
                 </a>
                 IgM Abs.
                </p>
                <ul>
                 <li>
                  The initial phase is dominated by a strong
                  <a href="https://en.wikipedia.org/wiki/T_independent_antigen_(TI)">
                   T-independent
                  </a>
                  accumulation of B cells in lymph nodes and the induction of specific Abs in the absence of germinal centers.
                 </li>
                 <li>
                  A second phase begins around week 2.5 to 3, in which relatively short-lived germinal centers develop in lymph nodes, despite a lymph node architecture that lacks clearly demarcated T and B cell zones. This response failed, however, to generate appreciable numbers of long-lived bone marrow plasma cells.
                 </li>
                 <li>
                  Finally, there is a slow accumulation of long-lived Ab-secreting plasma cells in bone marrow, reflected by a strong but ultimately ineffective serum Ab response.
                 </li>
                </ul>
                Overall, the study indicates that B. burgdorferi might evade B cell immunity by interfering with its response kinetics and quality.
               </blockquote>
               <hr/>
               <b>
                (Datum: 20. Juli 2015)
               </b>
               <br/>
               Borreliose-Nachrichten,
               <a href="http://www.borreliose-nachrichten.de/auswertung-unserer-umfrage-unter-betroffenen/">
                <b>
                 Auswertung unserer Umfrage unter Betroffenen
                </b>
               </a>
               , Stand: 14.7.2015
               <p>
                Wenn Sie selbst an dieser Umfrage teilnehmen möchten, klicken Sie
                <a href="http://www.borreliose-nachrichten.de/umfrage/">
                 hier
                </a>
                .
               </p>
               <p>
               </p>
               <table>
                <tr>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    <a href="http://www.borreliose-nachrichten.de/auswertung-unserer-umfrage-unter-betroffenen/">
                     <img alt="Zeit ist nach Beschwerdebeginn bis zur Diagnose" height="105" src="literatur/borreliose-nachrichten/11auuuub010.png" width="187"/>
                    </a>
                    <br/>
                    Wieviel Zeit ist nach Beschwerdebeginn bis zur Diagnose "Borreliose" vergangen?
                    <p>
                     <a href="http://www.borreliose-nachrichten.de/auswertung-unserer-umfrage-unter-betroffenen/">
                      <img alt="Gang- und Greifunsicherheit" height="105" src="literatur/borreliose-nachrichten/11auuuub034.png" width="187"/>
                     </a>
                     <br/>
                     Gang- und Greifunsicherheit
                    </p>
                    <p>
                     <a href="http://www.borreliose-nachrichten.de/auswertung-unserer-umfrage-unter-betroffenen/">
                      <img alt="Wahrnehmungs- und Orietierungsstoerungen" height="105" src="literatur/borreliose-nachrichten/11auuuub050.png" width="187"/>
                     </a>
                     <br/>
                     Konzentrations-, Denk-, Wahrnehmungs- oder Orientierungsstörung
                    </p>
                    <p>
                     <a href="http://www.borreliose-nachrichten.de/auswertung-unserer-umfrage-unter-betroffenen/">
                      <img alt="brain fogn" height="105" src="literatur/borreliose-nachrichten/11auuuub054.png" width="187"/>
                     </a>
                     <br/>
                     "Nebel" im Kopf / demenzähnliche Symptome
                    </p>
                    <p>
                    </p>
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Anzahl der Befragten: 863
                    <ul>
                     <li>
                      Bei 783 ( 90,73% ) kam es trotz antibiotischer Behandlung zu Beschwerde-Rückfällen.
                     </li>
                     <li>
                      <b>
                       703 ( 81,46% ) haben nicht im 1. Arztkontakt die Diagnose Borreliose erhalten.
                      </b>
                     </li>
                     <li>
                      840 ( 97,33% ) der 863 befragten Erkrankten ist das Auftreten der Symptome in Schüben mit symptom-armen Intervallen in individuell unterschiedlicher Länge bekannt.
                     </li>
                     <li>
                      846 ( 98,03% ) kennen die Symptome Erschöpfung, Leistungsverlust, fehlende Ausdauer / Kondition.
                     </li>
                     <li>
                      756 ( 87,60% ) kennen das Symptom Gelenkschmerz / -schwellung der Arme / Hände / Finger.
                     </li>
                     <li>
                      757 ( 87,72% ) kennen das Symptom Gelenkschmerz/ -schwellung der Beine / Füße.
                     </li>
                     <li>
                      794 ( 92,00% ) kennen das Symptom Rücken- und Schulterschmerzen.
                     </li>
                     <li>
                      794 ( 92,00% ) der 863 kennen das Symptom Kopf- und Nackenschmerzen mit Steifigkeit.
                     </li>
                     <li>
                      789 ( 91,43% ) kennen das Symptom Brennen, Stechen, Kribbeln an unterschiedlichen Körperstellen.
                     </li>
                     <li>
                      717 ( 83,08% ) kennen das Symptom Sehstörungen, Schleier / Schlieren-Sehen, entzündliche Augenveränderungen.
                     </li>
                     <li>
                      656 ( 76,01% ) kennen das Symptom Hörstörungen, Pfeifen, Rauschen oder Brummen, Tinnitus.
                     </li>
                     <li>
                      700 ( 81,11% ) kennen das Symptom Taubheitsgefühle / Lähmungserscheinungen.
                     </li>
                     <li>
                      776 ( 89,92% ) kennen das Symptom situations-unangemessenes Frieren oder Schwitzen, verändertes Temperaturempfinden.
                     </li>
                     <li>
                      <b>
                       718 ( 83,20% ) kennen das Symptom Gang- und Greifunsicherheit.
                      </b>
                     </li>
                     <li>
                      710 ( 82,27% ) der  863 Befragten kennen das Symptom Störungen der Feinmotorik / Koordinationsstörungen.
                     </li>
                     <li>
                      721 ( 83,55% ) der  863  Befragten kennen das Symptom nächtliches Schwitzen.
                     </li>
                     <li>
                      648 ( 75,09% ) kennen das Symptom nächtlicher Harndrang.
                     </li>
                     <li>
                      785 ( 90,96% ) kennen das Symptom muskelkater-ähnliche Gefühle ohne vorherige Belastung.
                     </li>
                     <li>
                      661 ( 76,59% ) kennen das Symptom Blasen- und sexuelle Funktionsstörung.
                     </li>
                     <li>
                      805 ( 93,28% ) kennen das Symptom Schlafstörungen (zu viel bzw. zu wenig / schlechtes Ein- und Durchschlafen).
                     </li>
                     <li>
                      722 ( 83,66% ) kennen das Symptom Schwindel.
                     </li>
                     <li>
                      <b>
                       805 ( 93,28% ) kennen das Symptom Konzentrations-, Denk-, Wahrnehmungs- oder Orientierungsstörung.
                      </b>
                     </li>
                     <li>
                      780 ( 90,38% ) kennen das Symptom Wortfindungsstörungen.
                     </li>
                     <li>
                      <b>
                       705 ( 81,69% ) kennen das Symptom "Nebel" im Kopf / demenz-ähnliche Symptome.
                      </b>
                     </li>
                     <li>
                      636 ( 73,70% ) kennen psychiatrische Symptome.
                     </li>
                     <li>
                      701 ( 81,23% ) kennen das Symptom Kurzatmigkeit  und Atemnot bei nur geringer Belastung.
                     </li>
                     <li>
                      589 ( 68,25% ) kennen das Symptom Atemwegsinfekte.
                     </li>
                     <li>
                      745 ( 86,33% ) kennen Herz-Kreislauf-Symptome, Blutdrucksteigerungen, Herzrhythmusstörungen, Herzklopfen.
                     </li>
                     <li>
                      718 ( 83,20% ) kennen Magen-Darm-Symptome.
                     </li>
                     <li>
                      636 ( 73,70% ) kennen das Symptom plötzliche Gewichtsveränderungen, Zu-/Abnahme ohne Änderung der Ernährung.
                     </li>
                     <li>
                      679 ( 78,68% ) kennen Hautsymptome  -  Juckreiz, Veränderungen etc.
                     </li>
                     <li>
                      481 ( 55,74% ) kennen das Symptom Haarausfall.
                     </li>
                    </ul>
                   </font>
                  </font>
                 </td>
                </tr>
               </table>
               <hr/>
               <b>
                (Datum: 13. Juli 2015)
               </b>
               <br/>
               Michael J Cook,
               <b>
                <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278789/">
                 Lyme borreliosis: a review of data on transmission time after tick attachment
                </a>
               </b>
               , Int J Gen Med. 2015; 8: 1 - 8. Published online 2014 Dec 19. doi:  10.2147/IJGM.S73791, PMCID: PMC4278789
               <br/>
               <table>
                <tr>
                 <td valign="top">
                  <font size="-2">
                   <a href="literatur/cook_transmission_after_attachment_tab.pdf">
                    <img src="literatur/cook_transmission_after_attachment_tab_tmb.png"/>
                   </a>
                   <br/>
                   click on figure to enlarge
                   <br/>
                   <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278789/">
                    Source
                   </a>
                  </font>
                 </td>
                 <td valign="top">
                  <font size="-2">
                   Conclusion:
                   <br/>
                   "The claims that removal of ticks within 24 hours or 48 hours of attachment will effectively prevent LB are not supported by the published data, and the minimum tick attachment time for transmission of LB in humans has never been established.
                   <p>
                    The definitive experimental data indicate transmission of LD spirochetes in &lt;16 hours and frequently in &lt;24 hours. No studies have been carried out to characterize transmission with attachment times of &lt;16 hours and some did not report any data for &lt;36 hours. The animal studies, however, did not comprehend significant variables such as the presence of spirochetes within the salivary glands at the start of feeding, nor the effect of delayed attachment once a tick adheres to a host. Both of these will reduce the time for infectious spirochetes to invade the host compared to the model that requires a change from dormancy to active migration from the midgut to the salivary glands and then to the host. Also, co-feeding and partial feeding of ticks with displacement from companion animals to humans must be considered a factor for rapid transmission of LD. "
                   </p>
                  </font>
                 </td>
                </tr>
               </table>
               <p>
               </p>
               <hr/>
               <b>
                (Datum: 19. Mai 2015)
               </b>
               <br/>
               Angela Senders, Helané Wahbeh, Rebecca Spain, and Lynne Shinto, "
               <a href="http://dx.doi.org/10.1155/2012/567324">
                <b>
                 Mind-Body Medicine for Multiple Sclerosis
                </b>
                : A Systematic Review
               </a>
               ", Autoimmune Diseases Volume 2012 (2012), Article ID 567324, 12 pages
               <p>
                Discussion:
                <br/>
                The objective of this paper was to assess the published evidence for using mind-body techniques for symptom management of multiple sclerosis. 4 high quality studies showed that
               </p>
               <p>
               </p>
               <table border="1">
                <tr>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Study
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Intervention
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Helpful for
                   </font>
                  </font>
                 </td>
                </tr>
                <tr>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Ghafari et al. 2009
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Relaxation
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Quality of Life
                   </font>
                  </font>
                 </td>
                </tr>
                <tr>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Grossmann et al. 2010
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Mindfulness-based stress reduction
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Depression
                    <br/>
                    Anxiety
                    <br/>
                    Fatigue
                    <br/>
                    Quality of Life
                   </font>
                  </font>
                 </td>
                </tr>
                <tr>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Oken et al. 2004
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Yoga
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Fatigue
                   </font>
                  </font>
                 </td>
                </tr>
                <tr>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    McClurg et al. 2006
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Biofeefback
                   </font>
                  </font>
                 </td>
                 <td valign="top">
                  <font face="verdana">
                   <font size="-2">
                    Bladder Incontinence
                   </font>
                  </font>
                 </td>
                </tr>
                <table>
                 <p>
                  According to this review, mind-body medicine had no effect on
                 </p>
                 <ul>
                  <li>
                   disability,
                  </li>
                  <li>
                   executive function, or
                  </li>
                  <li>
                   other cognitive measures.
                  </li>
                 </ul>
                 The remaining studies demonstrated benefit for balance and daily pain intensity, but had no effect on executive function, mood, or disability -although many methodological inadequacies were identified.
                 <p>
                  This paper demonstrates that studies of mind-body techniques for treating MS symptoms are feasible, and that more stringently designed, well-executed research is needed in this population to determine efficacy.
                 </p>
                 <p>
                  Literature
                  <br/>
                  S. Ghafari, F. Ahmadi, M. Nabavi, K. Anoshirvan, R. Memarian, and M. Rafatbakhsh, "Effectiveness of applying progressive muscle relaxation technique on quality of life of patients with multiple sclerosis," Journal of Clinical Nursing, vol. 18, no. 15, pp. 2171-2179, 2009.
                 </p>
                 <p>
                  P. Grossman, L. Kappos, H. Gensicke et al., "MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial," Neurology, vol. 75, no. 13, pp. 1141-1149, 2010.
                 </p>
                 <p>
                  B. S. Oken, S. Kishiyama, D. Zajdel et al., "Randomized controlled trial of yoga and exercise in multiple sclerosis," Neurology, vol. 62, no. 11, pp. 2058-2064, 2004.
                 </p>
                 <p>
                  D. McClurg, R. G. Ashe, K. Marshall, and A. S. Lowe-Strong, "Comparison of pelvic floor muscle training, electromyog- raphy biofeedback, and neuromuscular electrical stimulation for bladder dysfunction in people with multiple sclerosis: a randomized pilot study," Neurourology and Urodynamics, vol. 25, no. 4, pp. 337-348, 2006.
                 </p>
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 28. April 2015)
                 </b>
                 <br/>
                 <a href="http://lymeconnection.org/">
                  Lyme Connection
                 </a>
                 , "
                 <a href="http://lymeconnection.org/news_publications/meet_the_lyme_disease_experts.html">
                  Meet the Lyme Disease Experts:
                  <b>
                   Dr. Richard Horowitz
                  </b>
                 </a>
                 " (medical director,
                 <a href="http://www.cangetbetter.com/medical-center">
                  Hudson Valley Healing Arts Center
                 </a>
                 ), 2015 (in
                 <a href="literatur/Lyme_Expert_Richard_Horowitz.pdf">
                  cache
                 </a>
                 ).
                 <blockquote>
                  "People who come to see me who have chronic Lyme disease usually have multiple overlapping factors keeping them ill. I've labeled this Lyme-MSIDS:
                  <i>
                   Multiple Systemic Infectious Disease Syndrome
                  </i>
                  . MSIDS is a 16-point model.
                  <p>
                   First, the model is broken down into the three I's: 
 1. Infection, 
 2. Immune dysfunction, and 
 3. Inflammation.
                  </p>
                  <ol>
                   <li>
                    Infection is then broken down into four different subtypes:
                    <ul>
                     <li>
                      bacterial,
                     </li>
                     <li>
                      viral,
                     </li>
                     <li>
                      parasitic, and
                     </li>
                     <li>
                      Candida yeast infections,
                     </li>
                    </ul>
                    and many patients have several of these infections simultaneously, keeping them ill.
                    <p>
                     Bacterial infections include Lyme disease and other Borrelia species as well as other tick-borne infections like
                    </p>
                    <ul>
                     <li>
                      Anaplasma,
                     </li>
                     <li>
                      Ehrlichia,
                     </li>
                     <li>
                      Bartonella,
                     </li>
                     <li>
                      Mycoplasma species,
                     </li>
                     <li>
                      Q fever,
                     </li>
                     <li>
                      Rocky Mountain spotted fever,
                     </li>
                     <li>
                      tularemia and
                     </li>
                     <li>
                      Brucella.
                     </li>
                    </ul>
                    Then you've got viral infections showing up in ticks, like the
                    <ul>
                     <li>
                      Heartland,
                     </li>
                     <li>
                      Powassan, and
                     </li>
                     <li>
                      the newly discovered Bourbon virus.
                     </li>
                    </ul>
                    We don't see these viruses a lot, but we do occasionally see a reactivation of other viruses like EBV, CMV and HHV-6.
                    <p>
                     I think the Powassan virus is going to be a big problem in the future.  The Powassan infection rate in ticks in the Hudson Valley has risen from 1-2% to 5-6% in the past several years. It has a mortality rate between 15-30% and can be transmitted within 15 minutes of a tick bite. We therefore really need to emphasize prevention!"
                    </p>
                    <p>
                    </p>
                   </li>
                   <li>
                    The second part of the MSIDS model, immune dysfunction, is very important because there are often autoimmune manifestations present, due to an overstimulated immune system from Lyme.
                    <p>
                     ...
                    </p>
                   </li>
                   <li>
                    The third part of the MSIDS model, inflammation, is a key component that underlies many chronic disease states, and helps us to understand persistent symptoms in Lyme disease....
                    <p>
                    </p>
                   </li>
                   <li>
                    Other essential points on the MSIDS map that are important to address are hormonal dysfunction with POTS/dysautonomia. I see a lot of hormonal problems involving the adrenals, thyroids, and sex hormones. The same inflammatory cytokines we have been discussing can affect the pituitary and the HP axis (hypothalamus-pituitary axis) subsequently lowering the adrenals, affecting the thyroid, or lowering testosterone in young men. If the hormones are affected, people will not feel better until the hormonal imbalances are properly addressed. ...
                    <p>
                     ... Infections are therefore affecting the underlying terrain of the body causing free radical oxidative damage to the cells, and causing imbalances in hormones and the autonomic nervous system. It's not sufficient to just treat the infections. We must repair the damage from the infections to get a person back into balance.
                    </p>
                    <p>
                     ... During the history and physical, it's important to discuss the chief complaints in order to create a differential diagnosis, and focus testing and treatment on those symptoms. The Horowitz Lyme MSIDS Questionnaire is on page 34 in
                     <a href="http://www.cangetbetter.com/">
                      my book
                     </a>
                     , and has a list of the most frequent symptoms seen with Lyme. This was formulated from a
                     <a href="http://www.ilads.org/lyme/B_guidelines_12_17_08.pdf">
                      questionnaire
                     </a>
                     that was developed by Dr. Burrascano years ago. We expanded the original questionnaire and weighted the answers, adding sections to evaluate the risk of Lyme and associated co-infections. ... Health care providers and patients can therefore use it [the MSIDS Questionnaire] with confidence as an initial screening tool to evaluate the risk of having a tick-borne disorder. This would be especially useful in the case of a patient who comes in with a medical illness such as
                    </p>
                    <ul>
                     <li>
                      chronic fatigue syndrome (CFS),
                     </li>
                     <li>
                      fibromyalgia,
                     </li>
                     <li>
                      an autoimmune disorder like RA or multiple sclerosis (MS), or
                     </li>
                     <li>
                      a psychiatric illness like depression or anxiety.
                     </li>
                    </ul>
                    All of these illnesses can be caused by Lyme, which is known as the "great imitator". The questionnaire would reveal whether we are dealing with a multi-systemic illness, which is classic for Lyme disease. Then you add up the four sections of the questionnaire, and if their score is over 46, there's statistically a good chance that they suffer from Lyme disease.
                    <p>
                     ...  If the patient complains of tingling, numbness and burning sensations (suggestive of neuropathy), I then would check for
                    </p>
                    <ul>
                     <li>
                      vitamin deficiencies (B12, folic acid),
                     </li>
                     <li>
                      heavy metal toxicity (mercury, lead, arsenic),
                     </li>
                     <li>
                      thyroid and hormonal disorders,
                     </li>
                     <li>
                      immune deficiency, as well as checking for
                     </li>
                     <li>
                      autoimmune markers (anti-ganglioside antibodies) against the nerves. These antibodies are seen in patients with autoimmune disorders with demyelination, and also in POTS/dysautonomia, implying the need for immune support, with treatment like IVIG (IV immunoglobulin therapy).
                     </li>
                    </ul>
                    <p>
                     ... Mind-body techniques and spirituality can be used as a tool to help heal patients with chronic disease. In the last chapter of my book I discuss some of the scientific studies on meditation. There's a lot of evidence that integrating meditation into a healing process can be helpful. Earlier on, we talked about how some inflammatory cytokines are causing people to remain ill with fatigue, joint pain, muscle pain, sleep disorders, memory problems, and psychiatric issues like anxiety and depression. With meditation, you can lower inflammatory cytokines. ...
                    </p>
                   </li>
                  </ol>
                  <p>
                   ... patients who have had this disease for many years have difficulty eradicating every last Borrelia organism (and parasites like Babesia). However, I don't feel it's necessary to eliminate every last organism. We live with many different bacteria and parasites. We need however to get the immune system to work properly and find a homeostatic balance with these organisms.
                  </p>
                  <p>
                   ...  I've used the MSIDS model effectively in thousands of patients who have been sick for a long time. The majority of people who come to see me have seen ten to 20 doctors before they come to my medical practice. I do help the majority of these people get better; some are a little bit better, some are moderately better, some are significantly better, and some become symptom free. The most important point in helping these patients is to look for points on the MSIDS model that have not been previously diagnosed and/or adequately treated ..."
                  </p>
                  <p>
                   <a href="http://lymeconnection.org/news_publications/meet_the_lyme_disease_experts.html">
                    more
                   </a>
                   , in
                   <a href="literatur/Lyme_Expert_Richard_Horowitz.pdf">
                    cache
                   </a>
                   .
                  </p>
                 </blockquote>
                 <hr/>
                 <b>
                  (Datum: 25. April 2015)
                 </b>
                 <br/>
                 Cameron D,
                 <b>
                  <a href="http://danielcameronmd.com/relying-on-a-negative-lyme-disease-test-can-prove-deadly/">
                   Relying on a Negative Lyme Disease Test Can Prove Deadly
                  </a>
                 </b>
                 ,
                 <a href="http://danielcameronmd.com/">
                  Daniel Cameron
                 </a>
                 , April 21, 2015.
                 <blockquote>
                  "... a paper published in the March issue of
                  <a href="http://www.cardiovascularpathology.com">
                   Cardiovascular Pathology
                  </a>
                  , reports the adolescent, in fact, had died from Lyme carditis. [Esther C. Yoon, Eric Vail, George Kleinman, Patrick A. Lento, Simon Li, Guiqing Wang, Ronald Limberger, John T. Fallon,
                  <a href="http://www.cardiovascularpathology.com/article/S1054-8807(15)00025-3/fulltext">
                   Lyme disease: a case report of a 17-year-old male with fatal Lyme carditis
                  </a>
                  , March 21, 2015]
                  <p>
                   According to the report, the ELISA and Western blot IgM tests, conducted as part of the autopsy, were positive for Borrelia burgdorferi, the agent that causes Lyme disease. Additional tests, including PCR (polymerase chain reaction) and immonohistochemistry (ICH) staining found Borrelia spirochete present in the patient's liver, heart, lung, and brain tissues.
                  </p>
                  <p>
                   "The findings support B. burgdorferi as the causative agent for his fulminant carditis and that the patient suffered fatal Lyme carditis," the authors write.
                  </p>
                  <p>
                   Joseph Elone, a high school honor roll student, had aspired to be an environmental engineer and loved the outdoors. He had just returned home from a two-week stay at a camp in Rhode Island, a state that is endemic for Lyme disease, when he fell ill. According to his parents, Joseph initially developed a mild cough, occasional fevers, a sore throat, malaise, headaches and body aches.
                   <b>
                    Serology tests for Lyme disease and Anaplasmosis were negative.
                   </b>
                   "
                  </p>
                 </blockquote>
                 <hr/>
                 <b>
                  (Datum: 25. April 2015)
                 </b>
                 <br/>
                 Molins CR1, Ashton LV2, Wormser GP3, Hess AM4, Delorey MJ1, Mahapatra S2, Schriefer ME1, Belisle JT2.
                 <br/>
                 [1 = Division of Vector-Borne Diseases, Centers for Disease Control and Prevention,
                 <br/>
                 2 = Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins,
                 <br/>
                 3 = Department of Medicine, Division of Infectious Diseases, New York Medical College, Valhalla, New York,
                 <br/>
                 4 = Department of Statistics, Colorado State University, Fort Collins],
                 <p>
                  <b>
                   <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Molins+CR%2C+Ashton+LV%2C+Wormser+GP%2C+Hess+AM%2C+Delorey+MJ%2C+Mahapatra+S%2C+Schriefer+ME%2C+Belisle+JT.+Development+of+a+Metabolic+Biosignature+for+Detection+of+Early+Lyme+Disease.+Clin+Infect+Dis.+2015+Mar+11">
                    Development of a Metabolic Biosignature for Detection of Early Lyme Disease
                   </a>
                  </b>
                  , Clin Infect Dis. 2015 Mar 11.
                 </p>
                 <blockquote>
                  <i>
                   Background
                  </i>
                  : Early Lyme disease patients often present to the clinic prior to developing a detectable antibody response to Borrelia burgdorferi, the etiologic agent. Thus, existing 2-tier serology-based assays yield low sensitivities (29%-40%) for early infection. The lack of an accurate laboratory test for early Lyme disease contributes to misconceptions about diagnosis and treatment, and underscores the need for new diagnostic approaches.
                  <p>
                   <i>
                    Methods
                   </i>
                   : Retrospective serum samples from patients with early Lyme disease, other diseases, and healthy controls were analyzed for small molecule metabolites by liquid chromatography-mass spectrometry (LC-MS). A metabolomics data workflow was applied to select a biosignature for classifying early Lyme disease and non-Lyme disease patients. A statistical model of the biosignature was trained using the patients' LC-MS data, and subsequently applied as an experimental diagnostic tool with LC-MS data from additional patient sera.
                  </p>
                  <p>
                   Metabolic biosignature development selected 95 molecular features that distinguished early Lyme disease patients from healthy controls. Statistical modeling reduced the biosignature to 44 molecular features, and correctly classified early Lyme disease patients and healthy controls with
                  </p>
                  <ul>
                   <li>
                    a sensitivity of 88% (84%-95%), and
                   </li>
                   <li>
                    a specificity of 95% (90%-100%). Importantly,
                   </li>
                   <li>
                    the metabolic biosignature correctly classified 77%-95% of the of serology negative Lyme disease patients.
                   </li>
                  </ul>
                  <p>
                   <i>
                    Conclusion
                   </i>
                   : The data provide proof-of-concept that metabolic profiling for early Lyme disease can achieve significantly greater (p&lt;0.0001) diagnostic sensitivity than current two-tier serology, while retaining high specificity.
                  </p>
                 </blockquote>
                 See also:
                 <a href="http://www.niaid.nih.gov/topics/lymeDisease/Pages/NewDiagnosis.aspx">
                  New Approach to Diagnosing Lyme Disease Shows Promise
                 </a>
                 , National Institute of Allergy and Infectious Diseases, April 17, 2015.
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 24. März 2015)
                 </b>
                 <br/>
                 <b>
                  <a href="shgs/corryw/index.htm">
                   Corry Welker
                  </a>
                  , Rundmail
                  <a href="shgs/corryw/Rundm_60-2014.pdf">
                   60
                  </a>
                 </b>
                 (12 Seiten, 17. März 2014),
                 <b>
                  <a href="shgs/corryw/Rundmail_61,3-15.pdf">
                   61
                  </a>
                 </b>
                 (30 Seiten, 4. März 2015)
                 <br/>
                 Ein kleiner Auszug
                 <ol>
                  <li>
                   Nathalie Danielle van Burgel,
                   <a href="https://openaccess.leidenuniv.nl/handle/1887/21004">
                    <b>
                     Host-pathogen interactions
                    </b>
                    in Lyme disease and their
                    <b>
                     application in diagnostics
                    </b>
                   </a>
                   , Doctoral Thesis, Leiden University Medical Center, Leiden University, Issue Date: 2013-05-29.
                   <a href="https://openaccess.leidenuniv.nl/bitstream/handle/1887/21004/Proefschrift%2bvan%2bBurgel-Lyme.pdf?sequence=17">
                    full text
                   </a>
                   (in
                   <a href="literatur/Burgel_LUMC_2013.pdf">
                    cache
                   </a>
                   ).
                   <p>
                   </p>
                  </li>
                  <li>
                   Daniel J Cameron (International Lyme and Associated Diseases Society), Lorraine B Johnson (LymeDisease.org), and Elizabeth L Maloney,
                   <a href="http://informahealthcare.com/doi/pdfplus/10.1586/14787210.2014.940900">
                    <b>
                     Evidence assessments and guideline recommendations
                    </b>
                    in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease
                   </a>
                   , Expert Review of Anti-infective Therapy Vol.12, No.9:1103-1135, Sep 1, 2014.
                   <blockquote>
                    The guidelines address three clinical questions
                    <ol>
                     <li>
                      the usefulness of antibiotic prophylaxis for known tick bites,
                     </li>
                     <li>
                      the effectiveness of erythema migrans treatment and
                     </li>
                     <li>
                      the role of antibiotic retreatment in patients with persistent manifestations of Lyme disease.
                     </li>
                    </ol>
                    Healthcare providers who evaluate and manage patients with Lyme disease are the intended users of the new ILADS guidelines, which replace those issued in 2004 (
                    <a href="http://www.ncbi.nlm.nih.gov/pubmed/15581390">
                     Exp Rev Anti-infect Ther 2004;2:S1-13
                    </a>
                    ). These clinical practice guidelines are intended to assist clinicians by presenting evidence-based treatment recommendations, which follow the Grading of Recommendations Assessment, Development and Evaluation system.
                   </blockquote>
                   <p>
                   </p>
                  </li>
                  <li>
                   New York State Assembly BILL:  An act to amend the public health law, in relation to the identification, charging, reporting and investigation of
                   <b>
                    charges of professional misconduct
                   </b>
                   by health care professionals, BILL NUMBER:
                   <a href="http://assembly.state.ny.us/leg/?default_fld=&amp;bn=A07558&amp;term=2013&amp;Summary=Y&amp;Actions=Y&amp;Votes=Y&amp;Memo=Y&amp;Text=Y">
                    A7558B
                   </a>
                   , 5 December 2014.
                   <blockquote>
                    Prohibits the investigation of any claim of medical professional misconduct based solely on treatment that is not universally accepted by the medical
 profession.
                   </blockquote>
                  </li>
                  <li>
                   Vermont General Assembly, Act No. 134 (H.123) Health; population health:
                   <b>
                    <a href="http://legislature.vermont.gov/bill/status/2014/H.0123">
                     An act relating to Lyme disease and other tick-borne illnesses
                    </a>
                   </b>
                   (
                   <a href="http://legislature.vermont.gov/assets/Documents/2014/Docs/ACTS/ACT134/Act134%20Act%20Summary.pdf">
                    text
                   </a>
                   ), 2013 - 2014 Session.
                   <blockquote>
                    This act requires the Vermont State Board of Medical Practice, the Vermont Board of
 Osteopathic Physicians, the Office of Professional Regulation, and the Vermont Board of
 Nursing to issue a policy statement to physicians, naturopathic physicians, and advanced
 practice registered nurses, respectively. ... The policy statement must ... state that precluding errors, omissions, or other
 unprofessional conduct, the respective Board or Office of Professional Regulation will
 not pursue disciplinary action against a physician, naturopathic physician, or advanced
 practice registered nurse solely for use of medical care recognized by the guidelines of
 the Centers for Disease Control and Prevention, Infectious Diseases Society of America,
 or International Lyme and Associated Diseases Society for the treatment of a patient's
 Lyme disease or other tick-borne illness symptoms.
                   </blockquote>
                   <p>
                   </p>
                  </li>
                  <li>
                   Aus der Praxis der Norddeutschen Schlichtungsstelle:
                   <a href="http://www.norddeutsche-schlichtungsstelle.de/die-nicht-rechtzeitig-diagnostizierte-lyme-borreliose/">
                    Die
                    <b>
                     nicht rechtzeitig diagnostizierte
                    </b>
                    Lyme-Borreliose
                   </a>
                   <blockquote>
                    Seitens des verantwortlichen Klinikarztes wurde zu diesen Vorwürfen Stellung genommen. Bei Aufnahme sei eine korrekte Anamnese und klinische Befunderhebung vorgenommen worden. Von einem Insektenstich oder einer Zeckenbißverletzung sei nie die Rede gewesen. Auch seien in den Behandlungsunterlagen zweimal "keine Beschwerden" eingetragen worden. Klinische Hinweise auf eine Borreliose hätten seinerzeit nicht bestanden.
                    <p>
                     Der von der Schlichtungsstelle beauftragte Gutachter stellte fest: Eine Borreliose im Stadium I hat zweifelsfrei vorgelegen, dies sei
                    </p>
                    <ul>
                     <li>
                      aus den klinischen und
                     </li>
                     <li>
                      Laborbefunden sowie
                     </li>
                     <li>
                      aus der Wirksamkeit der Antibiotikatherapie
                     </li>
                    </ul>
                    abzuleiten. Es sei sehr wahrscheinlich, daß die zu Beginn des Klinikaufenthaltes aufgetretene allgemeine Symptomatik in Verbindung mit dem dokumentierten Hautbefund der rechten Wade bereits der Borreliose entsprach. Allerdings sei fraglich, ob zu diesem Zeitpunkt bereits die Borreliosereaktionstests positiv gewesen wären.
                    <p>
                     Für die Beurteilung sei davon auszugehen, daß zu Beginn der Kurbehandlung ein Insektenstich an der Wade vorgelegen hat, der von der Patientin bemerkt und von der behandelnden Schwester bestätigt wurde.
                    </p>
                    <p>
                     Das Vorliegen eines "Insektenstiches" gefolgt von der beschriebenen Rötung einhergehend mit Juckreiz seit 3 Tagen sowie allgemeinem Unwohlsein, Rücken- und Knieschmerzen hätten den behandelnden Klinikarzt veranlassen müssen, die Differentialdiagnose Borreliose in seine weiteren diagnostischen und therapeutischen Überlegungen einzubeziehen. Daß dies nicht erfolgt ist, ist als Diagnose- und demzufolge auch als Behandlungsfehler zu werten.
                    </p>
                    <p>
                     Dieser Fehler führte zu einer Verzögerung der Diagnostik und antibiotische Therapie um etwa sechs Wochen. Die in diesem Zeitraum bestehenden Beschwerden und Beeinträchtigungen durch die Borreliose sind dem ärztlichen Fehler anzulasten. Die Behandlung der Borreliose im Stadium I ist in der Regel kurativ, in Einzelfällen persistieren unspezifische Allgemeinsymptome wie Müdigkeit und Arthalgien für einige Wochen. Echte Therapieversager sind sehr selten. Somit sei auch für diesen Fall davon auszugehen, daß nach rechtzeitigem Therapiebeginn mit hoher Wahrscheinlichkeit mit einem umgehenden Abklingen der Symptomatik zu rechnen gewesen wäre.
                    </p>
                   </blockquote>
                  </li>
                 </ol>
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 20. November 2014)
                 </b>
                 <br/>
                 Robert C. Bransfield, M.D.,
                 <a href="http://www.mentalhealthandillness.com/NPLDA.xls">
                  <b>
                   The Neuropsychiatric Lyme Assessment
                  </b>
                 </a>
                 (in
                 <a href="literatur/bransfield_neuropsychiatric_lyme_disease_assessment.pdf">
                  cache
                 </a>
                 )
                 <p>
                  <i>
                   Excerpt
                  </i>
                 </p>
                 <ul>
                  <li>
                   Cognitive Symptoms
 The cognitive symptoms associated with Lyme disease can best be described as a slowness, weakness and inaccuracy of associations. Sample questions are included.
                   <ul>
                    <li>
                     Attention Span (Perception): The ability to focus and maintain attention on the environment
                     <ul>
                      <li>
                       Sustained Attention
                       <br/>
                       Can you sustain your attention upon significant events in your environment?
                      </li>
                      <li>
                       Allocation of Attention
                       <br/>
                       Can you prioritize and allocate your attention upon the most significant perceptions of your environment?
                      </li>
                      <li>
                       Distracted by Frustration
                       <br/>
                       Do you easily lose your capacity for attention when frustrated?
                      </li>
                      <li>
                       Distracted by Hyperacuity
                       <br/>
                       Are you easily distracted from excessive sensitivity to any of the following: *Auditory - Visual - Tactile - Olfactory
                      </li>
                     </ul>
                    </li>
                   </ul>
                  </li>
                  <li>
                   <i>
                    Memory
                   </i>
                   (*Working Memory, *Working Spatial Memory, Memory Retrieval (*Slowness))
                  </li>
                  <li>
                   <i>
                    Processing
                   </i>
                   (*Reading Comprehension, *Auditoty Comprehension, Sound Localization, *Spatial Perceptual Distortions (Microscopia, ...), *Optic Ataxia, Transposition of Laterality, *L-R-Confusion, *Calculation, *Fluency of Speech,  *Stuttering, Slurred Speech, Fluency of Written Language, *Handwriting, Depersonalization, Derealization, Agnosia, Apraxia)
                  </li>
                  <li>
                   <i>
                    Imagery
                   </i>
                   (Capacity for visual imagery, *Intrusive Images, *Hypnagogic Hallucinations, Vivid Nightmares, Illusions, Auditory - Visual - Smelling - Feeling Hallucinations)
                  </li>
                  <li>
                   <i>
                    Thought Processing / Exec Function
                   </i>
                   (*Brain Fog Sensation, *Prioretizing Multiple Tasks, *Concentration on Multiple Tasks)
                  </li>
                  <li>
                   <i>
                    Mood Symptoms
                   </i>
                  </li>
                  <li>
                   <i>
                    Behavioral Symptoms
                   </i>
                   (Disinhibition, Exaggerated Startle Reflex, Axplosive Anger, Sui-Homi-cidal, Accident Prone, Decreased Social Funtioning, Decreased Job/School Performance, MArital/Family Problems, Substance Abuse, Legal Difficulties, Dissociative Episodes, Compensatory Compulsions, Dropping Objects, Crying Spells)
                  </li>
                  <li>
                   <i>
                    Psychiatric Symptoms
                   </i>
                   (Depression, *Rapid Cycling Bipolar, Panic Disorder, Obsessive-Compulsive Disoirder, Social Phobia, Generalized Anxiety, Post Traumatic Stress Disorder)
                  </li>
                  <li>
                   <i>
                    Vegetative Functioning
                   </i>
                   <ul>
                    <li>
                     *Impaired Sleep Wakefulness Cycle
                    </li>
                    <li>
                     *Eating Disorder
                    </li>
                    <li>
                     Sexual
                    </li>
                    <li>
                     *Temperturre Control
                    </li>
                   </ul>
                  </li>
                  <li>
                   <i>
                    Neurological
                   </i>
                   <ul>
                    <li>
                     Headaches (General Headaches, *Cervical Radioculopathy, Migraine, Orgasm Migraine, TMJ, Tension, Cluster, Sinus)
                    </li>
                    <li>
                     *Cranial Nerves (*Photophobia, *Conjunctivitis, *Bell's Palsy,
                    </li>
                    <li>
                     Seizures (*Complex Partial)
                    </li>
                    <li>
                     Other Neurological (Numbness, Tingling, Sensory Loss, Burning, Static Electric Sensation, Crawling Sensation under Skin, Stabbing Sensation, Paresis, Tremor, Twitching, Muscle Tightness, Muscle Discomfort (restless leg), Myoclonic Jerks, Torticollis, Tourette's Syndrome, Ataxia, Fainting, Hemiated Disks, Spasticity, Meningismus, Rhomberg)
                    </li>
                   </ul>
                  </li>
                  <li>
                   <i>
                    Other Physical Symptoms
                   </i>
                   <ul>
                    <li>
                     Musculosceletal (Joint: *Bone Pain)
                    </li>
                    <li>
                     Cardiac
                    </li>
                    <li>
                     Pulmonary/Upper Respiratory
                    </li>
                    <li>
                     Gastro-Intestinal
                    </li>
                    <li>
                     Genital, Urological
                    </li>
                    <li>
                     Autoimmune Symptoms
                    </li>
                    <li>
                     Fluctuation of Symptoms (*Herxheimer Reaction, *Progression of Symptoms, *Symptoms Fluctuations throughout the Day, Stress Increases Symptoms, Infectious Disease Increases Symptoms, 28 Day Cycle or Longer, Perimenstrual Relaps, Antibiotic Reduce Symptoms)
                    </li>
                    <li>
                     Babesiosis Screen
                    </li>
                    <li>
                     Ehrlichiosis Screen
                    </li>
                   </ul>
                  </li>
                  <li>
                   <i>
                    Treatment
                   </i>
                   (Psychiatric, Medical)
                  </li>
                 </ul>
                 (Notation: * = highly diagnostic significance)
                 <hr/>
                 <b>
                  (Datum: 14. November 2014)
                 </b>
                 <br/>
                 <a href="https://www.change.org/">
                  change.org
                 </a>
                 -Petition von Carl Tuttle,
                 <a href="https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf">
                  <b>
                   Calling for a Congressional investigation of the CDC, IDSA and ALDF
                  </b>
                 </a>
                 Carl Tuttle, 33 David Dr, Hudson, NH03051,
                 <br/>
                 Website:
                 <a href="http://home.comcast.net/~runagain/site/?/home/">
                  New Hampshire Lyme Misdiagnosis
                 </a>
                 <br/>
                 Carl Tuttle,
                 <a href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(12)70054-3/fulltext">
                  Lyme disease antiscience
                 </a>
                 , Letter to the Editor, The Lancet Infectious Diseases, Volume 12, Issue 5, Page 362, May 2012  (in
                 <a href="literatur/tuttle/Lyme%20disease%20antiscience_The%20Lancet%20Infectious%20Diseases.pdf">
                  cache
                 </a>
                 )
                 <br/>
                 The Tuttle family was featured on New Hampshire Chronicle's "Living with Lyme" with the program archived on their site in six segments (
                 <a href="http://www.wmur.com/new-hampshire-chronicle/Living-With-Lyme-Disease-Part-1-of-6/-/13383450/13200964/-/hmcs7b/-/index.html">
                  Part 1
                 </a>
                 ,
                 <a href="http://www.wmur.com/new-hampshire-chronicle/Living-With-Lyme-Disease-Part-2-of-6/-/13383450/13200954/-/i81agm/-/index.html">
                  Part 2
                 </a>
                 ,
                 <a href="http://www.wmur.com/new-hampshire-chronicle/Living-With-Lyme-Disease-Part-3-of-6/-/13383450/13200976/-/isorsn/-/index.html">
                  Part 3
                 </a>
                 ,
                 <a href="http://www.wmur.com/new-hampshire-chronicle/Living-With-Lyme-Disease-Part-4-of-6/-/13383450/13200966/-/jeda2y/-/index.html">
                  Part 4
                 </a>
                 ,
                 <a href="http://www.wmur.com/new-hampshire-chronicle/Living-With-Lyme-Disease-Part-5-of-6/-/13383450/13200936/-/k01rai/-/index.html">
                  Part 5
                 </a>
                 ,
                 <a href="http://www.wmur.com/new-hampshire-chronicle/Living-With-Lyme-Disease-Part-6-of-6/-/13383450/13200926/-/kkp9jt/-/index.html">
                  Part 6
                 </a>
                 )
                 <p>
                  Auszug aus der Begründung zur Petition
                 </p>
                 <blockquote>
                  <b>
                   Persistent Lyme infection
                  </b>
                  :
                  <a href="http://home.comcast.net/~runagain/Persistence%20of%20Lyme%20Disease.doc">
                   273 Peer-Reviewed Studies
                  </a>
                  (in
                  <a href="literatur/tuttle/Persistence%20of%20Lyme%20Disease.pdf">
                   cache
                  </a>
                  )
 
 After spending four years on this subject the following statement from a physician on the front lines treating the late stage Lyme epidemic for a quarter century rings true:
                  <i>
                   "In the fullness of time, the mainstream handling of chronic Lyme disease will be viewed as one of the most shameful episodes in the history of medicine because elements of academic medicine, elements of government and virtually the entire insurance industry have colluded to deny a disease."
                  </i>
                  We have studies proving persistent infection after antibiotic treatment for
                  <a href="http://www.ncbi.nlm.nih.gov/pubmed/20718718">
                   mice
                  </a>
                  ,
                  <a href="http://jcm.asm.org/content/38/6/2191.abstract?sid=9cb0475c-43f1-4b99-a789-21a90c441f96">
                   dogs
                  </a>
                  ,
                  <a href="http://www.ncbi.nlm.nih.gov/pubmed/15863289">
                   ponies
                  </a>
                  ,
                  <a href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0029914">
                   monkeys
                  </a>
                  ,
                  <a href="https://sites.google.com/site/marylandlyme/pets/cows">
                   cows
                  </a>
                  ,
                  <a href="http://www.ncbi.nlm.nih.gov/pubmed/8106639?dopt=Abstract">
                   iris biopsy
                  </a>
                  , and
                  <a href="http://www.ncbi.nlm.nih.gov/pubmed/8240439?dopt=Abstract">
                   ligamentous tissue
                  </a>
                  but if you perform a simple Yahoo search for the following statement, "There is no convincing scientific evidence that chronic Lyme exists" you will find the top search results are connected to "elements of academic medicine" involved in the denial of the late stage Lyme epidemic.
                  <p>
                   <b>
                    Seronegativity in Lyme borreliosis
                   </b>
                   :
                   <a href="http://www.lymeinfo.net/medical/LDSeronegativity.pdf">
                    103 Peer-Reviewed Studies
                   </a>
                   (in
                   <a href="literatur/tuttle/LDSeronegativity.pdf">
                    cache
                   </a>
                   )
                  </p>
                  There has been a combined effort on the part of the CDC, IDSA and ALDF to use the media for propagating the Lyme disease disinformation campaign following
                  <a href="http://en.wikipedia.org/wiki/Propaganda_model">
                   Chomsky's propaganda model
                  </a>
                  . They have used
                  <a href="http://www.change.org/petitions/medscape-remove-or-correct-barbara-johnson-s-misleading-lyme-disease-presentation">
                   Medscape
                  </a>
                  ,
                  <a href="http://home.comcast.net/~runagain/Family%20Practice%20News.doc">
                   Family Practice News
                  </a>
                  , The
                  <a href="http://home.comcast.net/~runagain/Letter%20to%20the%20editor%20NEJM.doc">
                   New England Journal of Medicine
                  </a>
                  ,
                  <a href="http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(12)70054-3/fulltext">
                   The Lancet Infectious Diseases
                  </a>
                  and now
                  <a href="http://home.comcast.net/~runagain/Circulation%20Journal.doc">
                   The American Heart Association
                  </a>
                  to spread the disinformation. This deliberate campaign is aimed at purposely confusing our medical community to keep case numbers artificially low by omitting the late stage of the disease entirely as there is absolutely no medical training whatsoever for the later stages of this disease (
                  <a href="http://www.urbandictionary.com/define.php?term=willful%20ignorance">
                   Willful Ignorance
                  </a>
                  ) so patients are often ping ponged though the medical community for years or decades before obtaining a late stage Lyme diagnosis.
                  <a href="http://home.comcast.net/~runagain/Nine%20Step%20Program.doc">
                   Nine Steps to Deny an Epidemic on a National Level 101
                  </a>
                  <p>
                   <b>
                    Congenital Transmission of Lyme
                   </b>
                   :
                   <a href="http://home.comcast.net/~runagain/Congenital%20Transmission%20of%20Lyme.doc">
                    28 Peer-Reviewed Studies
                   </a>
                   (in
                   <a href="literatur/tuttle/Congenital%20Transmission%20of%20Lyme.pdf">
                    cache
                   </a>
                   )
                  </p>
                  <p>
                  </p>
                 </blockquote>
                 <b>
                  Weitere Informationen in der Petition
                 </b>
                 <ul>
                  <li style="font:10.0px verdana">
                   Dr Alan MacDonald on Alzheimer's and Lyme disease, "
                   <a href="http://youtu.be/r8tESJVvM88">
                    The Biology of Lyme Disease: An Expert's Perspective
                   </a>
                   "
                  </li>
                  <li style="font:10.0px verdana">
                   <a href="http://home.comcast.net/~runagain/Liegner%20Remarks%20WWLP.doc">
                    Remarks: World Wide Lyme Rally &amp; Protest Kenneth B. Liegner, M.D.
                   </a>
                   (in
                   <a href="literatur/tuttle/Liegner_Remarks_World_Wide_Lyme_Ralley_and_Protest.pdf">
                    cache
                   </a>
                   )
                  </li>
                  <li style="font:10.0px verdana">
                   <a href="http://lymedisease.org/news/lymepolicywonk/lymepolicywonk-the-cdc-the-fda-and-lyme-disease-lab-tests-two-tiered-tests-igenex-the-c6-and-the-new-culture-test.html">
                    Lyme disease testing flaws and conflicts of interests
                   </a>
                   (in
                   <a href="literatur/tuttle/lyme_policy_wonk.pdf">
                    cache
                   </a>
                   )
                  </li>
                  <li style="font:10.0px verdana">
                   <a href="http://home.comcast.net/~runagain/John%20Lykoudis.doc">
                    The Barry Marshall affect on chronic disease
                   </a>
                   (in
                   <a href="literatur/tuttle/John%20Lykoudis.pdf">
                    cache
                   </a>
                   )
                  </li>
                  <li style="font:10.0px verdana">
                   <a href="http://home.comcast.net/~runagain/inconvenient%20truths.doc">
                    Inconvenient truths
                   </a>
                   (in
                   <a href="literatur/tuttle/inconvenient%20truths.pdf">
                    cache
                   </a>
                   )
                  </li>
                  <li style="font:10.0px verdana">
                   <a href="http://home.comcast.net/~runagain/bullying%20of%20Lyme%20patients.doc">
                    Bullying of Lyme patients
                   </a>
                   (in
                   <a href="literatur/tuttle/bullying%20of%20Lyme%20patients.pdf">
                    cache
                   </a>
                   )
                  </li>
                  <li style="font:10.0px verdana">
                   Division of Public Health Services, Dept. of Health and Human Services, New Hampshire,
                   <a href="http://home.comcast.net/~runagain/Dept%20of%20Health%20Agenda.pdf">
                    Lyme Disease Discussion Aug 18, 2011 Time 1:00PM
                   </a>
                   (in
                   <a href="literatur/tuttle/New_Hampshire_DoH_Lyme_Disease_Discussion_2013.pdf">
                    cache
                   </a>
                   )
                  </li>
                 </ul>
                 <hr/>
                 <b>
                  (Datum: 6. November 2014)
                 </b>
                 <br/>
                 <a href="literatur/borreliose-antibiotika.xls">
                  Liste
                 </a>
                 (als
                 <a href="literatur/borreliose-antibiotika.pdf">
                  pdf
                 </a>
                 ) gegen Borrelien wirksamer
                 <b>
                  Antibiotika und Antiprotozoika
                 </b>
                 (zusammengestellt von Friedhelm Bausen, Stand Juni 2008)
                 <ol>
                  <li style="font: 10.0px verdana">
                   Typen
                  </li>
                 </ol>
                 <ul>
                  <li style="font: 10.0px verdana">
                   Zellwandsyntheseinhibitoren
                  </li>
                  <li style="font: 10.0px verdana">
                   Ribosom-Proteinsyntheseinhibitoren
                  </li>
                  <li style="font: 10.0px verdana">
                   Gyrase-Hemmer
                  </li>
                  <li style="font: 10.0px verdana">
                   Folatsäureantagonisten
                  </li>
                  <li style="font: 10.0px verdana">
                   Ansamycine
                  </li>
                 </ul>
                 <li style="font: 10.0px verdana">
                  Tabellierte Eigenschaften
                 </li>
                 <ul>
                  <li style="font: 10.0px verdana">
                   Minimale Hemmkonzentration (MIC)
                  </li>
                  <li style="font: 10.0px verdana">
                   Minimale bakterizide Konzentration (MBC)
                  </li>
                  <li style="font: 10.0px verdana">
                   Eliminationshalbwertszeit im Plasma, Zentralnervensystem
                  </li>
                  <li style="font: 10.0px verdana">
                   Liquorgängigkeit
                  </li>
                  <li style="font: 10.0px verdana">
                   intralzelluläre Wirksamkeit
                  </li>
                  <li style="font: 10.0px verdana">
                   Wirksamkeit gegen zystische Formen
                  </li>
                 </ul>
                 <li style="font: 10.0px verdana">
                  Pharmacokinetische Daten
                 </li>
                 <hr/>
                 <b>
                  (Datum: 11. Oktober 2014)
                 </b>
                 <br/>
                 The New York State Department of Health Office of Professional Medical Conduct (
                 <a href="https://www.health.ny.gov/professionals/doctors/conduct/">
                  OPMC
                 </a>
                 ) has closed the case of
                 <a href="http://www.nysenate.gov/story/dr-kari-w-bovenzi">
                  Dr. Kari W. Bovenzi
                 </a>
                 (in
                 <a href="aktive/Dr.Kari_W.Bovenzi_New_York_State_Senate.pdf">
                  cache
                 </a>
                 ) (Woman of Distinction 2013,
                 <a href="http://www.nysenate.gov/">
                  New York State Senate
                 </a>
                 ) without further action anticipated. According to Jacques Simon, her attorney, this may set an important precedent that
                 <b>
                  physicians will no longer be investigated
                 </b>
                 or charges threatened or levied when the issue is
                 <b>
                  solely extended antibiotic therapy
                 </b>
                 for patients being treated for Lyme disease (or suspected Lyme disease).
                 <p>
                  <b>
                   Hintergrund
                  </b>
                  <br/>
                  <a href="http://www.drkaricares.com/">
                   Kari W. Bovenzi
                  </a>
                  , "
                  <a href="http://www.drkaricares.com/2-uncategorised/5-why-lyme-doctors-need-defense-funds.html">
                   <i>
                    Why Lyme Doctors Need Defense Funds
                   </i>
                  </a>
                  "
                 </p>
                 <p>
                 </p>
                 <blockquote>
                  "It's an unfortunate fact of life these days that a group of physicians who treat tick-borne diseases in accordance with the authorized
                  <a href="http://www.ilads.org/">
                   ILADS
                  </a>
                  (International Lyme and Associated Diseases Society)
                  <a href="http://www.ilads.org/lyme/treatment-guideline.php">
                   Guidelines
                  </a>
                  invariably come under "review" by the New York State Department of Health's Office of Professional Medical Conduct.
                  <p>
                   ["insurance companies strictly adhere to Infectious Diseases Society of America (
                   <a href="http://www.idsociety.org/">
                    IDSA
                   </a>
                   )
                   <a href="http://cid.oxfordjournals.org/content/43/9/1089.full">
                    guidelines
                   </a>
                   " (
                   <a href="http://www.drkaricares.com/">
                    Quelle
                   </a>
                   ),
                   <br/>
                   <a href="http://www.lymenet.de/literatur/dbg_idsa_statement.pdf">
                    Kritik
                   </a>
                   an den IDSA guidelines von der
                   <a href="http://www.borreliose-gesellschaft.de/">
                    Deutschen Borreliose-Gesellschaft
                   </a>
                   ]
                  </p>
                  <p>
                   While years of reviews have yet to result in any charges for treating Lyme according to these Guidelines, the Department of Health persists in targeting the ILADS doctors for a "review" that is intrusive, stressful, and exceedingly expensive to manage.
                  </p>
                  <p>
                   Nearly every ILADS doctor in New York who treats Lyme patients either is currently, or has been, under investigation. This is a political strategy being employed by powerful competitive interests who have been successful in influencing the State's Health Department's policies.  New York is not the only state that has this problem, but it is one of the most egregious.  Nationally, the situation has become so onerous that seven states have already enacted "Doctor Protection" legislation to prevent the targeting of ILADS doctors by medical review boards.  New York has not enacted any such protections for our ILADS doctors.
                  </p>
                  <p>
                   Every doctor  who finds himself in the crosshairs of the OPMC's review process must retain a highly specialized legal defense team to deal with the mountain of work that comes with these "reviews".  For many of the doctors who have already been through this process, the legal bills have exceeded $50,000, and in some cases, even $100,000 or more.
                  </p>
                  <p>
                   The invariability of this expensive harassment has had a chilling effect on the involvement of any new practitioners who might want to get involved with Lyme disease.  Many doctors simply will not treat Lyme patients because of the threat of having to deal with OPMC reviews..."
                  </p>
                 </blockquote>
                 <hr/>
                 <b>
                  (Datum: 1. September 2014)
                 </b>
                 <br/>
                 <a href="http://www.mentalhealthandillness.com/">
                  Robert C Bransfield
                 </a>
                 , MD, DLFAPA,
                 <b>
                  Videos zu Lyme Disease
                 </b>
                 <blockquote>
                  <style type="text/css">
                   p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 10.0px 'verdana'}
     p.p4 {margin: 0.0px 0.0px 0.0px 0.0px; font: 10.0px 'verdana'; color: #0033ff}
                  </style>
                  <p class="p1">
                   The release of
                   <a href="https://www.youtube.com/watch?v=CVzXsKvN2ck">
                    Under Our Skin
                   </a>
                   ,
                   <a href="http://www.underourskin.com/#home-emergence">
                    2: Emergence
                   </a>
                   has brought further attention to films related to Lyme disease.
                  </p>
                  <p class="p1">
                   This is a list of some of the Lyme disease movies/videos. There are also many news video clips on Lyme disease. It is not a complete list, but a start. If anyone can expand onto this, feel free to do so.
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   <b>
                    Lymelife
                   </b>
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=H5j6QAkGbNU">
                    Lymelife 2009: Official Movie Trailer
                   </a>
                   . This video is not available in Germany.
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=VPWiCGSYtlw">
                    Invisible Illness and Incommunicable Diseases
                   </a>
                   , Emily Reach White at TEDxGreenville,
                   <a href="https://www.youtube.com/channel/UCsT0YIqwnpJCM-mx7-gSA4Q">
                    TED Talks
                   </a>
                  </p>
                  <p class="p1">
                   <a href="http://vimeo.com/95647143">
                    Lyme Disease a Silent Epidemic
                   </a>
                   , produced by France 5 Public Network and Grand Angle, directed by Chantal Perrin
                  </p>
                  <p class="p1">
                   <a href="http://vimeo.com/93360056">
                    Maladie de Lyme diffusé
                   </a>
                   sur France 5 le 20/5/14 (in French)
                  </p>
                  <p class="p1">
                   <a href="http://www.youtube.com/watch?v=mpB287Yx9iQ">
                    The Voices of Lyme Disease- Breaking the Silence
                   </a>
                   , created by Victoria Wilcox, a 16 year old girl and her friend, Sara Lynch. Youtube: "This video is not available. Sorry about that."
                  </p>
                  <p class="p1">
                   <a href="http://www.youtube.com/watch?v=Zj9zBXPutvs&amp;feature=youtube_gdata_player">
                    Invisibly Ill
                   </a>
                   , Documentary Film on Lyme Disease and Stealth Infections, Australia,
                   <a href="http://www.lymebook.com/australia-dvd-invisibly-ill-bec-mills">
                    feature length film
                   </a>
                  </p>
                  <p class="p1">
                   <a href="http://goanimate.com/movie/0XCA4kvs8vk4?utm_source=facebook">
                    Lyme disease? Bah! The Very Idea!
                   </a>
                   , great Lyme Disease parody
                  </p>
                  <p class="p1">
                   <a href="http://www.youtube.com/watch?v=7lSliucgygc">
                    Ode to Lyme Brain [Forgetfulness]
                   </a>
                  </p>
                  <p class="p1">
                   <a href="http://www.youtube.com/watch?v=cCB6ezBzSMY">
                    Lyme Awareness Video
                   </a>
                   ,
                   <a href="https://www.youtube.com/watch?v=8I9Gd9liOgU">
                    OneTrueMedia.com
                   </a>
                  </p>
                  <p class="p1">
                   <a href="http://vimeo.com/7165595">
                    Under the Eightball
                   </a>
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   <b>
                    Celebrity Videos
                   </b>
                  </p>
                  <p class="p1">
                   <a href="http://www.youtube.com/watch?v=6djL18mfXj8&amp;feature=youtu.be">
                    Yolanda Foster's Experience With Lyme: LRA Gala
                   </a>
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=uoTEP9lZetY&amp;list=PL53Pb2ML9856pvIsuW5KNzAblY1j-cmII">
                    Daryl Hall Speaks About Persistent Lyme Disease Infection
                   </a>
                  </p>
                  <p class="p1">
                   <a href="http://Lymedisease.org/">
                    Dorothy Leland
                   </a>
                   shared
                   <a href="http://lymedisease.org/news/touchedbylyme/touched-by-lyme-lyme-disease-awareness-through-figure-skating.html">
                    this
                   </a>
                   story
                  </p>
                  <p class="p1">
                   Debbie Gibson Reveals
                   <a href="http://www.ilads.org/ilads_news/2014/dr-robert-bransfield-on-good-morning-americas-interview-about-debbie-gibsons-battle-with-lyme/">
                    Drastic Weight Loss Caused by Lyme Disease
                   </a>
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=9aRoAiIMfL4">
                    Amy Tan with Ray Stricker
                   </a>
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=TYFdhWLip50">
                    Ben Stiller on David Letterman
                   </a>
                   discusses Lyme disease
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=pB9YGCvhCu0&amp;index=138&amp;list=PL53Pb2ML9857lVdyye5lD8f20hcvGC">
                    Multiple Celebrities
                   </a>
                   with Lyme Disease
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   <b>
                    Scientific
                   </b>
                  </p>
                  <p class="p1">
                   <a href="http://borrelialyme.forumatic.com/viewtopic.php?f=2&amp;t=3&amp;p=7#p7">
                    Alan MacDonald videos
                   </a>
                  </p>
                  <p class="p1">
                   Mason Kuhn, Lyme and Autism, video is half way down
                   <a href="http://our-lyme-autism-journey.blogspot.com/">
                    this
                   </a>
                   blog
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=LRQ-NhEkLXU">
                    Pr Luc Montagnier on Lyme disease, autism and chronic infections
                   </a>
                  </p>
                  <p class="p1">
                   <a href="http://www.seasonsonthefly.com/blog/?page_id=89">
                    Lyme Disease - Seasons On The Fly
                   </a>
                   , Dr Jason West
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   <b>
                    Political
                   </b>
                  </p>
                  <p class="p1">
                   <a href="http://www.youtube.com/watch?v=sM2VdwJJ6K4&amp;feature=uploademailToday">
                    Rep. Scavello Asks About Lyme Disease at Health Budget Hearing
                   </a>
                   , House Appropriations Committee, Department of Health.
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   <b>
                    Some ILADS videos
                   </b>
                  </p>
                  <p class="p4">
                   <span class="s1">
                    <a href="http://www.ilads.org/lyme/lyme-videos.php">
                     http://www.ilads.org/lyme/lyme-videos.php
                     <span class="s2">
                     </span>
                    </a>
                   </span>
                  </p>
                  <p class="p4">
                   <span class="s1">
                    <a href="http://www.ilads.org/lyme_programs/conference-videos.php">
                     http://www.ilads.org/lyme_programs/conference-videos.php
                     <span class="s2">
                     </span>
                    </a>
                   </span>
                  </p>
                  <p class="p4">
                   <span class="s1">
                    <a href="http://ilads.org/ilads_media/boston-videos-home/">
                     http://ilads.org/ilads_media/boston-videos-home/
                     <span class="s2">
                     </span>
                    </a>
                   </span>
                  </p>
                  <p class="p4">
                   <span class="s1">
                    <a href="http://www.ilads.org/media/conference_land.php">
                     http://www.ilads.org/media/conference_land.php
                     <span class="s2">
                     </span>
                    </a>
                   </span>
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   <b>
                    Other
                   </b>
                  </p>
                  <p class="p1">
                   <a href="https://www.youtube.com/watch?v=reqyYSAFb9I&amp;list=PL53Pb2ML9857lVdyye5lD8f20hcvGCQwT">
                    200 Videos
                   </a>
                   about Lyme disease
                  </p>
                  <p>
                  </p>
                  <p class="p1">
                   Also, do an Internet search of
                  </p>
                  <ul>
                   <li style="font:10.0px verdana">
                    Lyme + the names of the doctors involved with Lyme disease or
                   </li>
                   <li style="font:10.0px verdana">
                    Lyme + video + the names of the doctors involved with Lyme disease
                   </li>
                  </ul>
                  <p class="p1">
                   to find many additional videos.
                  </p>
                 </blockquote>
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 7. August 2014)
                 </b>
                 <br/>
                 <a href="http://onlyme-aktion.org/borreliose-petition-onlyme-aktion-org-setzt-erneut-zeichen/">
                  OnLyme-Aktion.org
                 </a>
                 Online-Petition an den Bundesminister für Gesundheit:
                 <a href="https://www.openpetition.de/petition/online/schutz-fuer-patienten-mit-borreliose-und-co-infektionen?utm_source=extern&amp;utm_medium=widget&amp;utm_campaign=schutz-fuer-patienten-mit-borreliose-und-co-infektionen">
                  <b>
                   Schutz für Patienten mit Borreliose und Co-Infektionen
                  </b>
                 </a>
                 <blockquote>
                  <font size="-2">
                   Aufgrund eines erbitterten Meinungsstreits in der medizinischen Fachwelt und der daraus resultierenden Verunsicherung von Ärzten ist die Versorgung von Patienten mit Borreliose und anderen zeckenübertragenen Infektionen nicht in ausreichendem Maße gewährleistet. Borreliose und Co-Infektionen stellen wegen dieses Streits einen Sonderfall dar, und Patienten sowie ihre behandelnden Ärzte bedürfen deshalb bis zur Klärung dieses Fachdisputs eines besonderen gesetzlichen Schutzes. Europäische Borreliosepatienten fordern deshalb ein Gesetz auf europäischer und auf der jeweiligen nationalen Ebene, das ihre Rechte auf adäquate Therapie garantiert - ähnlich den Gesetzen in den US-Bundesstaaten Vermont (vom 11.3.2014) und New York (Bill number:
                   <a href="http://open.nysenate.gov/legislation/bill/A7558a-2013">
                    A7558A
                   </a>
                   ).
                   <br/>
                   <br/>
                   Durch das Gesetz sollten die folgenden Forderungen realisiert werden:
                   <ol>
                    <li>
                     Aufklärungspflicht des behandelnden Arztes gegenüber dem Patienten über den existierenden medizinischen Meinungsstreit in Bezug auf Diagnostik und Therapie. Verpflichtende Aufklärung des Patienten über seine Wahlfreiheit hinsichtlich der Behandlung und Diagnostik. Garantie der Wahlfreiheit in Bezug auf die Therapie.
                    </li>
                    <li>
                     Ausschluss von Regressforderungen der Versicherer oder kassenärztlichen Vereinigungen gegenüber jenen behandelnden Ärzten, die sich nicht an die Empfehlungen der European Union Concerted Action on  Lyme Borreliosis (EUCALB) oder  an nationale Leitlinien halten.
                    </li>
                    <li>
                     Ersetzen des mangelhaften, nicht standardisierten ELISA Suchtest als Screening-Test durch den Western-Blot. Übernahme der Kosten für diesen Test durch die Krankenkassen. Bis zur Entwicklung eines standardisierten und zuverlässigen serologischen Tests stärkere Beachtung der klinischen Symptome in der ärztlichen Praxis. Verpflichtende Aufklärung der Patienten über die Mangelhaftigkeit existierender Tests.
                    </li>
                    <li>
                     Übernahme der Behandlungskosten - auch für indizierte Langzeit-Antibiosen - durch die Krankenkassen.
                    </li>
                    <li>
                     Anerkennung der Persistenz von Symptomen bei einem Teil der Patienten mit allen sozialversicherungsrechtlichen Folgen.
                    </li>
                    <li>
                     Multidisziplinäre, heterogene Besetzung aller nationalen Gremien (Leitlinien-Kommissionen, nationale Referenzzentren) mit Vertretern unterschiedlicher Ansätze unter Einbeziehung aller Studien.
                    </li>
                    <li>
                     Erhöhung der Forschungsausgaben für Diagnostik und Therapie. Initiierung von Langzeit-Therapie-Studien.
                     <br/>
                    </li>
                    <li>
                     Einführung einer europaweiten/nationalen Meldepflicht für Lyme-Borreliose und Co-Infektionen, einschließlich Erweiterung der Falldefinitionen.
                    </li>
                    <li>
                     Aufklärung der Bevölkerung über die zum Teil schwerwiegenden Folgen eines Zeckenstiches.
                     <br/>
                    </li>
                    <li>
                     Verbindliche Weiterbildung der Ärzte. Die konträren Ansichten in medizinischen Fachkreisen (mangels Evidenzen) - und der ausschließlich empfehlende Charakter existierender Leitlinien muss Bestandteil dieser Weiterbildung sein.
                    </li>
                   </ol>
                   <p>
                    <a href="https://www.openpetition.de/petition/online/schutz-fuer-patienten-mit-borreliose-und-co-infektionen?utm_source=extern&amp;utm_medium=widget&amp;utm_campaign=schutz-fuer-patienten-mit-borreliose-und-co-infektionen">
                     <b>
                      Begründung
                     </b>
                    </a>
                   </p>
                  </font>
                 </blockquote>
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 1. November 2013)
                 </b>
                 <br/>
                 <a href="http://lymerick.net/Bb-EarlySpread.htm">
                  <b>
                   Early spread of Borrelia burgdorferi into mammal tissues
                  </b>
                 </a>
                 , literature review by Marie Kroun
                 <blockquote>
                  <font size="-2">
                   Luft BJ, Steinman CR, Neimark HC, Muralidhar B, Rush T, Finkel MF, Kunkel M, Dattwyler RJ.
                   <b>
                    Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection
                   </b>
                   .
 JAMA 1992 Mar 11; 267(10): 1364-7, Erratum in JAMA 1992 Aug 19;268(7):872, Comment in JAMA. 1992 Aug 19;268(7):872; discussion on p 873.
                   <br/>
                   <blockquote>
                    Our findings demonstrate that B. burgdorferi can disseminate to CNS very early in the course of infection with little or no clinical evidence of CNS involvement.
                   </blockquote>
                   <p>
                    Galbe JL, Guy E, Zapatero JM, Peerschke EI, Benach JL.,
                    <b>
                     Vascular clearance of Borrelia burgdorferi in rats
                    </b>
                    .
 Microb Pathog. 1993 Mar;14(3):187-201.
                    <br/>
                   </p>
                   <blockquote>
                    Radiolabeled Borrelia burgdorferi, the etiologic agent of Lyme disease, injected intravenously into rats are cleared from the vasculature within 1 h of injection. 
 One low passage isolate showed trafficking between the circulation and possibly the vessel walls for the first 2 h after injection. 
 All strains used were resistant to the effects of normal and heat-inactivated rat serum. 
 During the first 2 h after injection, B. burgdorferi can be visualized in, and recovered from, the platelet-rich plasma.  ... These organisms invade organs (heart, kidneys, bladder, liver, spleen, brain) within 1-6 h after injection.
                   </blockquote>
                   <p>
                    Wormser GP, McKenna D, Carlin J, Nadelman RB, Cavaliere LF, Holmgren D, Byrne DW, Nowakowski J.  (fri PDF)
 Brief communication:
                    <b>
                     hematogenous dissemination in early Lyme disease
                    </b>
                    .
 Ann Intern Med. 2005 May 3;142(9):751-5. Summary for patients in: Ann Intern Med. 2005 May 3;142(9):I48.
                    <br/>
                   </p>
                   <blockquote>
                    CONCLUSIONS: The high rate, early onset, and prolonged duration of risk for spirochetemia explain why untreated patients with erythema migrans are at risk for dissemination of B. burgdorferi to anatomic sites beyond the lesion site. Differences in the strain of the infecting spirochete, as well as host factors, may be important determinants of hematogenous dissemination. ... Spirochetemia was not associated with duration of erythema migrans (P &gt; 0.2) or the size of the erythema migrans lesion (P = 0.18), both for the entire study sample (Figure) and separately for those with a single erythema migrans lesion and those with multiple lesions. The oldest lesion associated with spirochetemia was of 33 days duration.
                   </blockquote>
                   <p>
                   </p>
                  </font>
                 </blockquote>
                 <hr/>
                 <b>
                  (Datum: 1. Juli 2013)
                 </b>
                 <br/>
                 Bransfield RC,
                 <b>
                  <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474947/">
                   The Psychoimmunology of Lyme/Tick-Borne Diseases and its Association with Neuropsychiatric Symptoms
                  </a>
                 </b>
                 . The Open Neurology Journal, 2012, 6, (Suppl 1-M3) 88-93 1874-205X/12 2012 Bentham Open.
                 <blockquote>
                  <font size="-2">
                   ABSTRACT: Disease progression of neuropsychiatric symptoms in Lyme/tick-borne diseases can be better understood by greater attention to psychoimmunology. Although there are multiple contributors that provoke and weaken the immune system, infections and persistent infections are significant causes of pathological immune reactions. Immune mediated effects are a significant contributor to the pathophysiological processes and disease progression. These immune effects include
                   <li>
                    persistent inflammation with cytokine effects and
                   </li>
                   <li>
                    molecular mimicry and
                   </li>
                   <li>
                    both of these mechanisms may be present at the same time in persistent infections. 
 
 Sickness syndrome associated with interferon treatment and autoimmune limbic encephalopathies are models to understand inflammatory and molecular mimicry effects upon neuropsychiatric symptoms.
                    <p>
                     Progressive inflammatory reactions have been proposed as a model to explain disease progression in
                    </p>
                    <ul>
                     <li>
                      depression,
                     </li>
                     <li>
                      psychosis,
                     </li>
                     <li>
                      dementia,
                     </li>
                     <li>
                      epilepsy, and other mental illnesses
                     </li>
                    </ul>
                    and pathophysiological changes have been associated with
                    <ul>
                     <li>
                      oxidative stress,
                     </li>
                     <li>
                      <a href="https://en.wikipedia.org/wiki/Excitotoxicity">
                       excitotoxicity
                      </a>
                      ,
                     </li>
                     <li>
                      changes in
                      <a href="https://en.wikipedia.org/wiki/Homocysteine">
                       homocysteine
                      </a>
                      metabolism and
                     </li>
                     <li>
                      altered
                      <a href="https://en.wikipedia.org/wiki/Tryptophan_metabolism">
                       tryptophan
                      </a>
                      <a href="https://en.wikipedia.org/wiki/Catabolism">
                       catabolism
                      </a>
                      .
                     </li>
                    </ul>
                    Lyme disease has been associated with
                    <ul>
                     <li>
                      the proinflammatory cytokines IL-6, IL-8, IL-12, IL-18 and
                      <a href="https://en.wikipedia.org/wiki/Interferon_gamma">
                       interferon-gamma
                      </a>
                      ,
                     </li>
                     <li>
                      the chemokines
                      <a href="https://en.wikipedia.org/wiki/CXCL12">
                       CXCL12
                      </a>
                      and
                      <a href="https://en.wikipedia.org/wiki/CXCL13">
                       CXCL13
                      </a>
                      and
                     </li>
                     <li>
                      increased levels proinflammatory
                      <a href="https://en.wikipedia.org/wiki/Lipoprotein">
                       lipoproteins
                      </a>
                      .
                     </li>
                    </ul>
                    Borrelia burgdorferi surface glycolipids and flagella antibodies appear to elicit anti-neuronal antibodies and anti-neuronal antibodies and Borrelia burgdorferi lipoproteins can disseminate from the periphery to inflame the brain.
                    <p>
                     Autism spectrum disorders associated with Lyme/tick-borne diseases may be mediated by a combination of inflammatory and
                     <a href="https://en.wikipedia.org/wiki/Molecular_mimicry">
                      molecular mimicry
                     </a>
                     mechanisms.
                    </p>
                    <p>
                     Greater interaction is needed between infectious disease specialists, immunologists and psychiatrists to benefit from this awareness and to further understand these mechanisms.
                    </p>
                   </li>
                  </font>
                 </blockquote>
                 <p>
                  Bransfield RC,
                  <a href="http://www.ilads.org/ilads_news/2012/relationship-of-inflammation-and-autoimmunity-to-psychiatric-sequelae-in-lyme-disease/">
                   <b>
                    Relationship of Inflammation and Autoimmunity to Psychiatric Sequelae in Lyme Disease
                   </b>
                  </a>
                  . Psychiatric Annals. September 2012 - Volume 42, Issue 9: 337-341.DOI: 10.3928/00485713-20120906-07.
                 </p>
                 <blockquote>
                  <font size="-2">
                   CONCLUSIONS: Most symptoms associated with Lyme disease and other tick-borne diseases are immune mediated. A progressive sequence of immune effects is associated with a progressive development of cognitive, psychiatric, neurologic, and somatic symptoms. These progressive immune effects include persistent inflammation with cytokine effects, the release of proinflammatory lipoproteins from the outer coat of B. burgdorferi, and autoimmunity.
                   <p>
                    Prolonged inflammation, particularly the type associated with chronic infection within the CNS, is associated with further cognitive impairments, more severe psychiatric symptoms, gliosis, and dementia. Autoimmune effects also can be present at the same time and can include antineuronal antibodies and B. burgdorferilipoproteins that can disseminate from the periphery to inflame the brain.
                   </p>
                   <p>
                    These immune reactions can result in psychiatric symptoms such as obsessiveness, movement disorders, paranoia, and others. Autism spectrum disorders associated with Lyme disease and other tick-borne diseases appear mediated by a combination of inflammatory and autoimmune mechanisms from the mother's and/or infant's immune system. Understanding this pathophysiology will help physicians create new treatment options.
                   </p>
                  </font>
                 </blockquote>
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 21. Juni 2013)
                 </b>
                 <br/>
                 Donta ST, Noto RB, Vento JA,
                 <a href="http://journals.lww.com/nuclearmed/Fulltext/2012/09000/SPECT_Brain_Imaging_in_Chronic_Lyme_Disease.33.aspx">
                  <b>
                   SPECT Brain Imaging in Chronic Lyme Disease
                  </b>
                 </a>
                 , Clinical Nuclear Medicine 37, Issue 9, pe219-pe222
                 <blockquote>
                  <font size="-2">
                   <i>
                    Conclusions: Brain SPECT scans are abnormal in most patients with chronic Lyme disease, and these scans can be used to provide objective evidence in support of the clinical diagnosis. The use of certain antibiotic regimens seems to provide improvement in both clinical status and SPECT scans.
                   </i>
                   <p>
                    "Bildgebende Verfahren wie die SPECT (Einzelphotonen-Emissionscomputertomographie; aus dem Englischen: single photon emission computed tomography) können durch Messung der Perfusion Hinweise auf metabolische Veränderungen geben. Die SPECT erlaubt, die Perfusion einzelner Bereiche des Gehirns darzustellen. ... Alle 183 untersuchten Individuen erfüllten laut Autoren die Kriterien einer chronischen Lyme Borreliose. Perfusionsstörungen, vor allem im Frontal-, Schläfen- und Scheitellappen, wurden bei 75% der Patienten gefunden, bei seropositiven Patienten ebenso wie bei seronegativen Patienten. Verbesserungen oder komplette Normalisierung der Perfusion wurde bei 70% der behandelten Patienten nach mindestens 3 monatiger Gabe vor allem intrazellulär wirkender Antibiotika in einem Zeitraum von 1 bis 2 Jahren gesehen. Abnormalitäten im SPECT Scan, so die Autoren, werden bei der Mehrheit der Patienten/Innen mit chronischer Borreliose gesehen.
                   </p>
                   <p>
                    Die Aussage in der Arbeit wird wesentlich geschwächt, da keine Kontrollgruppe(n) untersucht wurde(n). So bleibt unklar, bei wie vielen Probanden im vergleichbaren Alters- und Geschlechterverhältnis (mit vergleichbarem Genussmittelkonsum und vergleichbarer Medikation) möglicherweise auch Auffälligkeiten/Abnormalitäten in der SPECT zu Tage treten. ... Ohne wohlausgewählte Vergleichsgruppen bleiben die Befunde leider weder objektiv noch beweisend. So könnten die Perfusionsstörungen durchaus Ausdruck anderer Störungen sein, die auf ganz andere Ursachen zurückgehen." (Quelle: DBG-Mitteilungen
                    <a href="http://www.borreliose-gesellschaft.de/Mitteilungen/DBG-Mitteilungen_2013-2.pdf">
                     2013-2
                    </a>
                    , Seite 6)
                   </p>
                  </font>
                 </blockquote>
                 <p>
                 </p>
                 <hr/>
                 <b>
                  (Datum: 30. April 2013)
                 </b>
                 <br/>
                 <a href="http://news.doccheck.com/de/author/michael-van-den-heuvel/">
                  Michael van den Heuvel
                 </a>
                 , "
                 <a href="http://news.doccheck.com/de/newsletter/13/96/?utm_source=DC-Newsletter&amp;utm_medium=E-Mail&amp;utm_campaign=Newsletter-DE-DocCheck+News+13.18+Montag+%28Arzt+x+5%29-2013-04-29&amp;user=a5235ec296376b876dfc4d724ad68159&amp;n=13&amp;d=28&amp;chk=56da65b7da40639ec8b32e918a793f9e">
                  <b>
                   Lyme-Borreliose: Würfelspiele mit ELISA
                  </b>
                 </a>
                 ",
                 <a href="http://news.doccheck.com/">
                  DocCheck
                 </a>
                 <a href="">
                  Newsletter
                 </a>
                 , 29. April 2013 (
                 <a href="http://news.doccheck.com/en/newsletter/92/636/?utm_source=DC-Newsletter&amp;utm_medium=E-Mail&amp;utm_campaign=Newsletter-EN-130605_News_EN-2013-06-05&amp;user=efe95d9dbc9e98c36c98e84bfebb820f&amp;n=92&amp;d=28&amp;chk=cf75fe7e9e07e96f24a4ff10fadf0788">
                  english
                 </a>
                 )
                 <blockquote>
                  <font size="-2">
                   <table>
                    <tr>
                     <td valign="top">
                      <iframe allowfullscreen="" frameborder="0" height="105" src="http://www.youtube.com/embed/JW2iJF8C3Rc" width="187">
                      </iframe>
                      <br/>
                      <font size="-2">
                       <a href="http://www.youtube.com/watch?v=JW2iJF8C3Rc&amp;feature=player_embedded">
                        watch on YouTube
                       </a>
                      </font>
                     </td>
                     <td valign="top">
                      <font size="-2">
                       Bei entsprechendem Verdacht untersuchen spezialisierte Labors eine Blutprobe mit Enzyme Linked Immunosorbent Assays (ELISAs) auf Antiäkörper. Das Verfahren hat gleich mehrere Nachteile: Sensitivität, Spezifität und Standardisierung entsprechen nicht der Erwartung. Laut Dr. med.
                       <a href="http://www.google.com/search?client=safari&amp;rls=en&amp;q=Schwarzbach+site:www.b-c-a.de/&amp;ie=UTF-8&amp;oe=UTF-8">
                        Armin Schwarzbach
                       </a>
                       vom
                       <a href="http://www.b-c-a.de/">
                        Borreliose Centrum Augsburg
                       </a>
                       bleiben bis zu 70 Prozent aller ELISA-Untersuchungen trotz einer Infektion negativ. "Das Problem ist, dass in den ELISA-Tests zu wenige rekombinante Antigene und Lysate in den falschen beziehungsweise nicht vollständigen Mischungen eingesetzt werden. Wir wissen mittlerweile, dass es zahlreiche neue Borrelien-Subspezies gibt", erklärt Schwarzbach. Problematisch ist die ausgeprägte Antigen-Variabilität und -Varianz einzelner Subspezies.
                      </font>
                     </td>
                    </tr>
                   </table>
                   <font size="-2">
                    <ul>
                     <li>
                      Je nach Veröffentlichung liegt die Sensitivität der [ELISA-]Tests bei 30 bis 60 Prozent.
                     </li>
                     <li>
                      Selbst Immunoblots erreichen nur 60 Prozent Sensitivität.
                     </li>
                     <li>
                      Neben ELISA und Immunoblots haben sich methodisch anspruchsvolle  Lymphozytentransformationstests (LTT) etabliert. Labors isolieren Lymphozyten aus einer Blutprobe und bestimmen, inwieweit eine Reaktion mit spezifischen Antigenen erfolgt. "Meines Erachtens ist der Test hilfreich, aber ebenfalls nicht ausschließend oder beweisend", so Schwarzbach.
                     </li>
                     <li>
                      Bei der Neuroborreliose gibt es mittlerweile interessante Arbeiten, die CXCL13 als Marker untersuchen. Bereits in frühen Phasen erhöht sich der Spiegel dieses
                      <a href="https://en.wikipedia.org/wiki/Chemokine">
                       Chemokins
                      </a>
                      <a>
                       [chemotaktischen Cytokins] im Liquor und sinkt bei erfolgreicher Behandlung. Schwarzbach sagt, das Verfahren könnte als Ergänzung sinnvoll sein, da nur 7 - 9 Prozent aller Patienten mit chronischer Neuroborreliose einen positiven Antikörper-Index hätten.
                      </a>
                     </li>
                    </ul>
                    <p>
                     <font size="-2">
                      Momentan existieren bei der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften nur zwei S1-Leitlinien, nämlich "Kutane Manifestationen der Lyme-Borreliose"  und "Neuroborreliose". Hinzu kommt die Leitlinie "
                      <a href="http://www.borreliose-gesellschaft.de/de/Leitlinien">
                       Diagnostik und Therapie der Lyme-Borreliose
                      </a>
                      " der
                      <a href="http://www.borreliose-gesellschaft.de/">
                       Deutschen Borreliose-Gesellschaft
                      </a>
                      .
                     </font>
                    </p>
                   </font>
                  </font>
                 </blockquote>
                 <hr/>
                 <font size="-1">
                  <b>
                   (Datum: 5. März 2013)
                  </b>
                  <br/>
                  Commonwealth of Massachusetts, "
                  <b>
                   <a href="http://www.malegislature.gov/Content/Documents/Committees/H46/LymeDiseaseCommissionFinalReport-2013-02-28.pdf">
                    Lyme Disease in Massachusetts
                   </a>
                   , 
 A Report Issued by the Special Commission to Conduct an Investigation and Study of the Incidence and Impacts of Lyme Disease
                  </b>
                  ", February 28th 2013
                  <br/>
                 </font>
                 <blockquote>
                  <font size="-2">
                   <i>
                    Education for the Medical Community
                   </i>
                   <br/>
                   1. It is most important that healthcare providers be apprised of the spectrum of Lyme 
 disease, especially regarding relapsing or persisting symptoms, even after one of two 
 courses of "standard" antibiotic treatment over a 1-2 month period of time. This condition 
 may/can be much more frequent than has been previously acknowledged or appreciated, 
 and the recent (2011) report of the Institute of Medicine (IOM), National Academy of 
 Sciences (the nation's most highly regarded scientific body) attests to the difficulties 
 surrounding the diagnosis and management of this complication of Lyme disease 
 (Critical Needs and Gaps in Understanding Prevention, Amelioration, and Resolution of 
 Lyme an Other Tick-Borne Diseases: The Short-Term and Long-Term Outcomes: 
 Workshop Report). Regardless of whether this continued symptomatology is termed post- 
 Lyme disease or chronic Lyme disease, the cause of the persisting symptoms has yet to 
 be delineated, and there are currently no tests to determine that the causative organisms 
 are still present or absent in a given individual; the currently available antibody-based 
 tests cannot be used to determine that one no longer has, or does have Lyme disease, or to 
 assess response to treatment. Clinical judgment and assessment of all available 
 information remain the keys to appropriate management of all patients with Lyme 
 disease. This point is made by the Centers for Disease Control &amp; Prevention (CDC) 
 (www.cdc.gov) and is noted on laboratory testing information, yet many physicians 
 incorrectly rule out Lyme disease solely on the basis of a "negative" lab test.
                   <p>
                    2. Healthcare providers need to be aware that currently published recommendations and 
 guidelines regarding treatment of Lyme disease are based on limited data. For example, 
 the recommendation that one does not need treatment for a tick bite if the tick has not 
 been imbedded for more than 48 hours was not based on testing in humans. Patients need 
 to be counseled to be aware of what are often only subjective symptoms (fatigue, aches 
 and pains, 'brain fog') that may occur several weeks to a few months after having been 
 bitten by a deer tick (Ixodes). It should be noted that these symptoms may be 
 inappropriately dismissed, or mischaracterized as psychiatric or stress-related. Guidelines 
 for antibiotic prophylaxis16 are also based on limited data. The recommendation that a 
 single day's treatment with doxycycline for an imbedded deer tick bite can prevent Lyme 
 disease has some published support; however, this approach may not always be effective, 
 and some physicians believe that it is ill-advised. Patients who have taken a prophylactic 
 dose need to be counseled to be aware that if symptoms develop over the subsequent few 
 months, they should seek medical attention. They should be made aware that antibody 
 production may be abrogated as a result of early dosing, thus potentially making 
 laboratory testing even more problematic in these situations.
                   </p>
                   <p>
                    3. Healthcare providers need also to be made aware that the recommendations regarding 
 antibiotic treatment of patients with persisting or relapsing symptoms are based primarily 
 on the results of one clinical trial. There have been a few other controlled treatment trials, 
 which did not show either any, or any sustained, benefit following treatment. But the 
 failure of the antibiotics used in these trials cannot be used to conclude that use of 
 different antibiotic regimens and durations of treatment would not be effective; there is 
 published information, in addition to physician experience, that suggest there are other 
 antibiotic regimens that may be effective. Until there are additional controlled treatment 
 trials to prove or disprove other antibiotic regimens, healthcare providers should make 
 themselves aware of available alternative regimens so that their patients can be provided 
 the opportunity to resolve their persisting symptoms.
                   </p>
                   <p>
                    4. Physicians should also be reminded of the Physician Protection Act17, which protects 
 them from any disciplinary action should they choose to diagnose and treat according to 
 clinical criteria, relying on history and symptoms even in the absence of positive lab 
 results. This may include prescribing antibiotics over a prolonged period of time when 
 warranted by the patient's presentation.
                   </p>
                  </font>
                 </blockquote>
                 <hr/>
                 <font size="-1">
                  <b>
                   (Datum: 6. February 2013)
                  </b>
                  <br/>
                  <a href="http://onlyme-aktion.org/mitmachen/aktuelle-aktionen/borreliose-offener-brief-an-bundesgesundheitsminister-daniel-bahr/">
                   <b>
                    Offener Brief
                   </b>
                   zur katastrophalen Versorgungslage von Borreliose-Patienten
                  </a>
                  , Januar 2013.
                 </font>
                 <p>
                 </p>
                 <blockquote>
                  <font size="-2">
                   "... Viele Ärzte behandeln Borreliose-Patienten höchstens 21 Tage antibiotisch - auch wenn sie bereits am fortgeschrittenen Stadium einer Borreliose leiden. Warum? Weil es bei der Kontroverse zwei "Meinungslager" gibt.
                   <p>
                    Lager A glaubt, dass die nach der Therapie weiter bestehenden Symptome auto-immun verursacht seien. Die Patienten erhalten nach 21 Tagen meist Antidepressiva und Schmerzmittel und werden nur noch symptomatisch behandelt, mit entsprechend geringer Wirkung. Der Haken an der Sache: Für diese "Auto-Immun-Hypothese" gibt es bis heute keinen Nachweis!
                   </p>
                   <p>
                    Lager B nimmt an, dass die persistierenden Symptome dieser Patienten durch eine noch nicht ausgeheilte Borreliose verursacht werden. Sie lassen den Patienten die Wahl, auch im Sinne der in Deutschland geförderten, partizipativen Entscheidungsfindung (
                    <a href="http://onlyme-aktion.org/wp-content/uploads/2013/01/Quellen-zum-offenen-Brief_28-Jan-2013.pdf#search=(3)">
                     3
                    </a>
                    ), eine erneute oder verlängerte antibiotische Behandlung zu versuchen. Diese Ärzte machen die Therapiedauer von der individuellen Vorgeschichte (u. a. Immunstatus, Vorerkrankungen, Co-Infektionen) und dem Ansprechen des Patienten auf die Therapie abhängig.
                   </p>
                   <p>
                    Bei der Borreliose im fortgeschrittenen Stadium verliert sich der Grund, warum die Patienten nach der Standardtherapie immer noch leiden, im Nebel nicht-bewiesener Hypothesen. Für eine persistierende Infektion sprechen inzwischen allerdings neue Forschungsergebnisse (
                    <a href="http://onlyme-aktion.org/wp-content/uploads/2013/01/Quellen-zum-offenen-Brief_28-Jan-2013.pdf#search=(4)">
                     4
                    </a>
                    )...
                   </p>
                  </font>
                 </blockquote>
                 <p>
                  <font size="-2">
                   Falls auch Sie Ihren Namen unter diesen offenen Brief setzen möchten, schreiben Sie bitte eine kurze Mail (die Namen reichen) mit dem Betreff “Offener Brief” an:
                   <br/>
                   <a href="mailto:kontakt@onlyme-aktion.org" target="_blank">
                    kontakt@OnLyme-Aktion.org
                    <br/>
                   </a>
                   Bitte denken Sie dabei auch an Ihre Freunde, Nachbarn und Verwandte – auch an jene ohne Internet. Es reicht das Einverständnis, dass die Namen unter dem Brief erscheinen dürfen!
                   <p>
                    <a href="http://onlyme-aktion.org/wp-content/uploads/2013/01/Quellen-zum-offenen-Brief_28-Jan-2013.pdf">
                     <b>
                      Literatur
                     </b>
                    </a>
                    zum Offenen Brief, Januar 2013
                    <!-- (im <a href="literatur/Quellen-zum-offenen-Brief_28-Jan-2013.pdf">Cache</a>)-->
                    .
                   </p>
                   <p>
                    [Eine umfangreiche Zusammenstellung von Arbeiten zu
                   </p>
                   <ul>
                    <li>
                     Behandlungsrückfällen und Therapieversagen nach Kurzzeit-Standardtherapie
                    </li>
                    <li>
                     Sensitivität/Spezifität der kommerziellen Zweistufen-Diagnostik auf Lyme-Borreliose
                    </li>
                    <li>
                     Erregerpersistenz]
                    </li>
                   </ul>
                  </font>
                  <!--
 <hr>
 <b>(Datum: 28. January 2013)</b><br>
 Dear Friends,
 <p>
 First, I want to thank each and every one of you who responded to my last update by donating to my legal defense fund.  Your generous response helped to reduce the outstanding balance, preserving my legal representation.  The hearing before the Connecticut Supreme Court is expected to take place early this year.  That proceeding is not able to accommodate a large audience, but I promise to keep you posted on the outcome!
 <p>
 Unfortunately, a very serious financial crisis is hitting my office which I must bring to your attention.  As you know, my office has been under an enormous amount of stress for  many years, due to the charges brought against me by the Connecticut Medical Examining Board (CMEB).  In addition to huge legal fees and fines, the imposition of four years of monthly monitoring has posed an enormous burden, financial and otherwise.  The monitor had to be hired through an agency, and his fees have been astronomical, averaging $4,000 per month (the average combined cost for the monitor and associated clerical work has been approximately <a href="http://lymedisease.org/news/lyme_disease_views/jones-update.html">$6,000 per month</a>).
 <p>
 ... 
 When I first learned of the monitoring requirement, which was unusually stringent in terms of both its frequency and duration, I feared that it could drive me into bankruptcy.  As a result, I have had to make some difficult modifications, to reduce our operating costs and keep the office open.  ...
 <p>
 My attorney has petitioned the CMEB on at least one occasion, requesting that they reduce the monitoring requirement.  The monitoring agency supported this request because the monitor has found no problems with my practice, but the CMEB denied it.  Some of my colleagues have set up a fund to try to help with these costs, for which I am very grateful, but this has not been sufficient.
 <p>
 ... In a nutshell, I am experiencing a financial crisis, and I will be forced to close my practice unless I am able to raise $40,000 within the next few days.  It pains me deeply that a great number of patients and their families could be left without adequate care, and once again to have to turn to you for assistance.  Any sum will be appreciated, but it must arrive at once!  I will do my best to keep you apprised of the situation, including the point at which our goal is reached.  At present, I regret that we do not have a Paypal option, but I will let you know if that changes.  Please make your checks out to me and send them to the following address:
 <blockquote>
 Charles Ray Jones, M.D.<br>
 111 Park Street, 1st Floor<br>
 New Haven, CT 06511<br>
 (please write "gift" in the memo field)
 </blockquote>
 <p>
 <table width="50%">
 <tr>
 <td>
 <hr>
 </td></tr></table>
 <font face="verdana"><font size=-1>
 <a href="letters/Jonesofficefundrasingletter2013.pdf">entire letter</a><br>
 Background: 
 <ul>
 <li><a href="http://lymedisease.org/news/lyme_disease_views/jones-update.html">Update on Dr. Charles Ray Jones</a>, Dec. 20, 2012.</li>
 <li><a href="https://sites.google.com/site/drjoneskids/overview-summary/update-winter-2012-13">UPDATE- WINTER 2012/13</a>, Charles Ray Jones, M.D., Pediatric & Adolescent Medicine Lyme Disease.</li>
 <li><a href="http://www.drjoneskids.com/">Lyme & Tick Borne Diseases - "Dr. Jones Kids"</a>.</li>
 <li><a href="http://lymeblog.com/modules.php?name=News&file=article&sid=637">The Trial of Dr. Charles Ray Jones</a>.</li>
 <li>P. Weintraub, <a href="http://www.lymedisease.org/lymetimes_archive/winter2001_spring2002.pdf#search=Jones">A feeling for the organism</a>, Lyme Times 32, Winter 2001/Spring 2002.</li>
 <li><a href="http://jud.state.ct.us/external/supapp/Cases/AROap/AP129/129AP446.pdf">CHARLES RAY JONES, M.D. v. CONNECTICUT MEDICAL EXAMINING BOARD</a> (AC 31675), DiPentima, C. J., and Bishop and Gruendel, Js., Argued April 20 -officially released June 21, 2011.</li>
 </ul>
 </font></font>
 <p>
 -->
                 </p>
                 <hr/>
                 <font size="-1">
                  <b>
                   (Datum: 19. January 2013)
                  </b>
                  <br/>
                  Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, Rossi M, Stricker RB (Lyme Disease Research Group, Department of Biology and Environmental Sciences, University of New Haven, New Haven, CT, USA) "
                  <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132871/" target="new">
                   <b>
                    Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
                   </b>
                   "
                  </a>
                  . Infect Drug Resist. 2011;4:97-113. doi: 10.2147/IDR.S19201. Epub 2011 May 3.
                 </font>
                 <blockquote>
                  <i>
                   Results
                  </i>
                  :
                  <br/>
                  <ul>
                   <li style="font: 9.0px Verdana">
                    <b>
                     Doxycycline
                    </b>
                    reduced spirochetal structures approx. 90% but increased the number of round body forms about twofold.
                   </li>
                   <li style="font: 9.0px Verdana">
                    <b>
                     Amoxicillin
                    </b>
                    reduced spirochetal forms by approx. 85% - 90% and round body forms by approx. 68%, while treatment with
                   </li>
                   <li style="font: 9.0px Verdana">
                    <b>
                     metronidazole
                    </b>
                    led to reduction of spirochetal structures by approx. 90% and round body forms by approx. 80%.
                   </li>
                   <li style="font: 9.0px Verdana">
                    <b>
                     Tigecycline
                    </b>
                    and
                    <b>
                     tinidazole
                    </b>
                    treatment reduced both spirochetal and round body forms by approx. 80% - 90%.
                   </li>
                   <p>
                    When quantitative effects on biofilm-like colonies were evaluated,
                   </p>
                  </ul>
                  <ul>
                   <li style="font: 9.0px Verdana">
                    the five antibiotics reduced formation of these colonies by only 30% - 55%.
                   </li>
                   <li style="font: 9.0px Verdana">
                    In terms of qualitative effects, only tinidazole reduced viable organisms by approx. 90%.
                   </li>
                   <li style="font: 9.0px Verdana">
                    Following treatment with the other antibiotics, viable organisms were detected in 70% - 85% of the biofilm-like colonies.
                   </li>
                  </ul>
                  <i>
                   Conclusions
                  </i>
                  :
                  <br/>
                  Antibiotics have varying effects on the different morphological forms of B. burgdorferi. Persistence of viable organisms in round body forms and biofilm-like colonies may explain treatment failure and persistent symptoms following antibiotic therapy of Lyme disease.
                 </blockquote>
                 <hr/>
                 <font size="-1">
                  <b>
                   (Datum: 26. Dezember 2012)
                  </b>
                  <br/>
                  <b>
                   <a href="literatur/lyme_issues&amp;hypotheses.html">
                    Lyme disease: issues and hypotheses
                   </a>
                  </b>
                  , a minireview (J. Gruber, editor)
                  <br/>
                 </font>
                 <font size="-2">
                  <ul>
                   <li>
                    Borreliae
                    <ul>
                     <li>
                      trigger our immune system to generate pathogen images in the form of e.g. antibodies or
                     </li>
                     <li>
                      <a href="literatur/lyme_issues&amp;hypotheses.html#3.2">
                       dysregulate
                      </a>
                      our hormone system.
                     </li>
                    </ul>
                   </li>
                   <li>
                    Vice versa, when given enough time, borreliae adapt to and modify our defense (formation of
                    <a href="symptoms/cycles/niches.htm">
                     niches
                    </a>
                    ).
                   </li>
                  </ul>
                  As a result of this interaction we might develop a chronic disease. Our illness becomes an
                  <a href="literatur/lyme_issues&amp;hypotheses.html#3.4">
                   integral part
                  </a>
                  , a new characteristic of us. To fight chronic illness antibiotic therapy needs to be augmented by restoration of our immune-hormone system.
                 </font>
                 <p>
                 </p>
                 <hr/>
                 <font size="-1">
                  <b>
                   (Datum: 25. Oktober 2012)
                  </b>
                  <br/>
                  Sapi E, Bastian SL, Mpoy CM, Scott S, Rattelle A, et al. (2012) "
                  <a href="http://xa.yimg.com/kq/groups/20271879/1182134680/name/SapiBiofilms%2Epdf">
                   <b>
                    Characterization of Biofilm Formation by Borrelia burgdorferi In Vitro
                   </b>
                  </a>
                  ".
                  <a href="http://www.plosone.org/home.action">
                   PLoS ONE
                  </a>
                  7(10) e48277. doi:10.1371/journal.pone.0048277  - im
                  <a href="literatur/SapiBiofilms_2012.pdf">
                   Cache
                  </a>
                 </font>
                 <blockquote>
                  <font size="-2">
                   Abstract
                   <br/>
                   Borrelia burgdorferi has long been known to be capable of forming aggregates and 
 colonies. It was recently demonstrated that Borrelia burgdorferi aggregate formation dramatically changes the in vitro 
 response to hostile environments by this pathogen.
                   <p>
                    In this study, we investigated the hypothesis that these aggregates are 
 indeed biofilms, structures whose resistance to unfavorable conditions are well documented. Biofilm 
 formation by Borrelia species might play an important role in their survival in diverse environmental conditions by providing 
 refuge to individual cells.
                   </p>
                   <p>
                    We studied Borrelia burgdorferi 
 for several known hallmark features of biofilm, including
                   </p>
                   <ul>
                    <li>
                     structural rearrangements in the aggregates,
                    </li>
                    <li>
                     variations in 
 development on various substrate matrices and
                    </li>
                    <li>
                     secretion of a protective extracellular polymeric substance (EPS) matrix
                     <br/>
                     <p>
                      using several modes of microscopic, cell and molecular biology techniques.
                     </p>
                    </li>
                    <li>
                     The atomic force microscopic results provided 
 evidence that multilevel rearrangements take place at different stages of aggregate development, producing a
                     <b>
                      complex, 
 continuously rearranging structure
                     </b>
                     .
                    </li>
                   </ul>
                   Our results also demonstrated that Borrelia burgdorferi
                   <ul>
                    <li>
                     is capable of developing 
 aggregates on different abiotic and biotic substrates, and
                    </li>
                    <li>
                     is also capable of forming floating aggregates.
                    </li>
                   </ul>
                   Analyzing the 
 extracellular substance of the aggregates for potential exopolysaccharides revealed the existence of both sulfated and non- 
 sulfated/carboxylated substrates, predominately composed of an alginate with calcium and extracellular DNA present.
                   <p>
                    In 
 summary, we have found substantial evidence that Borrelia burgdorferi is capable of forming biofilm in vitro.
                   </p>
                  </font>
                 </blockquote>
                 <hr/>
                 <font face="verdana">
                  <font size="-1">
                   <b>
                    (Datum: 14. Oktober 2012)
                   </b>
                   <br/>
                   <table>
                    <tr>
                     <td valign-="">
                      <iframe allowfullscreen="" frameborder="0" height="158" src="http://www.youtube.com/embed/68zYTzTlTlk" width="280">
                      </iframe>
                      <br/>
                      <font size="-2">
                       Cpn = Chlamydia pneumoniae
                      </font>
                     </td>
                     <td valign="center">
                      <font face="verdana">
                       <font size="-2">
                        W. Webley, PhD, Assistant Professor, University of Massachussetts, Amherst, MA: "
                        <b>
                         Biofilms an Chronic Health Conditions: Challenges for Patients, Doctors and Researchers
                        </b>
                        ", Sept. 24, 2009
                        <br/>
                        Chronische Infektionen unterscheiden sich mikrobiologisch wesentlich von akuten Infektionen. Darauf muß die Therapie abgestimmt werden. Im Vortrag werden Parallelen gezogen zwischen Cpn und Bb.
                        <font>
                        </font>
                       </font>
                      </font>
                     </td>
                    </tr>
                    <tr>
                     <table>
                      <hr/>
                      <font size="-1">
                       <b>
                        (Datum: 29. Juli 2012)
                       </b>
                       <br/>
                       Dr. Harald Bennefeld, FA für Neurochirurgie/ Sportmedizin, Chefarzt der neurologischen Klinik in Gyhum, Mitglied der Deutschen Borreliose-Gesellschaft e.V.
                       <p>
                        "
                        <b>
                         Therapie der Borreliose, insbesondere der chronischen Neuroborreliose, aus Sicht der neurolog. Rehabilitationsmedizin, des Akut-Krankenhauses und unter speziellen neurochirurgischen Aspekten
                        </b>
                        ",
                        <br/>
                        Vortrag am 29. September 2012 10:30 - 13:00 Uhr, Leipzig
                       </p>
                       <p>
                        Anmeldung bei
                        <a href="mailto:borreliose-leipzig@gmx.de">
                         Gert Schlegel
                        </a>
                        , Borreliose-SHG Leipzig, Hans-Marchwitza-Str. 28, 04279 Leipzig, Tel. (0341) 338-2155
                       </p>
                       <hr/>
                       <b>
                        (Datum: 29. Juli 2012)
                       </b>
                       <br/>
                       Deutsche Borreliose-Gesellschaft, Mitteilungen,
                       <a href="http://www.borreliose-gesellschaft.de/Mitteilungen/Mitteilungen_2012-4.pdf">
                        Juli 2012
                       </a>
                       ,
                       <b>
                        Interview vom 8.9.2010 mit Dr. Burgdorfer
                       </b>
                       , Auszug aus der Kurzfassung, Fragen stellten Matthias Jakob und Friedemann Weidner.
                      </font>
                      <blockquote>
                       <font size="-2">
                        <i>
                         Dr. Burgdorfer
                        </i>
                        : Wenn ein Patient von einem Zeckenstich berichtet, dann sollte der Arzt immer an eine Borreliose denken. Und auch wenn die Inkubationszeit vorüber ist, sollte er daran denken, dass vielleicht die Borrelie irgendwo im Gehirn dieses armen Kranken sitzt und hier und da gewisse Schwierigkeiten hervorbringt, die man nicht oder noch nicht definieren kann, weil die Physiologie der Borrelie immer noch so ein großes Rätsel ist.
                        <p>
                         <i>
                          Frage
                         </i>
                         : Wenn man einen Zeckenstich an seinem Körper entdeckt, was sollte man dann tun?
                        </p>
                        <p>
                         <i>
                          Dr. Burgdorfer
                         </i>
                         : Ein Arzt sollte konsultiert werden und er sollte sofort mit einer Antibiotika-Behandlung beginnen. Vor allem wenn eine Wanderröte, also ein roter Fleck um die Einstichstelle herum, entdeckt wird.
                        </p>
                       </font>
                      </blockquote>
                      <hr/>
                      <font size="-1">
                       <b>
                        (Datum: 26. März 2012)
                       </b>
                       <br/>
                       Brian A. Fallon, Elizabeth S. Levin, Pernilla J. Schweitzer, David Hardesty,
                       <a href="http://www.ncbi.nlm.nih.gov/pubmed/19944760">
                        <b>
                         Inflammation and central nervous system Lyme disease
                        </b>
                       </a>
                       , Neurobiol Dis. 2010 Mar;37(3):534-41 (im
                       <a href="../literatur/Fallon_Inflammation-and-central-nervous-system-Lyme-disease_2009.pdf">
                        Cache
                       </a>
                       ).
                      </font>
                      <blockquote>
                       <font size="-2">
                        Sequence homology has been noted between myelin basic protein and B.b. spirochetal flagellin and there are studies demonstrating cross-reactive polyclonal and monoclonal antibodies which recognize flagellar antigenic determinants as well as epitopes on neural cells. Such cross-reactivity could contribute to a chronic, relapsing-remitting, B. burgdorferi- triggered, immune-mediated neurological disorder similar to MS.
                       </font>
                      </blockquote>
                      <ul>
                       <li>
                        <font size="-2">
                         Walter Berghoff,
                         <a href="http://www.borreliose-gesellschaft.de/de/Informationen/LB_des_ZNS">
                          Exzerpte dieser Arbeit in deutscher Übersetzung
                         </a>
                         (im
                         <a href="literatur/fallon-berghoff.html">
                          Cache
                         </a>
                         )
                        </font>
                       </li>
                      </ul>
                      <p>
                      </p>
                      <hr/>
                      <font size="-1">
                       <b>
                        (Datum: 29.November 2011)
                       </b>
                       <br/>
                       <b>
                        Lyme Disease Symptoms
                       </b>
                       <a href="http://youtu.be/LkGuw6qniYg">
                        Pt. 1
                       </a>
                       ,
                       <a href="http://youtu.be/3SmH82D73R0">
                        Pt. 2
                       </a>
                       , excerpts from P.J. Langhoff, "
                       <a href="http://www.godsciencebook.com/">
                        God Science: The Secret World of Rampant Genetics, Hidden Illness, and Biotech Profiteering
                       </a>
                       ", Audio book, Allegory Press LLC, 2011.
                       <p>
                        Eleanor D. Hynote, Phyllis C. Mervine, Raphael B. Stricker, "
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22104184">
                         <b>
                          Clinical evidence for rapid transmission of Lyme disease following a tickbite
                         </b>
                        </a>
                        ", Diagn Microbiol Infect Dis. 2011 Nov 18.
                       </p>
                      </font>
                      <p>
                       <font size="-2">
                        <table>
                         <tr>
                          <td valign="top">
                           <div style="
 margin: 1em;
 margin-right: 2em;
 border: 1px solid #999999;
 border-left: 1px solid #AAAAAA;
 border-bottom: 1px solid #AAAAAA;">
                            <div style="
 border: 3px solid #F0F0F0;
 border-left: 1px solid #F8F8F8; 
 border-bottom: 1px solid #F8F8F8;">
                             <a href="literatur/rapid_transmission_of_lyme.jpg">
                              <img alt="patient characteristics" src="literatur/rapid_transmission_of_lyme_tmb.jpg"/>
                             </a>
                             <br/>
                             <font size="-2">
                              zum Vergrößern auf Bild klicken
                              <br/>
                              Quelle:
                              <a href="http://www.sciencedirect.com/science/article/pii/S0732889311004159">
                               ScienceDirect
                              </a>
                              <p>
                               We describe 3 cases in which transmission of Borrelia burgdorferi appears to have occurred in less than 24 h based on
                              </p>
                              <ul>
                               <li>
                                the degree of tick
                                <a href="http://dict.leo.org/ende?lp=ende&amp;lang=de&amp;searchLoc=0&amp;cmpType=relaxed&amp;sectHdr=on&amp;spellToler=&amp;search=engorgement">
                                 engorgement
                                </a>
                                ,
                               </li>
                               <li>
                                clinical signs of acute infection, and
                               </li>
                               <li>
                                immunologic evidence of acute Lyme disease.
                               </li>
                              </ul>
                              Health care providers and individuals exposed to ticks should be aware that transmission of Lyme disease may occur more rapidly than animal models suggest. A diagnosis of Lyme disease should not be ruled out based on a short tick attachment time in a subject with clinical evidence of B. burgdorferi infection.
                             </font>
                            </div>
                           </div>
                          </td>
                          <td valign="top">
                           <font size="-2">
                            The attachment time required for a tick to transmit B. burgdorferi, the spirochetal agent of Lyme disease, has important clinical implications. Studies in mice and rabbits suggest that a tick must be attached for at least 36 - 48 h in order for efficient transmission of B. burgdorferi to occur, and these studies have been interpreted to mean that removal of a tick within 36 - 48 h of attachment will prevent transmission of Lyme disease.
                            <p>
                             The animal transmission studies have several significant limitations, however:
                            </p>
                            <ol>
                             <li>
                              they were performed using laboratory strains of B. burgdorferi such as B31, and these strains may have transmission characteristics that differ from wild-type strains (Labandeira-Rey and Skare,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/11119536">
                               2001
                              </a>
                              ; Purser and Norris,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/11106398">
                               2000
                              </a>
                              ).
                             </li>
                             <li>
                              the studies did not factor in tick coinfections that may enhance the infectivity of the Lyme spirochete (des Vignes et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/11181154">
                               2001
                              </a>
                              ; Mather et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/2295326">
                               1990
                              </a>
                              ; Piesman et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/3571459">
                               1987
                              </a>
                              ; Zeidner et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/11116438">
                               2000
                              </a>
                              ).
                             </li>
                             <li>
                              the effect of other transmission factors such as tick saliva and host immunity was not evaluated in these animal models (Horka et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/19147403">
                               2009
                              </a>
                              ; Hovius,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/19749783">
                               2009
                              </a>
                              ; Ueti et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/18955472">
                               2009
                              </a>
                              ; Zeidner et al.,
                              <a href="http://www.ncbi.nlm.nih.gov/pubmed/9234760">
                               1997
                              </a>
                              ).
                             </li>
                            </ol>
                            Thus the transmission times derived from these studies may not apply to the clinical situation in humans and may give a false sense of security about the risk of Lyme disease following a tickbite.
                           </font>
                          </td>
                         </tr>
                        </table>
                        <p>
                        </p>
                        <hr/>
                        <font size="-1">
                         <b>
                          (Datum: 29.September 2011)
                         </b>
                         <br/>
                         <a href="http://www.borreliose-gesellschaft.de/Mitteilungen/Mitteilungen_2011-4.pdf">
                          September-Mitteilungen der
                          <b>
                           Deutschen Borreliose-Gesellschaft
                          </b>
                         </a>
                        </font>
                        <blockquote>
                         <font size="-2">
                          Aufruf zur Mitarbeit, Borreliose - eine Multisystemerkrankung, Borreliose-Wahrnehmung, Vermischte Meldungen, Meldepflicht im Saarland, Zecken im städtischen Grün, Fluconazol und Fehlbildungen, Literaturbesprechungen: Pathogenese (Lyme Neuroborreliose), Pathogenese (HGA), Differentialdiagnose Lyme Neuroborreliose vs. Bell's Palsy, Molekularbiologische Diagnostik der Borreliose, Epidemiologie der Borreliose, Ko-Transmission / Ko-Infektion der Zecken.
                          <p>
                          </p>
                         </font>
                        </blockquote>
                        <hr/>
                        <font size="-1">
                         <b>
                          (Datum: 19.September 2011)
                         </b>
                         <br/>
                         Knauer J, Krupka I, Fueldner C, Lehmann J, Straubinger RK. "
                         <b>
                          Evaluation of the preventive capacities of a topically applied azithromycin formulation against Lyme borreliosis in a murine model.
                         </b>
                         " J Antimicrob Chemother. 2011 Sep 15.
                         <p>
                          Our data indicate that topical treatment with a formulation containing azithromycin is a promising approach to prevent Lyme borreliosis shortly after a tick bite.
                         </p>
                        </font>
                        <p>
                        </p>
                        <blockquote>
                         <font size="-2">
                          Details: Laboratory mice were challenged with Borrelia burgdorferi sensu stricto by needle inoculation or via infected ticks as vectors. Then, an azithromycin-containing formulation was applied once daily to the sites of exposure for three consecutive days. In the case of needle inoculation, a 5% azithromycin formulation was applied starting 1 h, 3 days and 5 days after infection. In the case of tick exposure, 4%, 10% and 20% azithromycin formulations were applied, starting directly after the detachment of the engorged ticks. Concentrations of azithromycin in murine skin were &gt;3800-fold higher than the published minimal inhibitory concentration for B. burgdorferi as soon as 3 h after the first application. After needle inoculation, spirochaetes were not detectable in all infected mice after treatment, if the first application started 1 h or even after 3 days post-infection. Furthermore, no borrelial organisms were detected after topical treatment when ticks were used for spirochaete inoculation.
                         </font>
                        </blockquote>
                        <hr/>
                        <font size="-1">
                         <a name="harold_smith">
                         </a>
                         <b>
                          (Datum: 11. September 2011)
                         </b>
                         <br/>
                         <table>
                          <tr>
                           <td valign="center">
                            <iframe allowfullscreen="" frameborder="0" height="158" src="http://www.youtube.com/embed/JpPFKp3FXmQ" width="280">
                            </iframe>
                           </td>
                           <td valign="center">
                            <font face="verdana">
                             <font size="-2">
                              Stellungnahme von Harold Smith (
                              <a href="http://www.ilads.org/">
                               ILADS
                              </a>
                              ) zu Lyme Disease Care ("Pennsylvania Lyme Bill" HB272) vor dem Pennsylvania House Human Services Committee, August 30, 2011 (in Unterstützung der HB272). Ein wesentliches Problem sei eine Verzögerung der Diagnose auf Grund fehlender öffentlicher und ärztlicher Vorbildung and ein Verlassen auf Tests, welche nicht ausreichend diagnostisch sind. Am 15 Dezember 2011 hat das Committee dafür gestimmt, HB272 dem "House Floor" zu unterbreiten.
                             </font>
                            </font>
                           </td>
                          </tr>
                         </table>
                         <p>
                         </p>
                         <hr/>
                         <font size="-1">
                          <b>
                           (Datum: 5. Juli 2011)
                          </b>
                          <br/>
                          <a href="http://www.borreliose-gesellschaft.de/Mitteilungen/Mitteilungen_2011-3.pdf">
                           <b>
                            DBG-Mitteilungen 2011-3
                           </b>
                          </a>
                          <br/>
                         </font>
                         <font size="-2">
                          <ul>
                           <li>
                            Planung einer interdisziplinären S3-Leitlinie zur Lyme-Borreliose
                           </li>
                           <li>
                            Gutachter-Arbeitskreis
                           </li>
                           <li>
                            Aufruf zur Mitarbeit
                           </li>
                           <li>
                            Diagnostik der Borreliose
                           </li>
                           <li>
                            Kosten und Häufigkeit der Lyme-Borreliose
                           </li>
                           <li>
                            Nachrichten
                            <ul>
                             <li>
                              Meldepflicht in Rheinland-Pfalz
                             </li>
                             <li>
                              Prophylaxe
                             </li>
                             <li>
                              Buch zur Borreliose
                             </li>
                            </ul>
                           </li>
                           <li>
                            Literaturbesprechung
                           </li>
                           <li>
                            Personalien
                           </li>
                           <li>
                            Termine
                           </li>
                          </ul>
                         </font>
                         <p>
                         </p>
                         <hr/>
                         <font size="-1">
                          <b>
                           (Datum: 2. April 2011)
                          </b>
                          <br/>
                          Deutsche Borreliose-Gesellschaft:
                          <a href="http://www.borreliose-gesellschaft.de/Texte/Leitlinien.pdf">
                           <b>
                            Diagnostik und Therapie der Lyme-Borreliose
                           </b>
                          </a>
                          , Auflage Januar 2011 (
                          <a href="http://www.borreliose-gesellschaft.de/Texte/guidelines.pdf">
                           Diagnosis and Treatment of Lyme borreliosis
                          </a>
                          , Revised 2nd Edition, Dec 2010)
                          <p>
                          </p>
                          <hr/>
                          <b>
                           (Datum: 12. August 2010)
                          </b>
                          <br/>
                          <a href="http://www.immed.org/reachus.htm">
                           <b>
                            Garth L. Nicolson
                           </b>
                          </a>
                          , Ph.D. (
                          <a href="http://www.immed.org/index.htm">
                           Institute for Molecular Medicine
                          </a>
                          , Huntington Beach, California)
                          <p>
                           <font size="-2">
                            "Chronically ill patients with neurodegenerative, neurobehavioural and psychiatric diseases commonly have systemic and central nervous system bacterial and viral infections.  In addition, other chronic illnesses where neurological manifestations are routinely found, such as fatiguing and autoimmune diseases, Lyme disease and Gulf War illnesses, also show systemic bacterial and viral infections that could be important in disease inception, progression or increasing the types/severities of signs and symptoms."
                            <p>
                             Garth L. Nicolson, J. Haier, Role of Chronic Bacterial and Viral Infections in Neurodegenerative, Neurobehavioral, Psychiatric, Autoimmune and Fatiguing Illnesses:
                            </p>
                            <ul>
                             <li>
                              <a href="http://www.immed.org/NeuroDiseases/NeuroDegenPubs03.2010updates/BJMPnicolsonhaier-Part1.pdf">
                               Part 1
                              </a>
                              , British Journal of Medical Practitioners 2009;2(4):20-28,
                             </li>
                             <li>
                              <a href="http://www.immed.org/NeuroDiseases/NeuroDegenPubs03.2010updates/BJMPnicolsonhaier-Part2.pdf">
                               Part 2
                              </a>
                              ,  British Journal of Medical Practitioners 2010;3(1):301-311.
                             </li>
                            </ul>
                           </font>
                          </p>
                          <p>
                          </p>
                          <hr/>
                          <b>
                           (Datum: 24. Juni 2010)
                          </b>
                          <br/>
                          <a href="http://www.everth.de/html/uta_.html">
                           Uta Everth
                          </a>
                          ,
                          <b>
                           "
                           <a href="literatur/everth_2010.pdf">
                            Zielwertfindung und Standards in der Borrelien-Serologie
                           </a>
                           "
                          </b>
                          (
                          <a href="http://www.borreliose-gesellschaft.de/Veranstaltungen/2010BadHerrenalb/Programm/Vortrag_Everth">
                           Abstract
                          </a>
                          ), in "
                          <a href="http://www.borreliose-gesellschaft.de/Veranstaltungen/2010BadHerrenalb/Programm">
                           Lyme-Borreliose, Koinfektionen und Multisystemerkrankungen
                          </a>
                          ",
                          <a href="http://www.borreliose-gesellschaft.de/">
                           Deutsche Borreliose-Gesellschaft
                          </a>
                          , Bad Herrenalb, 28. - 30. 5. 2010.
                          <table>
                           <tr>
                            <td>
                             <font face="verdana">
                              <font size="-2">
                               <ul>
                                <li>
                                 Zur Bestimmung von Borrelia-
                                 <a href="terms.htm#antikoerper">
                                  Antikörpern
                                 </a>
                                 gibt es
                                 <ol>
                                  <li>
                                   keinen definitiven Referenz-Standard ("
                                   <a href="http://en.wikipedia.org/wiki/Gold_standard_(test)">
                                    Gold Standard
                                   </a>
                                   "),
                                  </li>
                                  <li>
                                   kein Referenz-Serum.
                                  </li>
                                 </ol>
                                 Da man nicht weiß, wer gesund und wer erkrankt ist, weiß man auch nicht, welchen Bruchteil der Erkrankten und welchen der Gesunden der serologische Antikörper-Nachweis erkennt. In diesem Sinn ist die Lage der Testschwelle ("Cut") beliebig, d.h. der Schwelle, jenseits derer der serologische Antikörper-Nachweis eine Person als erkrankt bezeichnet.
                                 <p>
                                 </p>
                                </li>
                                <li>
                                 Der
                                 <a href="http://en.wikipedia.org/wiki/Serologic_test">
                                  serologische
                                 </a>
                                 Antikörper-Nachweis
                                 <ul>
                                  <li>
                                   ist kein Aktivitätsmarker für ein Krankheitsgeschehen.
                                  </li>
                                  <li>
                                   stellt nur freie, d.h. nicht in
                                   <a href="terms.htm#immunkomplex">
                                    Immunkomplexen
                                   </a>
                                   gebundene Antikörper fest.
                                  </li>
                                  <li>
                                   ist negativ (erklärt also die getestete Person fälschlicherweise für gesund), wenn im Blutserum
                                   <ul>
                                    <li>
                                     die Konzentration der vom Test spezifisch gesuchten freien Antikörper unterhalb der Nachweisgrenze liegt (es gibt ein breites Spektrum von Antikörpern, von dem der Test nur einen kleinen Ausschnitt erkennt),
                                    </li>
                                    <li>
                                     überhaupt keine Antikörper vorliegen, z.B. weil das Immunsystem die Antigene nicht erkennt.
                                    </li>
                                   </ul>
                                   <p>
                                    Antikörper, die an rekombinante Antigene binden,  weisen 
 einen hohen Grad an Selektivität auf. Man geht aber auch bei 
 diesen Antikörpern von unspezifischen Bindungen aus, 
 sodass der Cut [d.h. die Trennung zwischen test-positiv und test-negativ] vom Hersteller jeweils angepasst wird. Die 
 analytische Sensitivität ist hierbei ungewiss [d.h. wieviele von den tatsächlich Kranken erkannt werden]. Dies ist auch 
 bedingt durch die Vielfalt an pathogenen Stämmen, die nicht 
 sicher von einzelnen Antigenen erfasst werden.
                                   </p>
                                  </li>
                                 </ul>
                                </li>
                                <li>
                                 Verbesserte Verfahren des serologischen Antikörper-Nachweises werden diskutiert.
                                </li>
                               </ul>
                              </font>
                             </font>
                            </td>
                            <td align="center">
                             <font face="verdana">
                              <font size="-2">
                               <img alt="Antikoerper und Antigene" border="1" src="literatur/everth_2010.jpg"/>
                               <p>
                                Antikörper ("Y") und Antigene
                               </p>
                              </font>
                             </font>
                            </td>
                           </tr>
                          </table>
                          <hr/>
                          <b>
                           (Datum: 26. Mai 2010)
                          </b>
                          <br/>
                          Informationen von
                          <a href="mailto:ch.welker@web.de">
                           Corry Welker
                          </a>
                          <p>
                           <b>
                            LB und Alzheimer/
                            <a href="http://www.lyme-disease-research-database.com/alan-macdonald-transcription.html">
                             Interview Dr. MacDonald
                            </a>
                            (ILADS-Arzt).
                           </b>
                           <br/>
                           <font size="-2">
                            Wie auch Dr. Miklossy, berichtete Dr. Alan MacDonald über seine Untersuchungen,  bezüglich Bb und Alzheimer. Er präsentierte Resultate und Hypothesen auf eine Tagung der LDA+ILADS in Philadelphia. Der Originaltext des Interviews datiert aus April 2008.
                            <p>
                             Vor allem der Fall eines Feuerwehrmannes, Paul Christensen, brachte ihn viel weiter. Dr. MacDonald konnte zeigen, dass die Hirnareale mit Alzheimer-ähnlichem Schaden  die gleichen waren wie die Areale mit  Spirochäten-DNA. Er benutzte dazu fluoriszierend gefärbtes Bb-DNA.
 Er betont die Ähnlichkeit mit dem Syphilis-Erreger und das Vorkommen der Sonderformen , die leicht übersehen würden. Ebenso die Biofilme, die schon im Film "Under our Skin" erwähnt wurden. Im Biofilm d.h. in der Bb-Kolonie seien eher die Sonderformen vorhanden, was diese Kolonien ziemlich AB-resistent mache, vor allem wegen einer gel-artigen Schutzschicht . Er erwähnt auch noch mal die Möglichkeit der vertikalen Infizierung von Mutter auf Kind durch die Plazenta. (Siehe frühere Artikel im Internet, auch im Buch Hans Horst). Auch dass LB lange Zeit eine latente/ruhende Infektion sein könne, oder dass Patienten bei Schwächung des Abwehrsystems aus irgendwelchen Gründen noch nach zwanzig oder dreißig Jahren Spätsymptome entwickeln können (Reaktivierung -zB Bb-Herde in der Haut bei ACA; sich dadurch entwickelnder Gewebeschaden hieße immer noch eine aktive Infektion),   Resultate, die medizinisch-politisch nicht gerne gehört werden...
                             <br/>
                             Bericht von Paul Christensen auf
                             <a href="http://www.canlyme.com">
                              www.canlyme.com
                             </a>
                             <br/>
                             <a href="http://www.molecularalzheimer.org">
                              Webseite Dr MacDonald
                             </a>
                             <br/>
                            </p>
                            <p>
                             <b>
                              FSME /RKI Zahlen 2009
                             </b>
                             nach Hinweis NGZ 6.5.2010:
                             <font size="-2">
                              "Die Zahl der Hirnhautentzündungen durch Zeckenbisse hat vergangenes Jahr leicht zugenommen. In 2009 erkrankten in D 313 Menschen an....FSME und somit  8 % mehr.....wie das RKI in Berlin mitteilte...."
                             </font>
                            </p>
                            <p>
                             Kenntnis der Infektionsorte ist notwendig für die Präzisierung der Risikogebiete.  Bei 300 Meldungen lag er in D. Die Zahl der Risikogebiete bleibt bei 136 bundesweit konstant und unverändert.  
 (Risikogebiet: deutlich mehr als 1 Fall auf 100.000 Einwohner innerhalb 5 Jahren.)
                             <br/>
                             Die Risikogebieten sind unverändert geblieben:
                            </p>
                            <ul>
                             <li>
                              78 in Bayern,
                             </li>
                             <li>
                              42 in Baden-Württ;
                             </li>
                             <li>
                              8 in (Süd)Hessen,
                             </li>
                             <li>
                              7 in Thüringen,
                             </li>
                             <li>
                              1 in Rh.Pfalz.
                             </li>
                            </ul>
                            Gebiete mit Einzelfällen in der Vergangenheit  werden beobachtet.
                            <p>
                             Die Inzidenz der FSME kann durch Steigerung der Impfrate reduziert werden, gäbe aber ein falsches Bild über das Risiko. Dann wären weitere Kriterien für die Risikoerfassung notwendig wie zB Zeckenvorkommen, Durchseuchung, Erfassung Impfquoten und Tierbefall, die es bisher nicht ausreichend gibt. Deshalb bastelt man an einen möglichen Korrekturfaktor.
                            </p>
                            <p>
                             Ältere Menschen scheinen sich weniger impfen zu lassen als die Kinder, hätten aber ein viel höheres Risiko nach Infektion ernsthaft zu erkranken.  
 Bei FSME-Verdacht:
                             <b>
                              Eine  frühere FSME-Impfung oder eine gegen Gelbfieber oder Japan-Enzephalitis oder ein durchgemachtes Denguefieber können die Diagnose fälschen;
                             </b>
                             hier seien Verlauftests unverzichtbar.
                             <i>
                              Impf-Empfehlung
                             </i>
                             : nur für Menschen, die a. in Risikogebieten wohnen/arbeiten und b. zeckenexponiert sind, inkl. beruflich Gefährdete da. Für diese Gruppen ist die Kostenerstattung der Kassen pflichtmäßig,
 Eine Impfprophylaxe wird auch als sinnvoll gesehen bei Freizeit-Zeckenexponierung, auch da wo nur vereinzelte Fälle auftraten. Ebenso für Reisende in Endemiegebiete außer Deutschland.
                             <br/>
                             Weitere Zahlen und Werte zu den einzelnen Landkreisen und jeweiligen Bundesländern von 2002 bis 2009 finden Sie bei:
                             <a href="http://www.rki.de/cln_160/nn_1759378/DE/Content/Infekt/EpidBull/Archiv/2010/17__10__Anlage__
 Tabelle,templateId=raw,property=publicationFile.pdf/17_10_Anlage_Tabelle.pdf">
                              http://www.rki.de/cln_160/nn_1759378/DE/Content/Infekt/EpidBull/Archiv/2010/17__10__Anlage__
 Tabelle,templateId=raw,property=publicationFile.pdf/17_10_Anlage_Tabelle.pdf
                             </a>
                             (14 Seiten)
                            </p>
                            <p>
                            </p>
                            <hr/>
                            <b>
                             (Datum: 1. September 2009)
                            </b>
                            <br/>
                            B Pawlicki,
                            <a href="literatur/BohdanP.htm">
                             <b>
                              The Use of Silver Hydrosol
                             </b>
                            </a>
                            in Treating Neurological Lyme Disease
                            <br/>
                            <blockquote>
                             Medication:
                             <ul>
                              <li>
                               <a href="http://www.google.com/search?hl=en&amp;lr=&amp;client=safari&amp;rls=en&amp;as_qdr=all&amp;q=antimicrob+agent+%28borrelia+OR+Lyme%29+%22Silver+hydrosol+%22&amp;btnG=Search">
                                silver hydrosol
                               </a>
                               orally - 2 x 120 ml/day
                              </li>
                              <li>
                               statins: atorvastatin - 1 x 40 mg/day
                              </li>
                              <li>
                               serotonin reuptake inhibitor: paroxentine - 20 mg/day
                              </li>
                              <li>
                               minocycline - 100 mg every second day
                              </li>
                              <li>
                               olmesartan - 4 x 20 mg/day.
                              </li>
                             </ul>
                             After improvement of health status: Maintenance therapy with
                             <ul>
                              <li>
                               oral silver hydrosol - 2 x 120 / day
                              </li>
                              <li>
                               all the above mentioned anti-inflammatory agents
                              </li>
                              <li>
                               <a href="http://www.google.com/search?client=safari&amp;rls=en&amp;q=%22low+dose+naltrexone+therapy%22&amp;ie=UTF-8&amp;oe=UTF-8">
                                low-dose naltrexone therapy
                               </a>
                              </li>
                              <li>
                               selenium, magnesium and niacin.
                              </li>
                             </ul>
                            </blockquote>
                            <p>
                            </p>
                            <hr/>
                            <b>
                             (Datum: 23. Juli 2009)
                            </b>
                            <br/>
                            Informationen der
                            <a href="http://www.borreliose-gesellschaft.de">
                             Deutschen Borreliose-Gesellschaft
                            </a>
                            <font size="-2">
                             <ul>
                              <li>
                               CE Kennedy, RS Azfar, PJ Honig,
                               <a href="http://dx.doi.org/10.1111/j.1525-1470.2008.00863.x">
                                Lyme Disease as a Cause of
                                <b>
                                 Acropapular Dermatitis of Childhood
                                </b>
                               </a>
                               , 
 Pediatric Dermatology, Published Online: 18 Mar 2009
                              </li>
                              <li>
                               M Elamin, Y Alderazi, G Mullins, MA Farrell, S O'Connell, TJ Counihan
                               <a href="http://dx.doi.org/10.1002/mus.21289">
                                <b>
                                 Perineuritis
                                </b>
                                in acute lyme neuroborreliosis
                               </a>
                               , Muscle &amp; Nerve, Volume 39, Issue 6, Pages 851 - 854.
                              </li>
                              <li>
                               BA Fallon; RB Lipkin; KM Corbera; S Yu; MS Nobler; JG Keilp; E Petkova; SH Lisanby; JR Moeller; I Slavov; R Van Heertum; BD Mensh; HA Sackeim
                               <a href="http://archpsyc.ama-assn.org/cgi/content/abstract/66/5/554">
                                <b>
                                 Regional Cerebral Blood Flow and Metabolic Rate
                                </b>
                                in Persistent Lyme Encephalopathy
                               </a>
                               , Archives of General Psychiatry, May 2009, Volume 66, No. 5, p.554-563.
                              </li>
                              <li>
                               A Marques, MR Brown, and T. Fleisher
                               <a href="http://dx.doi.org/10.1128/CVI.00167-09">
                                <b>
                                 Natural killer cell counts
                                </b>
                                are not different between patients with post-Lyme disease syndrome and controls
                               </a>
                               , Clininical and Vaccine Immunology, epub ahead of print June 10, 2009.
                              </li>
                              <li>
                               Santino I, Sessa R, Pantanella F, Tomao P, Di Renzi S, Martini A, Nicoletti M, Del Piano M,
                               <a href="http://www.ncbi.nlm.nih.gov/pubmed/19505407">
                                Detection of different Borrelia burgdorferi
                                <b>
                                 genospecies
                                </b>
                                in serum of people with different occupational risks: short report
                               </a>
                               , International Journal of Immunopathology and Pharmacology. 2009 Apr-Jun;22(2):537-41.
                              </li>
                              <li>
                               R Agarwal and G Sze,
                               <a href="http://dx.doi.org/10.1148/radiol.2531081103">
                                Neuro-Lyme Disease:
                                <b>
                                 MR Imaging
                                </b>
                                Findings
                               </a>
                               , Radiology, Published online before print July 8, 2009.
                               <blockquote>
                                Results: Of 392 patients suspected of having neuro-Lyme disease, 
 66 patients proved to have the disease on the basis of clinical criteria, serologic results, and response to treatment.
                                <ul>
                                 <li>
                                  7 of these 66 patients showed foci of T2 prolongation in the cerebral white matter,
                                 </li>
                                 <li>
                                  1 had an enhancing lesion with edema, and
                                 </li>
                                 <li>
                                  3 demonstrated nerve-root or meningeal enhancement.
                                 </li>
                                </ul>
                                Of the 7 patients with foci of T2 prolongation in the white matter, 3 were an age at which white matter findings due to small-vessel disease are common.
                                <br/>
                                Conclusion: In cases of nerve-root or meningeal enhancement, Lyme disease should be considered in the differential diagnosis in the proper clinical setting.
                               </blockquote>
                              </li>
                              <li>
                               J Aucott, C Morrison, B Munoz, PC Rowe, A Schwarzwalder and SK West,
                               <a href="http://www.biomedcentral.com/content/pdf/1471-2334-9-79.pdf">
                                <b>
                                 Diagnostic
                                </b>
                                challenges of
                                <b>
                                 early Lyme disease
                                </b>
                                : Lessons from a community case series
                               </a>
                               , BMC Infectious Diseases 2009, 9:79, Published: 1 June 2009
                               <blockquote>
                                Results: The majority (61%) of patients in this case series were diagnosed with early Lyme disease. Of those diagnosed with early Lyme disease, 13% did not present with erythema migrans; of those not presenting with a rash, 
 54% had been previously misdiagnosed. Among those with a rash, the diagnosis of erythema migrans was initially missed in 23% of patients whose rash was subsequently confirmed. Of all patients previously misdiagnosed, 41% had received initial antibiotics likely to be ineffective against Lyme disease.
                               </blockquote>
                              </li>
                             </ul>
                            </font>
                            <hr/>
                            <font size="-2">
                             <b>
                              (Datum: 19. Mai 2009)
                             </b>
                             <br/>
                             Informationen von
                             <a href="mailto:ch.welker@web.de">
                              Corry Welker
                             </a>
                             <ul>
                              <li>
                               An der
                               <a href="http://publichealth.yale.edu/">
                                Yale School of Public Health
                               </a>
                               konnte eine Forschergruppe um
                               <a href="http://info.med.yale.edu/eph/faculty/fish.html">
                                Durland Fish
                               </a>
                               an 30 verschiedenen Standorten der USA nachweisen, dass die Verschiebung der Jahreszeiten die
                               <b>
                                Wahrscheinlichkeit
                               </b>
                               erhöhen kann, nach einem Zeckenstich an Lyme-Borreliose zu erkranken. Bisher wusste man nur, dass der Klimawandel zur Vergrößerung des
                               <b>
                                geografischen Verbreitungsgebietes
                               </b>
                               von Zecken führen kann.
                               <br/>
                               <font size="-2">
                                Quelle:
                                <a href="http://pressetext.de/pteprint.mc?pte=090511002">
                                 Zecken durch Klimawandel gefährlicher: Verschiebung der Jahreszeiten macht Erreger hartnäckiger
                                </a>
                                , Pressetext Austria.
                                <blockquote>
                                 <font size="-2">
                                  Gatewood AG, Liebman KA, Vourc'h G, Bunikis J, Hamer SA, Cortinas R, Melton F, Cislo P, Kitron U, Tsao J, Barbour AG, Fish D, Diuk-Wasser MA.,
                                  <a href="http://www.ncbi.nlm.nih.gov/pubmed/19251900?ordinalpos=1&amp;itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum">
                                   Climate and tick seasonality are predictors of Borrelia burgdorferi genotype distribution
                                  </a>
                                  . Appl Environ Microbiol. 2009 Apr;75(8):2476-83. Epub 2009 Feb 27.
                                 </font>
                                </blockquote>
                                <p>
                                 <font size="-2">
                                  <li>
                                   <a href="http://www.borreliose-gesellschaft.de/Veranstaltungen/2009Tabarz/Vortraege">
                                    <b>
                                     Vortragsunterlagen zur Jahresversammlung 2009
                                    </b>
                                    in Tabarz
                                   </a>
                                   , Deutsche Borreliose-Gesellschaft (
                                   <a href="http://www.borreliose-gesellschaft.de/Veranstaltungen">
                                    Veranstaltungen 2006 - 2010
                                   </a>
                                   ).
                                  </li>
                                 </font>
                                 <font size="-2">
                                  <ul>
                                   <li>
                                    Aberer E.
                                    <a href="http://www.borreliose-gesellschaft.de/Unterlagen_2009_Tabarz/Aberer_Tabarz_2009.pdf">
                                     Die Haut bei Lyme-Borreliose
                                    </a>
                                    , Universitätsklinik für Dermatologie, Medizinische Universität Graz, 2009. (in
                                    <a href="literatur/aberer_tabarz_2009.pdf">
                                     Cache
                                    </a>
                                    )
                                   </li>
                                   <li>
                                    von Baehr R.
                                    <a href="http://www.borreliose-gesellschaft.de/Unterlagen_2009_Tabarz/vonBaehr_Tabarz_2009.pdf">
                                     Zellulär-immunologische Methoden zur verlaufsbeobachtung von patienten mit Borreliose vor und nach antibiotischer Behandlung
                                    </a>
                                    , Institut für medizinische Diagnostik Berlin. (in
                                    <a href="literatur/vonbaehr_tabarz_2009.pdf">
                                     Cache
                                    </a>
                                    )
                                   </li>
                                   <li>
                                    <a href="http://www.everth.de/html/uta_.html">
                                     Everth U
                                    </a>
                                    .
                                    <ol>
                                     <li>
                                      <a href="http://www.borreliose-gesellschaft.de/Unterlagen_2009_Tabarz/Everth_Tabarz_2009.pdf">
                                       Kriterien analytischer Leistungsfähigkeit am Beispiel kommerziell erhältlicher Testsysteme (ELISA)
                                      </a>
                                      , (in
                                      <a href="literatur/everth_tabarz_2009.pdf">
                                       Cache
                                      </a>
                                      )
                                     </li>
                                     <li>
                                      <a href="http://www.borreliose-gesellschaft.de/Unterlagen_2009_Tabarz/Everth_Poster_Tabarz_2009.pdf">
                                       Selected Aspects of Serology
                                      </a>
                                      . (in
                                      <a href="literatur/everth_poster_tabarz_2009.pdf">
                                       Cache
                                      </a>
                                      )
                                     </li>
                                    </ol>
                                   </li>
                                  </ul>
                                 </font>
                                </p>
                                <p>
                                </p>
                                <li>
                                 Jochen Süss, Olaf Kahl,
                                 <a href="http://www.tbd-symposium.com/Pages_public/ijstd_sym.aspx">
                                  <b>
                                   X International Jena Symposium on Tick-borne Diseases
                                  </b>
                                  (iJSTD)
                                 </a>
                                 ,  Weimar, 19-21 March 2009
                                 <ol>
                                  <li>
                                   <a href="http://www.tbd-symposium.com/Pages_public/ijstd_arc_arc07_proTh.aspx">
                                    Scientific Programme
                                   </a>
                                   ,
                                  </li>
                                  <li>
                                   Posters (
                                   <a href="http://www.tbd-symposium.com/Pages_public/ijstd_proPo_01.aspx">
                                    I
                                   </a>
                                   ,
                                   <a href="http://www.tbd-symposium.com/Pages_public/ijstd_proPo_02.aspx">
                                    II
                                   </a>
                                   ).
                                  </li>
                                 </ol>
                                 <p>
                                 </p>
                                </li>
                                <li>
                                 Rijksinstituut voor Volksgezondheid en Milieu (
                                 <a href="http://www.rivm.nl/over-rivm/profiel/">
                                  RIVM
                                 </a>
                                 ): neue vorläufige Forschungs-Resultate bez.
                                 <b>
                                  Zeckendurchseuchung und -stiche in den Niederlanden
                                 </b>
                                 ; Febr. 2009:
                                 <blockquote>
                                  <font size="-2">
                                   Das RIVM hat in 2007 und 2008 mit 300 Hausärzten bei circa 700 Teilnehmern die Daten bzw. Zeckenstiche + Sera untersucht. 42% der Personen stellten sich beim Arzt wegen EM vor und  58% wegen stattgefundener Stiche. Es wurden 323 bei den Teilnehmern entfernte Zecken untersucht. Die meisten davon waren Ix. ricinus-Zecken.   55% waren Nymphen;  44% adulte zecken und nur 1% war Larven.
                                   <p>
                                    Mit PCR wurde die Durchseuchung  ermittelt. Bartonella und Mykoplasmen wurden hierbei nicht berücksichtigt:
                                   </p>
                                   <table>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Borrelien
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       22%, davon B afz 16%, Bgar 4%; Bbss 2%; B valais 1%
                                      </font>
                                     </td>
                                    </tr>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Rickettsien
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       22%
                                      </font>
                                     </td>
                                    </tr>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Ehrlich/Anapl
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       10%
                                      </font>
                                     </td>
                                    </tr>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Babesien
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       4%
                                      </font>
                                     </td>
                                    </tr>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Min. 1 Infektion
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       46%
                                      </font>
                                     </td>
                                    </tr>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Mehrfach infiziert
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       12%
                                      </font>
                                     </td>
                                    </tr>
                                    <tr>
                                     <td>
                                      <font size="-2">
                                       Mehrere Borr. Typen
                                      </font>
                                     </td>
                                     <td>
                                      <font size="-2">
                                       5%
                                      </font>
                                     </td>
                                    </tr>
                                   </table>
                                   <p>
                                    Man erwartet weitere die Enddaten gegen Ende 2009.
                                    <a href="http://www.rivm.nl/cib/binaries/Tekenbetenonderzoek_feb2009_tcm92-58450.pdf">
                                     Verbreitungs-Karte der Teilnehmer und Statistik
                                    </a>
                                   </p>
                                  </font>
                                 </blockquote>
                                 <p>
                                 </p>
                                </li>
                                <li>
                                 <a name="B-C-A">
                                 </a>
                                 <a href="http://www.b-c-a.de/index.php?id=84">
                                  <b>
                                   Aktuelles zur chronischen Borreliose
                                  </b>
                                 </a>
                                 vom
                                 <a href="http://www.b-c-a.de/">
                                  Borreliose-Centrum-Augsburg
                                 </a>
                                 (BCA)
                                 <p>
                                  <font size="-2">
                                   "In der deutschsprachigen medizinischen Literatur wird die Krankheit "Chronische Borreliose" noch gerne negiert bzw. als nicht heilbares "Post Lyme Syndrom" bezeichnet. Die dahinter stehende wissenschaftliche Meinung vertritt die Auffassung, dass die Borrelien durch eine Behandlung mit Antibiotika über 2-3 Wochen vollständig vernichtet werden. Sollten danach noch Beschwerden auftreten, so resultieren diese nicht von den Borrelien sondern z.B. von noch weiter wirkenden chronischen Entzündungen.
                                  </font>
                                 </p>
                                 <p>
                                  Diese Auffassung wird vom BCA und der
                                  <a href="http://www.borreliose-gesellschaft.de/">
                                   Deutschen Borreliose-Gesellschaft
                                  </a>
                                  nicht geteilt. Sie berufen sich in diesem Zusammenhang auf umfangreiche Studien der
                                  <a href="http://www.ilads.org/" target="_blank">
                                   ILADS
                                  </a>
                                  sowie eigene Erkenntnisse und Erfahrungen. Danach sind Borrelien recht "intelligente", fortbewegungsfähige Spiralbakterien, die es recht gut verstehen, sich der körpereigenen Immunabwehr als auch bestimmten Antibiotika zu entziehen. Evtl. haben Sie bereits davon gehört, dass Borrelien "persistieren", d.h. sich "tarnen" und "verstecken" können.
                                 </p>
                                 <p>
                                  Die in der Deutschen Borreliose-Gesellschaft e.V. organisierten Ärzte und das BCA setzen auf eine Langzeitantibiose über mehrere Monate, evtl. auch mit wechselnden Präparaten. Diese Ärzte haben Erfahrung mit dem breiten Spektrum der Antibiotika und empfehlen Begleitmaßnahmen, um mögliche Nebenwirkungen der Antibiotika von Anfang an so weit als möglich zu kompensieren.
                                 </p>
                                 <p>
                                  Die wissenschaftliche Unterlegung der vom BCA vertretenen Diagnostik- und Therapie-Konzepte stützt sich u.a. auf folgende Publikationen:
                                 </p>
                                 <ol>
                                  <li>
                                   <a href="http://www.b-c-a.de/fileadmin/img/bca/BCALangzeitbehandlungAntibiotikaDontaStudie020309.pdf">
                                    Wirkungen der Langzeit-Antibiose bei chronischer Borreliose
                                   </a>
                                   <br/>
                                   <font size="-2">
                                    Mit diesem Beitrag stellt sich das BCA der Diskussion um die Notwendigkeit und Berechtigung der Langzeit-Antibiose, gegenüber der gerade viele Hausärzte noch erhebliche Vorbehalte haben. Leider noch zu unbekannt im deutschsprachigen Raum sind klinische Studien aus den letzten Jahren, die den Erfolg dieser Langzeit-Antibiose beweisen. Zu diesem Zweck werden in diesem Beitrag beispielhaft die Ergebnisse des renommierten Prof. Dr. med. Sam T. Donta, dem Direktor der Abteilung für Infektionskrankheiten und Biomolekular-Medizin - Bereich Lyme-Borreliose am Boston University Medical Center, aus dessen Studie von 2003 mit 239 Lyme-Borreliose Patienten dargestellt. Diese Studie unterlegt die Berechtigung der vom BCA durchgeführten Langzeit-Antibiosen und dass die chronische Lyme-Borreliose ein zu behandelndes Krankheitsbild ist.
                                   </font>
                                  </li>
                                  <li>
                                   <a href="http://www.b-c-a.de/fileadmin/img/bca/StrickerLangzeitbehandlungAntibiotikaIDSALecture110309deutsch.pdf">
                                    Langzeit-Antibiotika-Therapie verbessert die persistierenden, mit Lyme-Borreliose verbundenen Symptome
                                   </a>
                                   , Beitrag von Raphael B. Stricker M.D. (IDSA Vortrag 2006) - deutsche Übersetzung
                                  </li>
                                  <li>
                                   <a href="http://www.b-c-a.de/fileadmin/img/bca/BurrascanoLeitlinie2008deutsch.pdf">
                                    Fortschritte im Verständnis der Lyme-Krankheit - Diagnostische Hinweise und Richtlinien für die Therapie der Lyme-Borreliose und anderer durch Zecken übertragener Erkrankungen
                                   </a>
                                   , Joseph J. Burrascano M.D. (ILADS, 16. Ausgabe, 2008) - deutsche Übersetzung
                                  </li>
                                 </ol>
                                 <p>
                                  Bücher/Dokumente:
                                 </p>
                                 <ol>
                                  <li>
                                   Empfehlungen der Deutschen Borreliose Gesellschaft e.V. (Stand April 2008).
                                  </li>
                                  <li>
                                   Das sehr verständlich und übersichtlich geschriebene Buch "
                                   <a href="http://www.amazon.de/Krank-nach-Zeckenstich-Borreliose-behandeln/dp/3426873923/ref=sr_1_1?ie=UTF8&amp;s=books&amp;qid=1242749456&amp;sr=8-1">
                                    Krank nach Zeckenstich - Borreliose erkennen und wirksam behandeln
                                   </a>
                                   " von Dr. med. Petra Hopf-Seidel (ISBN 978-3-426-87392-2 / Preis: 9,95 Û / Droemer Knaur; Auflage: 1 (9. Juni 2008)).
                                  </li>
                                  <li>
                                   Noch ausführlicher und grundlegend für den ganzheitlichen Therapieansatz sind die Ausführungen im englischsprachigen Buch "
                                   <a href="http://www.lymedoctor.com/previewthebook.html">
                                    The Lyme Disease Solution
                                   </a>
                                   " von
                                   <a href="http://www.lymedoctor.com/">
                                    Kenneth B. Singleton
                                   </a>
                                   M.D., M.P.H. (ISBN 978-1-934812-00-6 / Brown Books, Dallas)."
                                  </li>
                                 </ol>
                                </li>
                               </font>
                              </li>
                             </ul>
                             <p>
                             </p>
                             <hr/>
                             <b>
                              (Datum: 3. März 2009)
                             </b>
                             <p>
                              <a href="http://www.borreliose-gesellschaft.de/FuerMitglieder/Mitgliederversammlungen/2009Tabarz">
                               Mitgliederversammlung
                              </a>
                              der
                              <b>
                               Deutschen Borreliose-Gesellschaft
                              </b>
                              am 20. März 2009, 16:40 Uhr, in Tabarz zwischen Eisenach und Gotha. Auf der Tagesordnung steht eine Satzungsänderung (
                              <a href="http://www.borreliose-gesellschaft.de/Veranstaltungen/2009Tabarz/Programm">
                               Vortragsprogramm
                              </a>
                              )
                             </p>
                             <hr/>
                             <b>
                              (Datum: 13. February 2009)
                             </b>
                             <p>
                              Pauliina Hartiala,
                              <a href="https://oa.doria.fi/bitstream/handle/10024/43547/D835Hartiala.pdf?sequence=1">
                               <b>
                                Immune evasion
                               </b>
                               by Borrelia burgdorferi
                              </a>
                              with special reference to CD38 mediated chemotaxis of neutrophils and dentritic cells, Department of Medical Microbiology and Immunology, University of Turku  and Turku Postgraduate School of Biomedical Sciences, Turku, Finland (
                              <a href="mailto:soijuv@hotmail.com">
                               Matti K. Viljanen
                              </a>
                              , MD, supervisor)
                             </p>
                             <hr/>
                             <b>
                              (Datum: 24. Oktober/2. November 2008)
                             </b>
                             <br/>
                             <b>
                              Deutsche Borreliose-Gesellschaft
                             </b>
                             <ul>
                              <li>
                               <a href="http://www.borreliose-gesellschaft.de/Mitglieder-Mitteilungen/Mitteilungen_16.pdf">
                                Mitteilungen
                               </a>
                              </li>
                              <li>
                               <a href="http://www.borreliose-gesellschaft.de/Texte_und_Empfehlungen/Empfehlungen.pdf">
                                Diagnostik und  Therapie der Lyme-Borreliose
                               </a>
                               , Stand Februar 2008.
                               <blockquote>
                                <font size="-2">
                                 Mitglieder der Arbeitsgruppe der Empfehlungen:
                                 <br/>
                                 Prof. Dr. med. Rüdiger von Baehr  FA für Innere Medizin  Institut für medizinische Diagnostik, Berlin - PD Dr. med. Walter Berghoff  FA für Innere Medizin, Rheinbach - Dr. med. Harald Bennefeld  FA für Neurochirurgie, Sportmedizin, Heinrich Mann Klinik Bad Liebenstein - Hans-Peter Gabel  FA für Allgemeinmedizin, Wolfenbüttel - Prof. Dr. med. Fred Hartmann  FA für Innere Medizin, Chefarzt a. D., Ansbach - Dr. med. Wolfgang Heesch  FA für Innere Medizin, Vellmar - Dr. med. Gabriele Herrmann  FÄ für Orthopädie, Berlin - Dr. med. Petra Hopf-Seidel  FÄ für Neurologie und Psychiatrie sowie  FÄ für Allgemeinmedizin, Ansbach - Dr. med. Bernd-Dieter Huismans  FA für Innere Medizin, Umweltmedizin, Crailsheim - Dr. med. Wolfgang Klemann  FA für Innere Medizin, Pforzheim    Dr. med. Uwe Neubert  FA für Dermatologie, Dermatologische Klinik LMU München, Akad. Direktor i. R.  - Dr. med. Andrea Roczinski  FÄ für Allgemeinmedizin, Königslutter - Dr. med. Armin Schwarzbach  FA für Laboratoriumsmedizin, Augsburg - Dr. med. Barbara Weitkus  FÄ für Kinderheilkunde, Berlin - Cord Uebermuth  FA für Augenheilkunde, Düsseldorf    Dr. med. Jochen Viebahn  FA für Allgemeinmedizin, Gummersbach - Dr. med. Peter Voss  FA für Allgemeinmedizin, Ulm
                                </font>
                               </blockquote>
                              </li>
                              <li>
                               B.-D. Huismans, W. Klemann,
                               <a href="http://www.grin.com/e-book/117294/">
                                Langzeitbehandlung mit Antiinfektiva bei persistierender Borreliose mit Borrelien-DNA-Nachweis durch PCR
                               </a>
                               , Grin Verlag, 20.10.2008
                              </li>
                              <li>
                               Miklossy J, Kasas S, Zurn AD, McCall S, Yu S, McGeer PL,
                               <a href="http://www.jneuroinflammation.com/content/5/1/40">
                                <b>
                                 Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation
                                </b>
                                in Lyme neuroborreliosis
                               </a>
                               , J Neuroinflammation. 2008 Sep 25;5(1):40 (frei zugängliche Neuerscheinung)
                               <blockquote>
                                <font size="-2">
                                 ABSTRACT
                                 <br/>
                                 BACKGROUND:
                                 <br/>
                                 The long latent stage seen in syphilis, followed by
 chronic central nervous system infection and inflammation, can be explained by
 the persistence of atypical cystic and granular forms of Treponema pallidum. We
 investigated whether a similar situation may occur in Lyme neuroborreliosis.
                                 <br/>
                                 METHOD:
                                 <br/>
                                 Atypical forms of Borrelia burgdorferi spirochetes were induced exposing
 cultures of Borrelia burgdorferi (strains B31 and ADB1) to such unfavorable
 conditions as osmotic and heat shock, and exposure to the binding agents
 Thioflavin S and Congo red. We also analyzed whether these forms may be induced
 in vitro, following infection of primary chicken and rat neurons, as well as rat
 and human astrocytes. We further analyzed whether atypical forms similar to
 those induced in vitro may also occur in vivo, in brains of three patients with
 Lyme neuroborreliosis. We used immunohistochemical methods to detect evidence of
 neuroinflammation in the form of reactive microglia and astrocytes.
                                 <br/>
                                 RESULTS:
                                 <br/>
                                 Under these conditions we observed atypical cystic, rolled and granular forms of
 these spirochetes. We characterized these abnormal forms by histochemical,
 immunohistochemical, dark field and atomic force microscopy (AFM) methods. The
 atypical and cystic forms found in the brains of three patients with
 neuropathologically confirmed Lyme neuroborreliosis were identical to those
 induced in vitro. We also observed nuclear fragmentation of the infected
 astrocytes using the TUNEL method. Abundant HLA-DR positive microglia and GFAP
 positive reactive astrocytes were present in the cerebral cortex.
                                 <br/>
                                 CONCLUSION:
                                 <br/>
                                 <ol>
                                  <li>
                                   The results indicate that atypical extra- and intracellular pleomorphic and cystic forms of Borrelia burgdorferi and local neuroinflammation occur in the brain in chronic Lyme neuroborreliosis. The persistence of these more resistant spirochete forms, and their intracellular location in neurons and glial cells, may explain the long latent stage and persistence of Borrelia infection.
                                  </li>
                                  <li>
                                   The results also suggest that Borrelia burgdorferi may induce cellular dysfunction and apoptosis.
                                  </li>
                                  <li>
                                   The detection and recognition of atypical, cystic and granular forms in infected tissues is essential for the diagnosis and the treatment as they can occur in the absence of the typical spiral Borrelia form.
                                  </li>
                                 </ol>
                                 <p>
                                 </p>
                                 <div style="
 margin: 1em;
 margin-right: 2em;
 border: 1px solid #999999;
 border-left: 1px solid #AAAAAA;
 border-bottom: 1px solid #AAAAAA;">
                                  <div style="
 border: 3px solid #F0F0F0;
 border-left: 1px solid #F8F8F8; 
 border-bottom: 1px solid #F8F8F8;">
                                   <table>
                                    <tr>
                                     <td face="verdana" font="" size="-2">
                                      <a href="http://www.jneuroinflammation.com/content/5/1/40/figure/F7" onclick="popup('http://www.jneuroinflammation.com/content/5/1/40/figure/F7','F7',800,470); return false;">
                                       <img align="top" alt="thumbnail" class="thumbnail" src="literatur/miklossyetal_2008.gif"/>
                                      </a>
                                     </td>
                                     <td face="verdana" font="">
                                      <font size="-2">
                                       <a href="http://www.jneuroinflammation.com/content/5/1/40/figure/F7">
                                        Figure 7
                                       </a>
                                       . Extra- and intracellular atypical and cystic forms of spirochetes in the cerebral cortex of a patient with pathologically and serologically confirmed chronic Lyme neuroborreliosis where
                                       <em>
                                        Borrelia burgdorferi sensu stricto
                                       </em>
                                       was cultivated from the brain.
                                       <ul>
                                        <li>
                                         A: Colony-like agglomeration of spirochetes as revealed by monoclonal anti-OspA antibody in the cerebral cortex.
                                        </li>
                                        <li>
                                         B: A close up of the central part of the mass seen in A. In addition to a few helically shaped spirochetes (arrow) numerous ring-shaped forms and spherules (asterisk) are visible, which are identical to those observed
                                         <em>
                                          in vitro
                                         </em>
                                         following 1 week Borrelia exposure of primary neurons (compare with
                                         <a href="http://www.jneuroinflammation.com/content/5/1/40/figure/F4">
                                          Fig. 4
                                         </a>
                                         G).
                                        </li>
                                        <li>
                                         C: Spirochetes showing loop or ring-shaped formations (arrows) in the cerebral cortex immunostained with a polyclonal anti-
                                         <em>
                                          Borrelia burgdorferi
                                         </em>
                                         antibody (Biodesign, B65302R). They are similar to those of
                                         <em>
                                          Treponema pallidum
                                         </em>
                                         (arrows in D) observed in the cerebral cortex of a patient with general paresis. Immunostaining was performed using a polyclonal anti-
                                         <em>
                                          Treponema pallidum
                                         </em>
                                         antibody (Biodesign, B65210R).
                                        </li>
                                        <li>
                                         E: Helically shaped OspA immunoreactive spirochetes in the cytoplasm of a cortical pyramidal neuron. In addition to one more typical form (arrow), fine OspA positive minute granules along filamentous forms are seen.
                                        </li>
                                        <li>
                                         F: Intracellular ring-shaped forms (arrow) showing positive immunoreaction with a polyclonal anti-
                                         <em>
                                          Borrelia burgdorferi
                                         </em>
                                         antibody (BB1017). They are identical to those observed in chicken primary neurons infected with Borrelia (compare F with
                                         <a href="http://www.jneuroinflammation.com/content/5/1/40/figure/F4">
                                          Figure 4
                                         </a>
                                         D). Near the asterisk a large strongly immunoreactive cyst form is visible.
                                        </li>
                                        <li>
                                         Spirochete forming loop in the cerebral cortex (G) and in the cytoplasm of an epithelial cell of the choroid plexus (H) are seen as visualized by anti-OspA and anti-bacterial peptidoglycan antibodies, respectively.
                                        </li>
                                        <li>
                                         I: A similar atypical spirochete forming loops in the cerebral cortex as visualized with Thioflavin S.
                                        </li>
                                        <li>
                                         J: In an area with colony-like spirochete aggregation in addition to some typical, regularly coiled Borrelia spirochetes (arrow) OspA positive cystic forms (asterisk) are seen.
                                        </li>
                                        <li>
                                         K: In the cerebral cortex near the colony-like spirochetal agglomerate a spirochete cyst (asterisk) similar to that observed
                                         <em>
                                          in vitro
                                         </em>
                                         is visible (compare it with
                                         <a href="http://www.jneuroinflammation.com/content/5/1/40/figure/F5">
                                          Figure 5
                                         </a>
                                         G-J). Immunostaining was performed using a monoclonal anti-OspA antibody.
                                        </li>
                                       </ul>
                                      </font>
                                     </td>
                                    </tr>
                                   </table>
                                  </div>
                                 </div>
                                </font>
                               </blockquote>
                              </li>
                             </ul>
                             <hr/>
                             <b>
                              (Datum: 28. August 2008)
                             </b>
                             <br/>
                             <ul>
                              <li>
                               18. Oktober 2008, Rotenburg an der Fulda,
                               <a href="http://www.borreliose-gesellschaft.de/Veranstaltungen/2008Rotenburg">
                                Herbstversammlung
                               </a>
                               der
                               <b>
                                Deutschen Borreliose-Gesellschaft
                               </b>
                               .
                               <a href="http://www.borreliose-gesellschaft.de/FuerMitglieder/Mitteilungen">
                                Mitteilungen
                               </a>
                              </li>
                              <li>
                               <a href="http://lyme08.pswrce.uci.edu/">
                                <b>
                                 Conference
                                </b>
                                on Lyme Borreliosis and Other Tick-borne Diseases
                               </a>
                               , October 19 - 22, 2008,
                               <a href="http://lyme08.pswrce.uci.edu/program1.pdf">
                                Program
                               </a>
                              </li>
                             </ul>
                             <p>
                             </p>
                             <hr/>
                             <a name="jones">
                             </a>
                             <b>
                              (Datum: 9. Juli 2008)
                             </b>
                             <br/>
                             <table>
                              <tr>
                               <td>
                                <a href="http://www.youtube.com/watch?v=MNGnsAgKT8s">
                                 <img alt="Charles Ray Jones in his practice" border="1" src="dr_jones.jpg"/>
                                </a>
                               </td>
                               <td>
                                <font face="verdana">
                                 <font size="-2">
                                  <i>
                                   CHARLES RAY JONES, M.D.
                                   <br/>
                                   Madison Towers
                                   <br/>
                                   111 Park Street, 1st Floor
                                   <br/>
                                   New Haven, Connecticut 06511
                                   <br/>
                                   Tel (203) 772-1123 - Fax (203) 772-0682
                                   <br/>
                                  </i>
                                  <br/>
                                  July 7, 2008
                                  <br/>
                                  <br/>
                                  Dear Friends,
                                  <br/>
                                  Urgent! I must raise $90,000 by July 14, 2008 and an additional $110,000 by August 10 in order to retain the legal team which has been representing me.
                                  <br/>
                                  <br/>
                                  If these sums are not raised, I will not be able to continue defending the charges brought against me by the Connecticut Department of Public Health for my treatment of children with Lyme disease, and I fear that I will be forced by the Connecticut Medical Examining Board to resign my license to practice medicine and to retire. This must not happen!
                                  <br/>
                                  <br/>
                                  I understand all too well the considerable hardship that Lyme disease has imposed on too many families, and regret the need to appeal to you yet again for donations to my legal defense fund.
                                  <br/>
                                  <br/>
                                  Yet the prospect of surrendering this critical fight is more daunting: If I do not continue to oppose these charges, how many more physicians will be left vulnerable to similar charges for their treatment of Lyme disease? How many more sick children will be abandoned?
                                  <p>
                                   Dr. Jones
                                   <br/>
                                   Charles Ray Jones, M.D.
                                  </p>
                                 </font>
                                </font>
                               </td>
                              </tr>
                              <tr>
                              </tr>
                             </table>
                             <blockquote>
                              <font size="-2">
                               Background:  The Panel assigned to hear Dr. Jones' case completed their review of the evidence presented over the course of 11 days of hearings that had begun on March 28, 2006, and handed down recommendations.  If these recommendations were accepted by the Medical Licensing Board, Dr. Jones would be fined $10,000, and be subjected to having his patient care monitored by a physician for a period of two years.  The process would be put into place within 60 days, with the monitoring physician reporting back to the Medical Board periodically.  The attorneys had the opportunity to submit briefs and to provide oral arguments to the Medical Licensing Board at their monthly meeting.  The Board would then decide whether to affirm the findings of the panel, to dismiss it, or to modify it in some way.  Their findings would be binding on Dr. Jones, unless the ruling was overturned on some level of the appeal process.
                              </font>
                             </blockquote>
                             <p>
                             </p>
                             <hr/>
                             <b>
                              (Datum: 17. Juni 2008
                             </b>
                             <br/>
                             Corry Welker informiert:
                             <br/>
                             <ul>
                              <li>
                               <b>
                                Untersuchung von Zecken
                               </b>
                               <ol>
                                <li>
                                 Zecken untersuchen lassen mittels PCR  für  35 Euro kann man bei:
                                 <a href="http://www.zeckenuntersuchung.de/">
                                  http://www.zeckenuntersuchung.de/
                                 </a>
                                 . Peter Rohleder fand diese Adresse.
                                </li>
                                <li>
                                 Selbst Zecken testen -zuhause oder unterwegs- geht auch, schrieb Frau Dr. Hopf-Seidel: Endverbraucherpreis 14.95 Euro, und der Test sei leicht mitzunehmen und über jede Apotheke zu bekommen/abfragbar.
                                 <blockquote>
                                  <font size="-2">
                                   Der Pharma-Großhandel listet den Test edv-mäßig unter "MEDtest Zecken/Borreliose".
 Aussagekraft: Der Test springe an bei ca. 300 Borrelien im Markierungsfeld, was wohl 30% Infektionsgefahr bedeute, sagte man mir. Weitere Info folgt.
                                   <br/>
                                   <a href="http://www.medtest-zuhause.de/index.html">
                                    MEDtest
                                   </a>
                                   ist das Gesundheitszentrum+ München, Rainfarn-Apotheke&amp;Sanitätshaus, Rainfarnstr 36 in D-80935 München, Tel.: (089) 312 023 01, wo man aber nur Packungen mit 100 Stück liefere an Praxen, Kliniken, Pharma-Großhandel etc.
                                   <br/>
                                   Ein Vorzeige-Exemplar wurde mir für die SHG zugesagt. Diesbezüglich und Details kann man nachfragen bei Herrn Grundmann oder Dr. Helm, Gesundheitszentrum+ München, 089 - 312 023 01.
                                  </font>
                                 </blockquote>
                                </li>
                               </ol>
                              </li>
                              <li>
                               Deutsche Borreliose-Gesellschaft,
                               <a href="http://www.borreliose-gesellschaft.de/Texte/Empfehlungen.pdf">
                                <b>
                                 Diagnostik und Therapie der Lyme-Borreliose: Empfehlungen der Deutschen Borreliose-Gesellschaft
                                </b>
                               </a>
                               , 5. Mai 2008
                               <br/>
                               <blockquote>
                                <font size="-2">
                                 Von einer Arbeitsgruppe der Deutschen Borreliose-Gesellschaft mit folgenden Mitgliedern verfasst:   R. von Baehr, W. Berghoff, H. Bennefeld,   H.-P. Gabel, F. Hartmann, W. Heesch, G. Herrmann,  P. Hopf-Seidel, B.-D. Huismans, W. Klemann,  U. Neubert, A. Roczinski, A. Schwarzbach,  B. Weitkus, C. Uebermuth, J. Viebahn, P. Voss
                                 <br/>
                                 Diese Empfehlungen wurden im Rahmen der Jahresversammlungen 2006 und 2007 der BorrelioseGesellschaft von Mitgliedern der Arbeitsgruppe vorgestellt. Kritische Hinweise und Ergänzungen wurden  in diesen Empfehlungen berücksichtigt. Die vorliegende Fassung entspricht dem Stand der Diskussion  vom Februar 2008. Diese Empfehlungen werden weiter diskutiert und aktualisiert werden.
                                </font>
                               </blockquote>
                              </li>
                              <li>
                               Dr. Hopf-Seidel und Dr. rer.nat Gradl (Fa. Viathen) halten ein
                               <b>
                                Tageskongress über Chronische Borreliose
                               </b>
                               im Hotel am Wöhrdersee, Nürnberg, am 28. Juni 08, 9.30-15.30 Uhr. Klinische Symptomatik, immunologische Grundlagen und therapeutische Ansätze stehen auf dem Programm. Veranstalter ist Viathen Healthcare. Tagesgebühr: 79 - 84 Euro. Anmeldung ist erforderlich. Tel. 0381-808-3400 (
                               <a href="tagungen/programme/chronBorr-28-Juni-2008.pdf">
                                weiteres
                               </a>
                               )
                               <p>
                               </p>
                              </li>
                              <li>
                               Nardelli DT, Callister SM,
                               <a href="mailto:rfschell@wisc.edu">
                                Schell RF
                               </a>
                               ,
                               <a href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2223850">
                                <b>
                                 Lyme arthritis: current concepts and a change in paradigm
                                </b>
                               </a>
                               . Clin Vaccine Immunol. 2008 Jan;15(1):21-34. Epub 2007 Nov 14. Review.
                               <blockquote>
                                <div style="margin: 1em; margin-right: 2em;       border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;">
                                 <div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;">
                                  <a id="f1" name="f1">
                                  </a>
                                  <table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;">
                                   <tr align="left" valign="top">
                                    <td align="center" width="100">
                                     <a class="icon-reflink" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2223850&amp;rendertype=figure&amp;id=f1" onclick="startTarget(this, 'figure', 1024, 800)">
                                      <img alt="FIG. 1." border="1" class="icon-reflink" src="literatur/nardelli_2008-picrender.gif" title="FIG. 1."/>
                                     </a>
                                     <br/>
                                     <font face="verdana">
                                      <font size="-2">
                                       click on image to enlarge
                                      </font>
                                     </font>
                                    </td>
                                    <td>
                                     <div class="figure-table-caption-in-article">
                                      <span>
                                       <font size="-2">
                                        Proposed mechanism for the development of Th17 cells and arthritis following infection with
                                        <em>
                                         B. burgdorferi
                                        </em>
                                        .
                                        <ol>
                                         <li>
                                          Infection with
                                          <em>
                                           B. burgdorferi
                                          </em>
                                          stimulates the TLR-mediated release of proinflammatory cytokines, such as IL-6. IL-6, in combination with endogenous TGF-β,
                                         </li>
                                         <li>
                                          induces the development of Th17 cells from T-cell precursors.
                                         </li>
                                         <li>
                                          Th17 cells produce IL-17,
                                         </li>
                                         <li>
                                          which stimulates the production of other proinflammatory cytokines, such as IL-1β and TNF-α.
                                         </li>
                                         <li>
                                          IL-17 also induces from fibroblasts and synovial cells the production of IL-6, which serves to continue the inflammatory feedback loop.
                                         </li>
                                        </ol>
                                        This process may occur until the borrelial load is reduced such that TLR-mediated production of IL-6 is insufficient to influence Th17 cell production.
                                       </font>
                                      </span>
                                     </div>
                                    </td>
                                   </tr>
                                  </table>
                                 </div>
                                </div>
                                <div style="clear:both;">
                                </div>
                               </blockquote>
                               <p>
                               </p>
                              </li>
                              <li>
                               Petra Hopf-Seidel,
                               <a href="http://www.amazon.de/Krank-nach-Zeckenstich-Borreliose-behandeln/dp/3426873923/ref=pd_bxgy_b_img_a">
                                <b>
                                 Krank nach Zeckenstich
                                </b>
                               </a>
                               , MensSana Abteilung; Droemer-Knaur Verlag, 9. Juni 2008, Preis 9.95 Euro.
                               <blockquote>
                                <font size="-2">
                                 "Borreliose erkennen und wirksam behandeln" ist aus schulmedizinischer und ganzheitlicher Sicht geschrieben mit breitgefächerten Informationen.  Neben ausführlicher Info über Zecken, vermittelte Erreger und Begleiterkrankungen handelt fast die Hälfte des Buches über Symptomatik, Diagnostik und Therapie der chronischen Borreliose mit Empfehlungen für verschiedene Antibiotika. Im Anhang gibt es Adressen, Glossar und einen ausführlichen Index.
                                 <p>
                                  Dr. Petra Hopf-Seidel ist seit 1980 Ärztin. Sie lebte 3 Jahre in Malaysia, wo sie sich u. a. mit ganzheitlicher Therapie beschäftigte. Nach der Ausbildung zur Allgemeinmedizinerin schloss sie eine Ausbildung zur Fachärztin für Neurologie und Psychiatrie an und erwarb die Zusatzbezeichnung "Chirotherapie". Seit 2005 arbeitet sie in ihrer Privatpraxis für Neurologie und Psychiatrie in Ansbach.
                                 </p>
                                </font>
                               </blockquote>
                              </li>
                              <li>
                               <a href="http://www.amazon.de/s/ref=nb_ss_b/302-1897692-2818435?__mk_de_DE=%C5M%C5Z%D5%D1&amp;url=search-alias%3Dstripbooks&amp;field-keywords=Oschmann+Kraiczy&amp;x=23&amp;y=19">
                                Patrick Oschmann, Peter Kraiczy
                               </a>
                               ,
                               <a href="http://www.amazon.de/Lyme-Borreliose-Frühsommer-Meningoenzephalitis-Patrick-Oschmann/dp/3895994081/ref=sr_1_1?ie=UTF8&amp;s=books&amp;qid=1213701116&amp;sr=1-1">
                                <b>
                                 Lyme Borreliose und Frühsommer-Meningoenzephalitis
                                </b>
                               </a>
                               , Uni-Med, Bremen, Januar 1998.
                               <blockquote>
                                <font size="-2">
                                 In neuropsychologischen Tests sind nach Literaturangaben die Defizite objektivierbar. Das EEG und der Liquor cerebrospinalis sind fast immer normal (im Vergleich zur europäischen Literatur erstaunt das regelhafte Fehlen entzündlicher Liquorveränderungen einschließlich einer intrathekalen spezifischen Antikörpersynthese zum Zeitpunkt der Diagnosestellung). Im MRT können zum Teil "white mater lesions" gefunden werden. Unter antibiotischer Therapie seien bei einem Teil der Patienten  eine Besserung der Klinik, neuropschych. Testresultate sowie der Befunde im SPECT zu beobachten.
                                 <p>
                                 </p>
                                </font>
                               </blockquote>
                               Siehe dazu auch:
                               <a href="labtests/Labtests.htm#blanc">
                                Blanc F, Jaulhac B, Fleury M et al
                               </a>
                               .,
                               <a href="http://www.neurology.org/cgi/content/abstract/69/10/953">
                                <b>
                                 Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients
                                </b>
                               </a>
                               . Neurology. 2007 Sep 4;69(10):953-8
                               <p>
                               </p>
                               <ul>
                                <li>
                                 30 der 40 Patienten mit Neuroborreliose hatten einen Antikörperindex AI =
                                 <a href="labtests/Labtests.htm#csfserumratio">
                                  Liquor/Serum Verhältnis
                                 </a>
                                 &gt; 1. Damit ergibt sich eine AI-
                                 <a href="terms.htm#sensitivitaet">
                                  Sensitivität
                                 </a>
                                 = 30/40 x 100% = 75%.
                                </li>
                                <li>
                                 2 der 74 Patienten mit einer anderen neurologischen Diagnose hatten einen AI &gt; 1. Damit ergibt sich eine AI-
                                 <a href="terms.htm#spezifizitaet">
                                  Spezifität
                                 </a>
                                 = 72/74 x 100% = 97%.
                                </li>
                               </ul>
                              </li>
                             </ul>
                            </font>
                            <p>
                            </p>
                            <hr/>
                            <b>
                             (Datum: 20. Mai 2008)
                            </b>
                            <br/>
                            <a href="mailto:rstricker@usmamed.com">
                             Raphael B. Stricker
                            </a>
                            , Infectious Diseases Society of America (IDSA) Lecture,
                            <a href="http://www.journals.uchicago.edu/doi/abs/10.1086/518853">
                             Counterpoint:
                             <b>
                              Long-Term Antibiotic Therapy Improves Persistent Symptoms
                             </b>
                             Associated with Lyme Disease
                            </a>
                            , Clinical Infectious Diseases 2007;45:149-157
                            <br/>
                            <font size="-2">
                             <a href="http://www.journals.uchicago.edu/doi/pdf/10.1086/518853">
                              Pay per Article - Login
                             </a>
                             : US $15.00
                             <br/>
                             <blockquote>
                              <b>
                               Methods
                              </b>
                              : Review of the pathophysiology of B. burgdorferi infection and the peer-reviewed literature on diagnostic Lyme disease testing, standard treatment results, and coinfection with tickborne agents, such as Babesia, Anaplasma, Ehrlichia, and Bartonella species. Examination of uncontrolled and controlled trials of prolonged antibiotic therapy in patients with persistent symptoms of Lyme disease.
                              <br/>
                              <b>
                               Results
                              </b>
                              : The complex "stealth" pathology of B. burgdorferi allows the spirochete to invade diverse tissues, elude the immune response, and establish long-term infection. Commercial testing for Lyme disease is highly specific but relatively insensitive, especially during the later stages of disease. Numerous studies have documented the failure of standard antibiotic therapy in patients with Lyme disease. Previous uncontrolled trials and recent placebo-controlled trials suggest that prolonged antibiotic therapy (duration, &gt;4 weeks) may be beneficial for patients with persistent Lyme disease symptoms. Tickborne coinfections may increase the severity and duration of infection with B. burgdorferi.
                             </blockquote>
                            </font>
                            <hr/>
                            <b>
                             (Datum: 15. Mai 2008)
                            </b>
                            <br/>
                            M.K. Viljanen (Turku Immunology Centre, Finland),
                            <a href="http://www.med.utu.fi/mikrobiologia/tutkimus/viljanen.pdf">
                             <b>
                              Host Defence in Lyme Borreliosis
                             </b>
                            </a>
                            <font size="-2">
                             <blockquote>
                              One of the most debated questions in Lyme
 borreliosis research is pathogenesis of antibiotic
 treatment resistant disease manifestations. Two main
 hypotheses presented to explain this phenomenon
 are persistent infection and infection-induced
 autoimmunity. We have succeeded in establishing
 a much-needed animal model for this disease
 entity (Yrjänäinen et al., submitted). Our results show
 that the presence of vegetative spirochetes is no
 prerequisite for the persisting symptoms. However,
 using this model we have found out that when the
 mice receive immunosuppressive treatment with
 anti-TNF-alpha after a latent period of several weeks,
 borreliae are activated from a dormant state and
 the animals develop spirochetemia (Yrjänäinen et al.,
 manuscript in preparation). Thus, our results support
 the persistent infection hypothesis.
                              <br/>
                             </blockquote>
                             more:
                             <ul>
                              <li>
                               <a href="heta.yrjanainen@utu.fi">
                                Yrjänäinen H
                               </a>
                               , Hytönen J, Söderström K-O, Oksi J, Hartiala K, Viljanen MK (2006). "Persistent joint swelling and borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment." Microbes and Infection 8: 2044-51 (2006).
                              </li>
                              <li>
                               Yrjänäinen et al.,
                               <a href="http://www.journals.uchicago.edu/doi/abs/10.1086/513873">
                                Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice
                               </a>
                               , J Infect Dis 195: 1489-1496.
                               <br/>
                               <a href="http://www.journals.uchicago.edu/doi/abs/10.1086/586907">
                                Correspondence: Stricker RB
                               </a>
                               ,  J Infect Dis. 2008 May 1;197(9):1352-3
                               <br/>
                              </li>
                              <li>
                               Hartiala P, Hytönen J, Pelkonen J, Kimppa K, West A, Penttinen MA, Suhonen J, Lahesmaa R, Viljanen MK,
                               <a href="http://www.jleukbio.org/cgi/content/abstract/82/1/33">
                                , "Transcriptional response of human dendritic cells to Borrelia garinii - defective CD38 and CCR7 expression detected. J Leukocyte Biol 82: (1); 33-43 (2007).
                               </a>
                              </li>
                             </ul>
                            </font>
                            <hr/>
                            <p>
                            </p>
                            <hr/>
                            <font face="Verdana">
                             <font size="-2">
                              <b>
                               <a href="altebekannte.htm">
                                Ältere
 Bekanntmachungen
                               </a>
                              </b>
                              . Sie wurden von hier z.T.
                             </font>
                            </font>
                            <ul>
                             <li>
                              <font face="Verdana">
                               <font size="-2">
                                in das
                                <a href="terms.htm">
                                 Lexikon
                                </a>
                                oder
                               </font>
                              </font>
                             </li>
                             <li>
                              <font face="Verdana">
                               <font size="-2">
                                auf die Seite
                                <a href="aktive/history.htm">
                                 Lyme-Aktivismus
                                </a>
                               </font>
                              </font>
                             </li>
                            </ul>
                            <font face="Verdana">
                             <font size="-2">
                              verlagert.
                             </font>
                            </font>
                           </font>
                          </p>
                         </font>
                        </font>
                       </font>
                      </p>
                     </table>
                    </tr>
                   </table>
                  </font>
                 </font>
                </table>
               </table>
              </font>
             </font>
            </p>
           </font>
          </font>
         </p>
        </font>
       </font>
      </p>
     </td>
    </tr>
   </table>
  </body>
 </html>
